A novel approach for local treatment of breast cancer by Vaidya, J.S.
 
A NOVEL APPROACH FOR LOCAL TREATMENT OF  
BREAST CANCER  
DISSERTATION FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY  
BY  
JAYANT SHARAD VAIDYA 
AT  
UNIVERSITY COLLEGE LONDON 
1996-2001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Jayant S Vaidya FRCS MS DNB PhD 
Department of Surgery 
University College London 
67-73 Riding House Street 
London W1W 7EJ 
j.vaidya@ucl.ac.uk 
2  
 
DEDICATED TO 
MY FATHER    
DR. SHARAD G. VAIDYA 
AND 
MY MOTHER 
DR. NIRMALA S. VAIDYA
3 4  
TABLE OF CONTENTS 
Abstract.......................................................................................................9 
Local treatment of breast cancer and the significance of local recurrence11 
The shift from radical surgery to conservative surgery.................................. 13 
Historical Perspectives  13 
The Halstedian Era – focus on local therapy  13 
Fisher’s theory of biological pre-determinism - focus on systemic therapy  14 
Extent of Local therapy  15 
The ‘accepted wisdom’ is shaken?  16 
The latest Oxford Overview  18 
Local recurrence after breast conserving therapy............................................ 19 
Does local recurrence harbinger poor prognosis? If so, is it only a marker or a 
determinant? 20 
Is margin status important for local control of disease?  22 
Does local recurrence occur because of a Field defect?  25 
Is multicentricity an important source of recurrence of breast cancer? - the 
site of local recurrence  25 
Multicentricity of breast cancer: Whole organ analysis and clinical 
implications ..............................................................................................27 
Introduction.......................................................................................................... 29 
Method .................................................................................................................. 30 
Results.................................................................................................................... 36 
Discussion............................................................................................................. 41 
Summary................................................................................................................ 43 
5 Can magnetic-resonance imaging detect the clinically relevant 
multicentric foci?...................................................................................... 45 
Introduction...........................................................................................................47 
Method...................................................................................................................47 
Results.....................................................................................................................48 
Discussion..............................................................................................................50 
The novel technique of intra-operative radiotherapy................................51 
Introduction...........................................................................................................53 
The Physics and Radiobiology............................................................................54 
Positioning the X-ray source  57 
Development of the machine for Brain tumours  58 
Conceptualisation and adaptation for the breast: use of special applicators  58 
The technique of giving intra-operative radiotherapy.....................................59 
Sterilisation issues  59 
Operative technique  59 
Postoperative care  67 
Radiation safety  67 
The pilot study of intra-operative boost radiotherapy............................. 69 
Time course : events leading up to the setting up of the pilot study............71 
Long-term strategy for improving the delivery of local treatment for breast 
cancer......................................................................................................................71 
Background............................................................................................................72 
Methods and Design ............................................................................................73 
Results.....................................................................................................................74 
Discussion..............................................................................................................75 
6 Percutaneous minimally invasive Stereotactic Interstitial primary 
radiotherapy using the Photon Radiosurgery System for women found 
unfit to undergo surgery...........................................................................79 
Background........................................................................................................... 81 
The Physics........................................................................................................... 82 
The Technique...................................................................................................... 82 
Description of the first case............................................................................... 83 
Results and Discussion........................................................................................ 86 
The randomised trial of targeted intraoperative radiotherapy.................95 
The problem of local treatment of breast cancer............................................ 97 
Methods and Design............................................................................................ 98 
Title of the trial..................................................................................................... 99 
Hypothesis ............................................................................................................ 99 
Eligible patients.................................................................................................... 99 
Exclusion criteria................................................................................................100 
End Points..........................................................................................................100 
Local tumour control (defined as recurrent tumour in the ipsilateral breast) 100 
Cosmetic result  100 
Patient satisfaction  100 
Health economics  100 
Trial Schema.......................................................................................................101 
Treatment Policy Statements............................................................................102 
Treatments..........................................................................................................102 
Surgery 102 
Radiotherapy 102 
Patients with Lobular cancer and Extensive Intraduct Component  103 
The issue of positive margins  103 
7 Adjuvant Systemic Therapy  103 
Trial Administration.......................................................................................... 103 
Data Monitoring Committee (DMC).............................................................. 103 
Randomisation.................................................................................................... 103 
Statistical Considerations.................................................................................. 104 
Patient Numbers and Power Calculations  104 
Recent modification of trial design  104 
Statistical Analysis  105 
Ethical Considerations...................................................................................... 106 
Preliminary Results............................................................................................ 106 
Discussion........................................................................................................... 107 
Conclusion...............................................................................................109 
References ...............................................................................................115 
Acknowledgments...................................................................................125 
Appendix..................................................................................................127 
 
8  
Abstract 
Early local recurrence of breast 
cancer most commonly (over 90%) 
occurs at the site of the primary 
tumour. This is true whether or not 
radiotherapy is given and 
irrespective of the margin status. 
Whole-organ analysis of mastectomy 
specimens on the other hand, reveals 
that 63% of breasts harbour occult 
cancer foci and 80% of these are 
situated remote from the index 
quadrant. Therefore, these occult 
cancer foci may be clinically 
irrelevant and it may not be 
necessary to treat the whole breast 
with radiotherapy. This 6-wks long 
course of post-operative radiotherapy 
after breast conserving therapy is not 
only inconvenient and costly, but 
may cause many women from 
geographically remote areas to 
choose mastectomy. Targeted 
Intraoperative radiotherapy 
(TARGIT) to the peri-tumoural area 
alone might provide adequate local 
control. ‘Intrabeam’ (PeC) is a 
portable electron-beam driven device 
that can deliver therapeutic radiation 
(soft x-rays) in 20-30 minutes within 
a standard operating theatre 
environment. The pliable breast 
tissue - the target - is wrapped 
around a spherical applicator - the 
source - providing truly conformal 
radiotherapy. The prescribed dose is 5 
& 20Gy at 1cm and 0.2cm respectively, 
from the tumour bed. The biologically 
effective dose is 7-53Gy for α/β=10 and 
20-120Gy for α/β=1.5.  In our pilot 
study of 26 patients (age 30-80 years, 
T=0.42-4.0cm), we replaced the routine 
post-operative tumour bed boost with 
targeted intra-operative radiotherapy. 
There have been no major 
complications and no patient has 
developed local recurrence, although 
the median follow-up time is short at 34 
months. The cosmetic outcome is 
satisfying to both the patient and the 
clinician. Having established the 
feasibility, acceptability and safety in 
the pilot study, we started in March 
2000, a randomised trial that compares 
TARGIT with conventional post-
operative radiotherapy for infiltrating 
duct carcinomas, with local recurrence 
and cosmesis as the main outcome 
measures. Patient accrual in this trial 
has been excellent and it has attracted 
several international collaborative 
groups. If proven effective, TARGIT 
could eliminate the need for post-
operative radiotherapy potentially 
saving time, money and breasts. 
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10 CHAPTER 1 
 
 
Local treatment of breast cancer and the 
significance of local recurrence 
11 12 The shift from radical surgery to 
conservative surgery 
Historical Perspectives 
The Edwin Smith Papyrus was 
written about 1700 BC but is based 
on writings of the Old Kingdom 
(2640 BC) -- the time of Imhotep. It 
describes breast cancer thus…“If 
thou examinst a man having bulging 
tumors on his breast, and if thou 
puttst thy hand upon his breast upon 
these tumors, and thou finds them 
very cool, there being no fever at all 
when thy hand touches him, they 
have no granulation, they form no 
fluid, they do not generate secretions 
of fluid, and they are bulging to thy 
hand. Thou should say concerning 
him: One having bulging tumors. An 
ailment with which I will not 
contend”. It describes eight cases of 
tumours or ulcers of the breast that 
were treated by cauterisation, with a 
tool called "the fire drill." The 
futility of such treatment was also 
recognised by the author- "There is 
no treatment." 
 
Breast cancer, an enigmatic disease 
with an unpredictable natural history 
has been a fertile soil for the 
development of hypothetical models 
each with their therapeutic 
consequence.  Until the discovery of 
the cellular nature of cancer the 
disease was managed according to 
Gallenic principles, the disease being 
visualised as an excess of 
melancholia (black bile) that 
coagulated within the breast [Porter, 
1998] ridding the body of this excess 
of black bile involved venesection, 
purgation, cupping, leaching, enemas 
and bizarre diets (many “alternative” 
treatments of breast cancer to this day 
are in fact a form of neo-galenism). 
In the mid 19th Century the humoral 
theory of breast cancer was overturned 
by a mechanistic model which 
described the disease as a phenomenon 
arising locally within the breast and 
then spreading centrifugally along 
lymphatics to be arrested in the first 
echelon of lymph nodes which acted as 
a barrier to onward spread by their 
innate filtering capacity.  A second 
echelon of lymph nodes existed like the 
casement walls of a medieval town 
protecting the citadel at its centre. 
Charles Moore, (1821-79) a surgeon 
from the Middlesex Hospital in London 
believed that the only way to cure 
breast cancer was very extensive 
surgery, in which the tumour was not 
violated [Moore, 1867]. Samuel Gross 
(1838-89) [Gross, 1880] agreed with 
this and emphasised the importance or 
axillary dissection. The therapeutic 
consequences of such a belief was the 
development of the Halsted radical 
mastectomy, at the end of the 19
th 
century
  [Halsted, 1894b;Halsted, 
1894a]. 
The Halstedian Era – focus on local 
therapy 
William Halsted (1852-1922) operated 
at a time when the triumph of 
mechanistic principles was at its peak. 
The common man had begun enjoying 
the fruits of the industrial revolution. 
However, on the more fundamental 
level, it was at this time, that, the limits 
of Newtonian laws of nature in the 
physical sciences were being realised 
by Einstein and Hiensenburgh. 
Biological and medical sciences, on the 
other hand, were still considered too 
different from the physical sciences to 
13 Fisher’s theory of biological pre-
determinism - focus on systemic 
therapy 
be affected by these changes. 
Naturally, Halsted’s ‘complete 
operation’ was based on 
straightforward and logical concepts 
about tumour biology: that the 
tumour spreads centrifugally in the 
breast to the surrounding lymphatics 
and lymph nodes and thence to the 
rest of the body. His classical 
operation included en bloc dissection 
of the breast and surrounding tissue 
including the lymphatic drainage 
sites. ‘The suspected tissues should 
be removed in one piece, (1) lest the 
wound become infected by the 
division of tissue invaded by the 
disease or by lymphatic vessels 
containing cancer cells, and (2) 
because shreds or pieces of 
cancerous tissue might readily be 
overlooked in a piecemeal 
extirpation’[Halsted, 1894b;Halsted, 
1894a]. His surgical expertise was 
remarkable…‘the operation, as we 
perform it, is literally an almost 
bloodless one…’ and for the first 
time, breast cancer seemed curable. 
His recurrence rates (6% local + 14% 
regional) at 3 years of follow up 
were very low, compared to the other 
series at that time (56%-82%). 
Clearly, he believed that ‘we are 
encouraged to hope for a much 
brighter, if not very bright, future for 
operations for cancer of the breast’ 
and titled his paper ‘The results of 
operations for cure of cancer of the 
breast’. Halsted’s pioneering work in 
breast cancer served as a model for 
many other solid cancers and his 
principles are still successful in 
cancers such as squamous carcinoma 
of the head and neck -the commando 
operation and cervix - the 
Wertheim’s operation. 
Unfortunately, only 23% of patients 
treated by Halsted survived 10 years 
[Lewis and Rienhoff, 1932]. The first 
attempted solution to this was surgery 
that was even more radical. Internal 
mammary lymph nodes that receive 
about 25% of the lymphatic drainage of 
the breast were not removed in the 
‘complete operation’. Non-randomised 
studies indicated that operations that 
were more radical improved survival 
[Urban, 1978]. However, in randomised 
trials, overall, no real benefit could be 
demonstrated at a five year follow up 
[Lacour et al., 1976] [Meier et al., 
1985]. Although a subsequent subgroup 
analysis at 10 year follow up [Meier et 
al., 1989]did suggest a possible benefit 
in those with medial and central 
quadrant tumours, this was based on a 
small number of patients (78 patients) 
and this effect was not seen in a larger 
trial with similar follow up which 
involved 1453 patients [Lacour et al., 
1983]. Although the patients who did 
not receive the extended radical 
mastectomy had more local recurrences, 
these occurred mostly in patients who 
developed distant metastasis and the 
overall the survival in the two groups 
was not different. Moreover, even when 
the tumour seemed to have been 
completely ‘removed with its roots’, the 
patients still developed distant 
metastases and succumbed: 30% of 
node-negative and 75% of node positive 
patients eventually succumbed to breast 
cancer when they were treated by 
radical surgery alone [Fisher and 
Gebhardt, 1978]. Prompted by the 
failures of radical operations to cure 
patients of breast cancer, Bernard Fisher 
[Fisher, 1980] postulated that cancer 
spreads via blood stream even before its 
clinical detection and possibly during 
tumour manipulation during surgery, 
14 with the outcome determined by the 
biology of tumour host interactions. 
Based on this concept of “biological 
pre-determinism”, he postulated that 
1) the extent of local treatment 
would not affect survival 2) systemic 
treatment of even seemingly 
localised tumours would be 
beneficial and may offer a chance of 
cure. This was not the first time that 
the radicality of surgery was 
questioned. It has been questioned 
since 1923 [Ewing, 1928]. Geoffrey 
Keynes of St Bartholomew’ Hospital 
believed that wide excision and 
radiotherapy would have the same 
survival as mastectomy [Keynes, 
1937;Keynes, 1952]. However, it 
was only in the early 1960s that 
several pioneers in the field set up 
randomised clinical trials to test the 
hypothesis. Indeed the results of 
these trials testing of the hypothesis 
that adjuvant systemic treatment 
should improve survival provide a 
‘proof of principle’. However, we 
must realise that the proof is more to 
the letter than in the spirit. It was 
expected that the adjuvant systemic 
therapy would probably be able to 
‘cure’ the patients who had ‘micro-
metastatic’ disease. This is evident 
from the size of the first ground-
breaking trial reported in the New 
England Journal of medicine in 
[Bonadonna et al., 1976]. This trial 
was reported at a follow up only 27 
months and with only 386 patients, it 
had only a 27% power to detect the 
25% relative risk reduction, i.e., 6% 
in their 24% relapse rate. They had 
80% power to detect only a 50% 
reduction in relapse rate- clearly the 
expectations were much higher than 
the reality. It was a fortunate play of 
chance that this trial was positive, 
otherwise, chemotherapy for breast 
cancer would have had a premature 
death. As we now know several 
subsequent trial results were 
contradictory and it was only when the 
1985 Oxford overview [Early Breast 
Cancer Trialists' Collaborative Group, 
1988] was performed that the truth was 
evident – that the benefits from 
systemic therapy are modest - a relative 
risk reduction of about 25% which is 
about 8-10% in absolute terms. 
Although this was a great triumph, we 
must realise that we have progressed 
little since the last 15 years. As far as 
systemic ‘cure’ of the disease is 
concerned, the way forward is to 
develop new models of disease based 
on non-mechanistic principles such as 
mathematics of non-linear dynamics 
and chaos theory, using tools such as 
neural networks and to develop novel 
systemic treatments that are more 
specific and aimed to tame rather than 
kill cancer cells. Of course, the utopian 
wish that an evolution of a new 
treatment should follow the “proper” 
route -from philosophical model to 
laboratory and finally to the bedside- is 
has only rarely been realised and most 
advances in use today are a result of 
either serendipity or innovative new 
treatments tested in clinical trials. 
Nevertheless, one cannot stop waiting 
for the giant leap that a Kuhnian 
revolution could make.  
The rest of this chapter and indeed this 
thesis concentrates on local control of 
the disease. 
Extent of Local therapy 
As regards the extent of local treatment, 
there have been several randomised 
trials that have tested less vs. more 
surgery and the effect of adjuvant 
radiotherapy. In general these trials also 
suffered from small numbers and 
although some individual trials did have 
significant results on their own, it was 
necessary to pool the data together in 
the Oxford overview [Early Breast 
Cancer Trialists' Collaborative Group, 
1995;Early Breast Cancer Trialists' 
15 The questions whether radiotherapy can 
replace more extensive surgery and 
whether radiotherapy is needed after 
mastectomy have been answered to a 
greater accuracy in the 2000 overview 
because many more trials results were 
now available. 
Collaborative Group, 2000]to make 
the issues clear. The main issues at 
stake were: 
1)  Does more extensive surgery 
improve survival? 
2)  Does addition of radiotherapy 
to mastectomy improve 
survival? And can it 
substitute for less extensive 
surgery in terms of both local 
control and survival? 
Does more extensive surgery 
improve survival? 
The 1995 Oxford overview [Early 
Breast Cancer Trialists' 
Collaborative Group, 1995] of 26000 
women from 36 of these trials 
concluded that more radical local 
treatment, whether surgery or 
adjuvant radiotherapy, does not have 
any influence on appearance of 
distant disease and overall survival. 
This is in spite of the increase in 
local recurrence rates with less 
radical local treatment, i.e., although 
post-operative radiotherapy had a 
substantial effect on reducing local 
recurrence rates, it did not improve 
overall survival or distant disease 
free survival. At the same time, the 
collateral support for the Fisher’s 
hypothesis came from the fact that 
although the “early” detection of 
cancer (before systemic spread) by 
screening improved mortality, it did 
so only in women >50 years and the 
reduction in mortality was very 
modest – only a 25 % overall relative 
risk reduction. Thus, the above data 
could be taken as powerful 
corroboration of Fisher’s theory that 
metastases of any importance have 
already occurred before  the clinical 
or radiological detection of at least 
75% of breast cancers.  
The CRC group (the Kings-Cambridge 
Trial) was the first to point out that 
there was an excess of non-breast 
cancer mortality in the group of women 
who were randomised to receive 
radiotherapy and had a left-sided breast 
cancer. They suggested that this could 
be because of the orthovoltage 
radiotherapy which had considerably 
more scatter and would have damaged 
the coronary vessels [Haybittle et al., 
1989;Houghton et al., 1994;Cuzick et 
al., 1994]. Thus in the CRC trial, 
although the breast cancer mortality 
was reduced by radiotherapy, this 
beneficial effect was completely erased 
by the harmful effect on the heart, thus 
showing overall no survival benefit. 
Other radiotherapy trials also did not 
find any improvement in overall 
survival with radiotherapy (Manchester 
Christie and Stockholm trials). This 
finding was borne out in the overview 
of randomised trials testing the benefit 
of radiotherapy after mastectomy 
[Cuzick et al., 1987]  
In addition to cardiac deaths, there was 
increased incidence of second 
malignancy in those treated with 
radiotherapy. Ipsilateral but not 
contralateral lung cancer risk was 
increased 3 fold [Neugut et al., 1994] 
and this increased multiplicatively 32 
fold among smokers. Risk of squamous 
carcinoma of oesophagus cancer was 
also increased-cell carcinoma increased 
RR 5.42 (95% CI, 2.33 to 10.68) 
[Ahsan and Neugut, 1998]. 
The ‘accepted wisdom’ is shaken? 
What does radiotherapy add to either 
conservative surgery or mastectomy?  Thus by mid-1990s there was 
widespread belief that the extent of 
16 local treatment did not affect the 
long-term outcome. This was 
probably already determined by the 
time the cancer was diagnosed. The 
publication of two large Danish trials 
has shaken this ‘proven’ consensus. 
In these trials, involving women with 
larger breast tumours and/or many 
involved lymph nodes, who received 
adjuvant chemotherapy or tamoxifen 
[Overgaard et al., 1997;Overgaard et 
al., 1999;Ragaz et al., 1997]. Not 
surprisingly, there was a reduction in 
local recurrence rates - but there was 
also an improvement in the overall 
10 year-survival rates - 
(9%[Overgaard et al., 1997] and 
10%[Ragaz et al., 1997]). The trials 
have been criticised because the 
surgery for these fairly large tumours 
was inadequate, thus accentuating 
the benefit by radiotherapy. 
However, the radiotherapy 
techniques in these two studies 
minimised the dose to the heart and 
included internal mammary chain in 
the field.  These factors could have 
contributed to the large improvement 
in survival. Another explanation for 
this large magnitude of the 
difference in survival rates could be 
a statistical quirk. Let us assume that 
radiotherapy does impart a small 
survival benefit. When several trials 
are conducted, the different 
magnitudes of effects seen are 
expected to follow normal 
distribution. A sufficiently large trial 
would be highly likely to detect this 
small difference whereas a small trial 
will rarely yield a positive result 
because of type II error. The effect in 
a small trial will need to be larger 
than the real effect (just by chance) 
for it to be detected at all, 
consequently, small trials that are 
positive will usually be those which 
reveal a larger than real effect.  
A meta-analysis by Tim Whelan 
attempted to look at a specific group- 
mainly those who received systemic 
adjuvant therapy. Their hypothesis was 
that this is probably the only group in 
which any secondary spread from 
recurrent disease might have an impact 
on survival. They found that overall 
there is indeed a small reduction in 
mortality from adjuvant radiotherapy 
[Whelan et al., 2000].  
The evidence to support the belief that 
adequate local treatment is important 
not only to reduce local recurrence but 
also to reduce death from breast cancer, 
was in fact already available in some 
early surgical trials. 
The initial Guy’s trials of conservative 
surgery were started in the 1960s were 
the first to refute the Fisher’s theory that 
extent of local treatment would not affect 
survival. They found that radical surgery 
imparted a significant survival benefit 
[Atkins et al., 1972], and this beneficial 
effect has actually been accentuated after 
25 years of follow up [Fentiman, 
1998;Fentiman, 2000]. In the first series 
374 women (>50yrs) with T1, T2, N0 
and N1 tumours were randomized to 
either Halsted mastectomy or wide 
excision. Both groups were given 25-27 
Gy to the gland fields and the wide 
excision group received additionally 35-
38 Gy to the breast. Hence the wide 
excision group had no axillary surgery 
and subsequent axillary irradiation using 
what is now regarded as a low dose of 
radiotherapy. After 25 years, local 
relapse occurred in 26% of the 
mastectomy group and 50% of the wide 
excision group (chi
2=21.6, P < 0.001). 
The breast cancer mortality rate at 25 
years was 56% in the mastectomy group 
and 63% in those treated by wide 
excision (chi
2 = 5.33, P = 0.02). The first 
analysis of this trial indicated that 
increased risk of axillary relapse was 
restricted to (clinically) N1 cases and so 
a second trial was conducted with entry 
only for those with clinically negative 
axillae (N0 series). Of 355 cases entered, 
133 were randomized to mastectomy and 
17 122 to wide excision, with the same 
radiotherapy schedule as was used as 
in the original series. After 25 years 
local relapse occurred in 18% of the 
mastectomy cases and 54% of the 
wide excision group (chi square = 
30.6, P < 0.001). There were 
significantly more distant relapse in 
the latter group (chi square = 6.32, P 
= 0.01), and a significant increase in 
breast cancer deaths (57% versus 
44%,;chi square = 4.27, P = 0.04). 
These two trials, conducted before the 
widespread introduction of systemic 
adjuvant therapy, both indicate the 
long-term effects of inadequate 
primary treatment. Inadvertent failure 
to treat the axilla effectively led not 
only to significantly increased axillary 
relapse rates but also to more deaths 
from metastatic disease. 
In a large study from Denmark, 
[Axelsson et al., 1992] analysed the 
records of 13,851 patients registered 
by the Danish Breast Cancer 
Cooperative Group (DBCG). They 
found that node negativity was 
determined not only by small tumour 
size, but also by the number of 
lymph nodes removed. Where 10 or 
more negative lymph nodes were 
removed, significantly better axillary 
recurrence-free survival (P<0.0001), 
over-all recurrence-free survival 
(P<0.0001) and survival (P<0.005) 
were found. To see whether axillary 
surgery may perhaps be less 
important they, analysed the records 
of 4771 patients with tumour 
diameters <= 10 mm [Axelsson et 
al., 2000]. As expected, they found 
more axillary metastases in group 
T1b tumours than in T1a. Mean 
number of positive nodes was related 
to number of nodes removed, and 
again, when 10 or more nodes were 
removed a significantly lower 
axillary recurrence rate and better 
recurrence-free survival were 
demonstrated. It was not possible to 
define a patient group where axillary 
surgery was superfluous. The authors 
concluded that adequate axillary 
surgery is necessary for adequate local 
control. 
Another study, albeit non-randomised, 
also suggested that local control does 
impact overall survival. This study from 
Cardiff [Shukla et al., 1999], used 
prospective long-term follow-up 
monitoring of two contemporaneous 
groups of patients, within a single unit, 
who were treated identically except for 
the one variable of local treatment 
policy, i.e., conservative or radical. A 
total of 451 patients with operable 
breast cancer were chosen from 567 
consecutive patients with breast cancer 
who were treated between 1970 and 
1979 in the University Department of 
Surgery. Two hundred forty-one 
patients were treated using a 
conservative approach and 210 were 
treated using a radical approach. At 132 
months, the survival rate (58% vs. 42%) 
and median survival time (> 132 vs. 100 
months) were significantly improved 
for the radically treated group (P < .01). 
The treatment groups were comparable 
in terms of age, menopausal status, 
tumour size, histologic grading, and 
Nottingham Prognostic Index values 
and the advantage of the radical policy 
persisted when examined in relation to 
each of these prognostic factors. This 
was related to a reduced loco-regional 
recurrence rate and provided evidence 
that local therapy influences long-term 
outcomes for patients with breast 
cancer.  
The latest Oxford Overview 
The speculation about a small potential 
survival benefit from radiotherapy has 
been borne out in the latest world 
overview. The Oxford Group has 
repeated the meta-analysis of 
randomised trials testing the value of 
radiotherapy. They used individual 
18 patient data and included 40 
published and unpublished trials 
[Early Breast Cancer Trialists' 
Collaborative Group, 2000] with 
special attention to the Danish trials. 
This meta-analysis (see figure) 
showed that radiotherapy reduced the 
local recurrence from 27.2% to 8.8% 
at 10 years. Breast cancer mortality 
was indeed reduced (2p=0.0001) but 
other mortality was increased 
(2p=0.0003). Thus, there was no 
statistically significant difference in 
survival. The main hazard of 
radiotherapy was vascular (RR 1.3) 
which was the only cause separately 
statistically significant. In addition, 
mortality from respiratory and 
second neoplasms was also 
increased. Overall, the 20-year 
survival was 37.1% with 
radiotherapy versus 35.9% control 
(2p=0.06), and 10-year survival was 
56.6% vs. 54.5%, respectively. After 
the first 2 years, the annual death rate 
among patients allocated to 
radiotherapy was about 21% higher. 
If the harmful effects of adjuvant 
radiotherapy could be completely 
avoided, possibly by using modern 
radiotherapy techniques, it would be 
expected to produce an absolute 
increase in 20-year survival of about 
2-4% (except for women at 
particularly low risk of local 
recurrence). The average hazard seen 
in these trials would, however, 
reduce this 20-year survival benefit 
in young women and reverse it in 
older women. Radiotherapy in 
general reduced the relative risk of 
local recurrence by two thirds (66% 
relative risk reduction= e.g. from 
30% to 10% i.e., a 20% absolute risk 
reduction) and reduced the risk of 
breast cancer death by about a fifth 
of that reduction (i.e., 66/5= 13.5% 
relative risk reduction = e.g. 20/5 = 
4% absolute risk reduction). Thus, 
the magnitude of the beneficial effect of 
radiotherapy is small and if 
radiotherapy side effects can be 
completely avoided, it could improve 
the 20 year survival by about 2-4% the 
benefit mainly limited to those women 
who have a high risk of local 
recurrence.  
These latest results have shown that 
survival benefit from adequate local 
treatment is small, but real and since it 
can become apparent only after long 
term follow up, it can be missed. Of 
note, this small benefit is equivalent in 
magnitude to that obtained by adjuvant 
systemic chemotherapy in those above 
50 years of age! 
 
 
Local recurrence after breast 
conserving therapy 
Local recurrence of breast cancer is a 
very emotionally laden subject and is 
associated with a sense of failure for 
both the patient and the doctor. There 
are several separate issues to consider 
here:  
1)  Is local recurrence a failure of 
local therapy only and can be 
salvaged/ prevented by more 
aggressive local therapy, or is it 
a more sinister harbinger of 
outcome – i.e., is the 
determinant or expression of a 
poor prognosis?  
2)  Is margin status important for 
local control of disease?  
3)  Is multicentricity an important 
source of recurrence of breast 
cancer? 
4)  Is it possible that local 
recurrence is an expression of a 
field defect in the index 
quadrant? 
 
19 Does local recurrence harbinger 
poor prognosis? If so, is it only a 
marker or a determinant? 
On one hand, local recurrence could 
be an expression of metastatic 
disease or a source of tertiary spread. 
The evidence from randomised 
studies indicates that although local 
recurrence is a harbinger of poor 
prognosis, it is probably not the 
cause or determinant of it. Thus, 
local recurrence is only an indicator 
of poor prognosis but not its 
determinant. This is true in the 
setting of both after mastectomy as well 
as breast conserving therapy- as 
evidence from these trials clearly 
demonstrates.  
The CRC trial 
In a trial involving 35 clinicians in the 
UK, 585 patients were randomised to 
either receive radiotherapy or not. 
Radiotherapy reduced the risk of local 
recurrence significantly (RR 0.43; 95% 
CI 0.29- 0.63) but there was no overall 
difference in survival.  The NSABP-B06 trial 
In this trial, patients were 
randomised to receive either 
lumpectomy only, lumpectomy + 
radiotherapy or total mastectomy + 
axillary clearance. Radiotherapy 
reduced the risk of local recurrence 
from as much as 35% in those who 
received lumpectomy only, 
compared to 10% in those who 
received lumpectomy + radiotherapy 
but the survival of this whole group 
receiving lumpectomy only was not 
in any way less than those receiving 
radiotherapy after lumpectomy. 
Overall, there was no difference in 
the survival of all there groups. But, 
after adjustment for fixed co-variates 
such as tumour size and nodal status, 
ipsilateral breast tumour recurrence 
(IBTR) is a powerful independent 
predictor of distant metastasis. The 
patients who developed an IBTR had 
a 3.14 times the risk of distant 
disease. However, it is emphasised 
by Fisher that ‘this is only a marker 
of risk for, and not a cause of, distant 
metastases. Thus, whole breast 
radiotherapy or mastectomy only 
prevent the expression of the marker 
of high risk but do not actually lower 
the risk of distant disease. [Fisher et 
al., 1991a;Fisher et al., 1992;Fisher, 
1980] [Fisher, 1980;Fisher et al., 
1995] 
The two European trials- EORTC 
trial 10801 and DBCG trial 82-TM 
A combined analysis of these trials 
has recently been published. A total 
of 1,807 patients with stage I and II 
breast cancer were randomised to 
receive Modified Radical 
Mastectomy (MRM) or Breast 
Conserving Therapy (BCT). When 
all patients with a local recurrence in 
these trials were analysed, the survival 
rates were 58% and 59% for MRM and 
BCT respectively and the actuarial 
survival curves and the actuarial loco-
regional control curves were similar. 
The type of primary local treatment 
(MRM or BCT) did not have any 
prognostic impact. The overall survival 
after MRM or BCT was similar in these 
two European randomised trials. This 
further reinforced the concept that early 
local recurrence is an indicator of a 
biologically aggressive tumour; early 
loco-regional relapse carries a poor 
prognosis and salvage treatment only 
cures a limited number of patients, 
whether treated by MRM or BCT 
originally [van Tienhoven et al., 1999].  
The proportion of patients who develop 
distant metastases within 10 years of 
developing local recurrence is reported 
to be from 64 % to 85%. Wilner and 
colleagues report that [Willner et al., 
1997], although the prognosis after 
local recurrence was poor in general 
(42% overall), there did exist a 
subgroup with relatively better 
prognosis: patients with a single chest 
wall or axillary recurrent nodule (in a 
patient aged > 50 years), a disease-free 
interval of > or = 1 year, pT1-2N0 
primary tumour, and without tumour 
necrosis, and whose recurrence is 
locally controlled. This subgroup of 12 
patients (out of a total of 145) had 5- 
and 10-year survival rates of 100% and 
69%, respectively. One may say that 
this could only be a result of serious 
data dredging, however, there are 
supportive data from the Guy’s Hospital 
[Fentiman et al., 1985]. In this study 73 
patients who presented with local skin 
recurrence, but with no evidence of 
distant dissemination, after a radical 
mastectomy. They found that only 10 
per cent of those with multiple lesions 
survived 5 years, and none was alive at 
10 years, whereas 42 per cent of those 
21 with single lesions survived 5 years 
and 22 per cent were alive and well 
at 10 years' post recurrence. The 
authors emphasise the importance of 
adequate local treatment of a single 
skin nodules. These data suggest 
local relapse is not necessarily a 
harbinger of poor prognosis in a 
small subset of patients. 
The NSABP-04 trial 
In this trial, 1665 women were 
randomised into three groups a) 
women treated with either total 
mastectomy only b) Total 
mastectomy + radiotherapy and c) 
Radical mastectomy. There was no 
difference in survival rates of these 
three groups despite the fact that in 
the Total mastectomy group almost 
40% of patients would have had 
positive lymph nodes that would be a 
potential source of distant spread 
[Fisher et al., 1981]. This study has 
been criticised [Harris and Osteen, 
1985] on the grounds that the total 
mastectomy ‘only’ group did in fact 
have several nodes excised and this 
alone could have reduced the 
difference compared with the group 
that received either formal axillary 
surgery or axillary radiotherapy. 
The Oxford Overview 
In this overview [Early Breast 
Cancer Trialists' Collaborative 
Group, 2000]it was clearly found 
that the local recurrence after wide 
local excision and axillary clearance 
was substantially reduced from 22% 
to 7.2% by radiotherapy 
(2p<0.00001). Radiotherapy also 
reduced breast cancer mortality by 
14% but increased non-breast cancer 
mortality by 34%. In absolute terms, 
this was a reduction in breast cancer 
mortality from 21.3% to 18.6% 
(difference=2.7%) and increase in non-
breast cancer mortality from 3.6 to 
5.4% (difference = 1.8%). Thus, the 
overall mortality was not changed by 
radiotherapy (24% vs. 24.9%, 2p>0.1). 
Discussion 
From all these trials, it appears that 
local recurrence, cannot, in general be a 
source of tertiary spread in more than 
say 5% of cases – because if it were, 
then we would have expected that the 
group which did not receive any 
radiotherapy and experienced three 
times the local recurrence as the group 
which received radiotherapy, would 
have fared much worse in terms of 
overall survival.  This however, was not 
the case. Those who did not develop 
local recurrence because they received 
radiotherapy were simply prevented (by 
radiotherapy) from expressing their 
poor prognosis locally, which was 
expressed systemically; thus overall 
survival was equal in the two arms. 
Is margin status important for local 
control of disease?  
Whether a positive margin is a marker 
of a high risk of local recurrence or a 
cause of it –can only be ascertained by a 
clinical trial in which patients with 
positive margins are randomised to 
either receive further surgical excision 
before radiotherapy, or have only the 
routine radiotherapy. Such a trial has 
not yet been performed. However, 
several surrogate findings can give us 
some clues. The answer seems to be 
similar to that for local recurrence- just 
as local recurrence is only a marker for 
distant disease, a positive margin 
appears to be a marker for a disease that 
is likely to behave aggressively- locally 
recurrent and with poor long term 
22 prognosis. One study from the Royal 
Marsden Hospital found that positive 
margins did not have any bearing on 
local recurrence [Assersohn et al., 
1999] 
Randomised studies 
A subgroup analysis was performed 
by the CRC group [Potyka et al., 
1999] to explore the importance of 
positive margins after wide local 
excision of invasive cancers. 
Although the group of patients with 
positive margins were at a higher 
risk of suffering local recurrence, the 
proportional reduction of this risk by 
radiotherapy in this group was equal 
to that for those with negative 
margins. If positive margins were the 
cause of local recurrence, we would 
have expected radiotherapy to have a 
much larger effect on the group with 
positive margins compared to the 
group with negative margins. In 
actual fact, it was found that 
radiotherapy reduces the risk of local 
recurrence whether or not margins 
are positive.  
For DCIS however, it appears that in 
addition to absence of radiotherapy, 
young age, symptomatic detection of 
DCIS, and growth pattern, involved 
margin is an important predictor of 
local recurrence [Bijker et al., 2001], 
although one cannot be certain that it 
is indeed the determinant. 
Non randomised series 
In case of DCIS, Nigel Bundred’s 
group [Chan et al., 2001] and Mel 
Silverstein’s group have found that 
positive margins are associated with 
increased risk of local recurrence and 
that addition of radiotherapy did not 
fully compensate for ‘inadequate’ 
surgery. However Mel Silverstein 
found that if the margin of excision was 
more than 1mm then radiotherapy did 
not make much statistically significant 
difference in the local recurrence rate 
that was already very low [Silverstein et 
al., 1999]. However, these findings in 
DCIS appear to be different from those 
in invasive carcinoma. 
Obedian and Haffty have presented a 
retrospective analysis [Obedian and 
Haffty, 2000]of 871 patients (treated 
between 1970-90) of whom 294 had re-
excision. For this analysis, patients 
were divided into four groups based on 
final pathologic margin status: negative 
(n = 278), dose (typically within 2 mm, 
n = 47), positive (n = 55), or 
indeterminate (n = 491). Breast relapse-
free survival at 10 years was 98% for 
patients with negative margins versus 
98% for those with close margins 
versus 83% for those with positive 
margins versus 82% for those with 
indeterminate margins. It is noteworthy, 
firstly, that more than half of these 
patients had indeterminate margins- not 
all of which could be considered to 
have positive margins. In addition, 
patients with negative margins were 
more likely than those with positive 
margins to have T1 mammographically 
detected lesions, to have negative nodal 
status, and to have undergone re-
excision. Patients with positive margins 
were more likely to receive adjuvant 
chemotherapy or hormone therapy (P = 
0.001). The authors themselves state 
that although the negative margin status 
conferred an overall survival and distant 
metastasis-free survival advantage, this 
difference is confounded by the earlier 
stage of disease in these patients; not 
surprisingly, margin status did not 
influence overall survival in 
multivariate analysis. 
In a German study of 1036 evaluable 
patients, [Rauschecker et al., 1998] with 
a median follow-up of 97 months, 237 
23 events (local recurrence, regional 
recurrence, distant metastases, 
contralateral breast cancer or death 
of the patient without previous 
recurrence) occurred. The local 
recurrence rate of the whole patient 
population was 8.8% at 8 years. Out 
of all prognostic factors examined, 
only tumour size and grade had a 
significant influence on recurrent 
disease. Although, event-free 
survival decreased in cases with 
'uncertain' tumour margins, the width 
of the margin has no influence on 
disease recurrence.  
Park and colleagues [Park et al., 
2000] studied in 533 patients, the 
relationship between pathologic 
margin status and outcome at 8 years 
after breast-conserving surgery and 
radiation therapy. Each margin was 
scored (according to the presence of 
invasive or in situ disease that 
touched the inked surgical margin) 
as one of the following: negative, 
close, focally positive, or extensively 
positive. The patients with close 
margins and those with negative 
margins both had a local recurrence 
rate of 7%, those patients with 
extensively positive margins had an 
LR rate of 27%, whereas patients 
with focally positive margins had an 
intermediate rate of LR of 14% - 
which was reduced to 7% if they had 
received adjuvant systemic therapy. 
In a multiple logistic regression 
model, pathologic margin status and 
the use of adjuvant systemic therapy 
were the most important factors 
associated with LR among patients 
treated with breast-conserving 
surgery and radiation therapy.  
Moore and colleagues [Moore et al., 
2000] found that lobular cancers had 
a high incidence of positive margins 
(51%). However, in randomised 
trials, many of which included those 
that did not routinely evaluate margin 
status, lobular cancers did not behave 
differently from the usual invasive 
ductal cancers after breast conservative 
surgery. However, in another study, 
with similar main results, [Mai et al., 
2000] the high risk of positive margins 
for ILC was limited to those that were 
greater than 2cm in size and moderate 
or high nuclear grade. 
In the analysis within one randomised 
trial of adjuvant or neo-adjuvant 
systemic therapy, it was found that 
among 184 patients, 38% had a positive 
margin [Assersohn et al., 1999] and had 
not received any further local surgery. 
However, the local recurrence rate and 
survival was not in any way different in 
this group. 
Freedman and colleagues studied the 
association between a positive resection 
margin and the risk of ipsilateral breast 
tumour recurrence (IBTR) after 
conservative surgery and radiation. In a 
series of 1,262 patients with clinical 
Stage I or II breast cancer were treated 
by breast-conserving surgery, axillary 
node dissection, and radiation between 
March 1979 and December 1992. Forty-
one percent had a single excision, and 
59% had a re-excision. The final 
margins were negative in 77%, positive 
in 12%, and close (< or = 2 mm) in 
11%.  Chemotherapy +/- tamoxifen was 
used in 28%, tamoxifen alone in 20%, 
and no adjuvant systemic therapy in 
52%. At 10 years, a significant 
difference in IBTR became apparent 
(negative 7%, positive 12%, close 14%, 
p = 0.04). The highest risk was 
observed in patients with persistently 
positive (13%) or close (21%) (p = 
0.02) margins. IBTR was delayed in 
patients who received adjuvant systemic 
therapy but this delay to IBTR was seen 
mainly in patients with close or positive 
margins, with little impact on the time 
to failure in patients with negative 
24 Aromatase activity in the index 
quadrant is higher than other quadrants 
[O'Neill et al., 1988] and via oestrogen 
it can stimulate mutagenesis, growth 
and angiogenesis [Lu et al., 1996] 
margins. At 5-years the cumulative 
incidence of IBTR in patients with 
close or positive margins was 1% 
with adjuvant systemic therapy and 
13% with no adjuvant therapy. 
However, by 10 years, the CI of 
IBTR was similar (18% vs. 14%) 
due to more late failures in the 
patients who received adjuvant 
systemic therapy. Thus, a close or 
positive margin is associated with an 
increased risk of IBTR even in 
patients who are EIC-negative or 
receiving higher boost doses of 
radiation, which was reduced by 
systemic therapy. 
In the NSABP-B06 trial [Fisher et al., 
1992], all the local recurrence in the no-
Radiotherapy arm occurred in the index 
quadrant again suggesting that it is 
probably a field defect. 
Several studies have investigated 
whether young age was a risk factor for 
local recurrence after breast conserving 
therapy and whether radiotherapy had a 
differential effect according to age. 
Patients with ipsilateral breast tumour 
recurrence (IBTR) have an increased 
risk of carrying mutant p53 gene (23% 
vs. 1%)[Turner et al., 1999b;Turner et 
al., 1999a]. In addition, young patients 
(<40 years) with IBTR have a 
disproportionately increased risk (40%) 
of carrying a deleterious BRCA1/2 gene 
mutation [Turner et al., 1999b]. This 
suggests that such local recurrence is 
probably related more to the 
background genetic instability rather 
than a different tumour biology at 
younger age. 
The concept of margin is in itself 
ambiguous. As will be discussed in 
the next chapter, many small cancers 
in addition to the primary tumour in 
about are present in 2/3rds of breast 
specimens.  Thus, any one of these 
occult cancers could be present at the 
‘margin’ of excision of the dominant 
tumour, irrespective of how widely it 
was excised. As has been seen in 
many of these studies, it is the 
grossly or diffusely involved margin 
that is probably indicative of 
significant and residual disease that 
could give rise to local recurrence, 
rather than the focally involved 
margin which many times might 
represent only incidental ‘biopsy’ of 
a multicentric focus in the breast. 
Is multicentricity an important 
source of recurrence of breast 
cancer? - the site of local recurrence 
A striking fact about local recurrence 
after conservative therapy with or 
without radiotherapy is that it almost 
always occurs in the same area as the 
primary tumour. In large series of breast 
conservation studies, it has been seen 
that >90% of early breast recurrences 
occur in the quadrant that harboured the 
primary tumour ([Harris et al., 1981], 
[Clark et al., 1982], [Schnitt et al., 
1984], [Clarke et al., 1985], [Kurtz et 
al., 1989b], [Boyages et al., 1990], 
[Fowble et al., 1990], [Fisher et al., 
Does local recurrence occur 
because of a Field defect? 
The morphologically normal cells 
surrounding breast cancer 
demonstrate a loss of heterozygocity, 
which frequently is identical to that 
of the primary tumour [Deng et al., 
1996]. So these ‘normal’ cells are 
already on the brink of becoming 
cancer.  
25 1992], [Clark et al., 1992], [Veronesi  et al., 1993]).  
 
Study No.  of 
patients 
Proportion of recurrences in the index 
quadrant 
Clark RM, 1982  680  96% 
Schnidt SJ, 1984  231  83% 
Boyages J, 1990  783  81% 
Kurtz, JM, 1990  1593  86% 
Fisher B, 1992 (RT)  488  100% 
Veronesi U, 1993  570  90% 
Clark 1992 (RT arm)  416  (19/23) 83% 
Clark 1992 (no RT arm)  421  (103/108) 86% 
TOTAL 5182  91% 
 
It is important to recognise that this 
is true whether or not radiotherapy is 
given [Clark et al., 1992]). That 
means that whatever that is the cause 
of local recurrence – its location 
remains in the index quadrant and is 
not affected by radiotherapy.   
Secondly, we also know that local 
recurrence occurs in the index 
quadrant irrespective of clear 
margins. Of the breast conserving 
trials that have tested the effect of 
radiotherapy, the NSABP-B06, 
[Fisher et al., 1985] [Fisher, 
1980;Fisher et al., 1996] Ontario 
[Clark et al., 1992;Clark et al., 
1996], Swedish [Liljegren et al., 
1999] and Scottish [Forrest et al., 
1996] trials had less extensive 
surgery compared with the Milan III 
trial [Veronesi et al., 1993]. The 
recurrence rate in the Milan III trial 
was low (8.8% vs. 24-27% in other 
trials) even in the control group 
albeit at the cost of cosmesis. 
Nevertheless, radiotherapy reduced it 
even further and at the same 
proportional rate as in other trials. If 
local recurrence was caused by 
residual disease, then radiotherapy 
should have affected much larger 
proportional reduction in those patients 
with positive margins or less extensive 
surgery. However, radiotherapy also 
reduces the rate of local recurrence in 
those patients with negative margins, 
which further suggests that it does not 
arise from overlooked foci of DCIS. We 
propose that the recurrence could arise 
a) from circulating metastatic cancer 
cells lodging in the highly vascular 
surgical bed rich in cytokines e.g., IGF 
I, VEGF (local relapse does harbinger a 
poorer prognosis) or b) genetic 
instability of morphologically normal 
cells adjacent to the tumour. Thus 
although the margins of excision are 
morphologically clear they may be 
genetically unstable. In fact, loss of 
heterozygosity has been already found 
in morphologically normal breast tissue 
around breast cancer.[Deng et al., 
1996]. In addition, the milieu in the 
index quadrant is probably congenial to 
mutagenesis – aromatase activity in the 
index quadrant is higher than other 
quadrants [O'Neill et al., 1988] and via 
oestrogen it can stimulate mutagenesis, 
growth and angiogenesis [Nakamura et 
al., 1996]. 
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27 28 Introduction  
William Halsted’s paradigm of 
systematic centrifugal spread of 
breast cancer was the prevalent 
consensus for nearly 50 years. 
However, the fact that many of his 
patients, even when nodes were not 
involved died from breast cancer, in 
spite of having had a ‘curative 
operation to remove the tumour from 
its roots’, led many researchers, 
Bernard Fisher in particular, to seek 
alternative theories to explain the 
natural history of breast cancer, and 
suggest that less mutilating 
operations might have similar 
outcomes especially in terms of 
survival. In the mid-20
th century, the 
science of randomised clinical trials 
was developing fast and people 
started contemplating testing the 
hypothesis that less radical surgery 
would have equivalent survival 
outcome to the more radical 
approach.  
Around the time when the 
conservative breast surgery was 
being tested in clinical trials, many 
studies tried to explore the reasons 
for recurrence of breast cancer. 
Several autopsy studies since the 
1970s revealed that multiple occult 
cancers were not uncommon in 
thyroid and in the prostates of elderly 
men. A remarkable autopsy study 
from Denmark [Nielsen et al., 1987] 
was reported in 1987. These 
investigators studied 110 women 
who had died of medico-legal 
causes. They simulated a bilateral 
modified radical mastectomy and 
then studied the specimens 
exhaustively. The whole breast was 
sectioned and examined. They 
studied some 60,000 paraffin blocks. 
The median age of these women who 
had mostly died of accidental causes 
was 39 years. Even then 20% of the 
breast specimens revealed microscopic 
breast carcinoma. This was mostly in 
situ carcinoma but 10% of these were 
invasive cancers. The proportion of 
women rose to 1/3
rd in the above 50 age 
group. Clearly, most of these occult 
cancers would not have surfaced in 
these women’s lifetimes. From 
population studies, it can be estimated 
that more than only about a quarter of 
these occult lesions would go on to 
become clinically overt cancers.  
Many studies have investigated the 
multicentric nature of breast cancer in 
mastectomy specimens ([Qualheim and 
Gall, 1957],[Gallager HS and Martin, 
1969], [Hutter and Dim, 1971], [Shah et 
al., 1973], [Rosen et al., 1975], [Lagios, 
1977], [Westman-Naeser et al., 1981], 
[Sarnelli and Squartini, 1986], [Spinelli 
et al., 1992], [Anastassiades et al., 
1993]). Although some of these studies 
([Gallager HS and Martin, 1969], 
[Hutter and Dim, 1971], [Lagios, 1977]) 
used radiography, it was Egan ([Egan et 
al., 1969], [Egan, 1982]) who 
standardised the “correlated 
pathological-radiological” method of 
whole organ analysis which provides 
optimum sampling of breast tissue. The 
incidence of multicentricity found in 
these studies have varied from 18%, 
when 1-2 random samples from each 
quadrant are examined ([Spinelli et al., 
1992]), to 69% when 5mm sections of 
whole breast are examined using the 
Egan’s method ([Egan, 1982]). The 
principal aim of all these studies has 
been to find the incidence of 
multicentric foci (MCF) in the breast. 
Holland et al [Holland et al., 1985]in 
their landmark paper  addressed the 
additional issue of distribution of MCF 
in terms of their distances from the 
primary tumour. They showed that 
MCF were within 2 cm of the tumour 
edge in 53% patients and within 4cm in  
29 90% of patients. The findings 
expressed in this manner gave an 
impression that most MCF are 
present close to the tumour.  
We studied the spatial relationship 
within the breast of multicentric foci 
(MCF) with respect to the primary 
tumour in 30 patients using the 
Egan’s technique. We used two new 
approaches to this problem and 
investigated the spatial distribution 
not only in one dimension in terms 
of distances from the primary 
tumour, but also in two- and three- 
dimensional analysis within the 
respective breast specimen, viz., 1) 
We plotted the relative distribution 
of MCF and the primary tumour 
within the 4 breast quadrants and 2) 
we calculated the volume of breast 
tissue that would be required to be 
surgically excised, expressed as a 
percent of the total breast volume, to 
include all MCF in each breast. 
Since we analysed the spatial 
distribution of all lesions, we chose 
not to differentiate between 
multicentric and multifocal lesions 
[Holland et al., 1990]. 
Method  
Thirty modified radical mastectomy 
specimens were studied. All patients 
had their diagnosis established by 
fine needle aspiration cytology with the 
primary tumour in situ. The patients had 
opted for modified radical mastectomy 
after all available surgical options 
including conservative surgery had been 
explained to them. The specimens were 
studied using the Egan’s correlated 
pathologic-radiological method which 
involves freezing, slicing, radiography, 
grossing and microscopy ([Egan et al., 
1969], [Egan, 1982]). The superior and 
lateral margins of the breast specimen 
and the 6’o clock position were marked 
with ink. Axillary tissue was excised 
and processed separately for dissection 
of axillary lymph nodes, so that the 
patient’s definitive treatment was not 
delayed. The breast specimen was 
placed in a tray, covered with silver foil 
and kept in a -80°C freezer for 4-24 
hours. A transverse line across the 
nipple was marked to indicate the plane 
of x-axis. 
The breast was sliced using a ham 
slicer. 5mm thick slices were cut in 
saggital plane starting from the medial 
side.  The slices were laid on acrylic 
sheets and were radiographed with a 
mammography machine  (100 mA and 
22 kV) using high quality 
mammography plates. The radiologist 
examined the mammograms and 
marked any suspicious areas.  
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Grossing  
The breast specimen was grossed into 5 mm saggital slices 
 
 
5mm slices of a mastectomy specimen  
Breast slices and mammogram of slices 
(not the same patient) 
 
 
Gross examination of the slices was 
then carried out. In every slice, areas 
that looked or felt suspicious to 
palpation, and those marked on 
radiographs, were excised. These 
suspicious areas were fixed in 
formalin, embedded in paraffin and 
studied microscopically. The 
following lesions were considered as 
significant: a focus showing ductal 
hyperplasia with atypia (ADH), ductal 
carcinoma in situ (DCIS), infiltrating 
duct carcinoma (IDC), atypical lobular 
hyperplasia (ALH), lobular carcinoma 
in situ (LCIS) and infiltrating lobular 
carcinoma (ILC). The analysis for 
spatial distribution as described below 
was repeated after exclusion of ADH, 
ALH and LCIS.  
32 For orientation in space, the point on 
the base of the breast directly below 
the nipple was considered the origin 
of the frame of reference. The 
horizontal line from medial to lateral 
side across the nipple projection was 
called x-axis; the vertical line from 
inferior to superior edge across the 
nipple-projection was called y-axis; and 
the line from the origin to nipple was 
called z-axis. All measurements were 
made in centimetres. The slice through 
nipple was numbered 0; the medial 
slices were numbered -1, -2, -3... and 
the lateral slices +1, +2, +3... .  
X 
Y 
Z 
Superior 
Medial 
The origin 
 
Orientation in Space  
Breast was considered to be a hemisphere and the point on 
the base of the breast immediately deep to the nipple was 
considered the origin. X-axis was in the medial to lateral 
direction, y-axis from inferior to superior direction and z-
axis from the base to nipple. 
33 The x-, y- and z co-ordinates of 
centre of each suspicious MCF were 
then measured. Since each slice was 
0.5 cm thick, the slice number 
divided by 2 was equal to the x co-
ordinate in cm. The y and z co-
ordinates were measured on each 
slice.  The radius of the tumour and 
all the 3 co-ordinates of the tumour 
centre were also measured. These co-
ordinates indicated the position 
within the breast of MCF and the 
primary tumour. We then calculated 
1) distances of MCF from the tumour 
edge, 2) the relative distribution of 
primary tumour and MCF in the 4 
quadrants of the breast, and, 3) percent 
breast volume that would be required to 
be excised to include all MCF. The 
Microsoft Excel Ver. 5.0 computer 
programme was used for the above 
calculations. We wish to point out that 
the last two methods of analysis are 
novel and not attempted by previous 
investigators. 
X
Y
Z
Superio
Medial 
The 
X X   - -c co o- -o or rd di in na at te e   = =   s sl li ic ce e   n nu um mb be er r   / /2 2   
Y Y   c co o- -o or rd di in na at te e   
Z Z   c co o- -o or rd di in na at te e   
Orientation in space  
Determination of co-ordinates on each slice 
The following calculations were made: 
1) Distance of each MCF from edge of tumour was calculated using the formula: 
df =    (xf-xt)
2 + (yf-yt)
2 + (zf-zt)
2- rt 
(df = Distance of each MCF from the edge of the tumour, xf,  yf, zf = the co-
ordinates of the MCF, xt, yt, zt =   the co-ordinates of tumour centre and rt = the 
radius of the tumour) 
34 2) The relative distribution of the 
MCF and primary tumour in the four 
quadrants of the breast were 
calculated and plotted in two 
dimensions using the x and y co-
ordinates. 
3) For each case, the total breast 
volume (Vb) and the volume of 
breast tissue that would be required to 
be excised so that all MCF are included 
(Vt) was calculated. We expressed the 
latter as percent of total breast volume.  
bt
wt
rt+df
Planes of 
tumour 
centre
Vt/vb x 100=
percent 
breast volume 
that would 
need excision 
to include the 
MCF
 
Volume calculations: Once the co-ordinates of each MCF and each tumour 
was known, the proportional volume of breast tissue that would be required to 
The following formulae were used for 
this calculation: 
 
Total volume of breast  Vb = 2/3 x Π x h/2 x b/2 x w 
Breast volume that would be 
required to be excised to include 
the farthest MCF 
Vt = 4/3 x Π x (rt +df) x (ht)   
x (bt)   
The percentage of breast volume 
that would be required to be 
excised to include all MCF 
=Vt / Vb x 100 
 
[h= Vertical height, b= Horizontal width and w= Depth of the breast at nipple, ht 
and  bt  = the height and breadth of the breast at the site of the tumour or (rt + df) 
whichever is smaller] 
Statistical analysis was done using 
Chi-square test and standard tests for 
correlation and regression. 
Most mastectomies, all the pathological 
specimen handling, its design and actual 
performance (except microscopy), data collection and analysis was 
performed by the author. 
Results  
The patients’ ages ranged from 28 to 
72 years (mean 49 years). 20 patients 
were post-menopausal and 10 were 
pre-menopausal. The mean breast 
dimensions were: height: 15cm 
(range 9.5 - 18.5cm), breadth: 13cm 
(range 10 - 17cm) and depth: 4.5cm 
(range 3 - 5.5cm). Mean tumour size 
was 2.98cm (range 1.5 - 5cm). Mean 
breast volume was 458cc (range 164 
- 747cc). We calculated that if the 
tumours were excised with a 0.5 cm 
margin, the excised tissue would 
constitute on an average 9% of the 
total breast volume. This suggested 
that, on average, the patients 
included in the study would have 
been suitable for conservative 
surgery, although that was not the 
entry criteria for the study and in 
fact, 3 patients’ tumours were 4cm 
diameter and one was 5cm diameter; 
these would not have been suitable 
for breast conserving surgery. 
A total of 667 blocks were prepared 
from the 30 breast specimens. 
Nineteen breasts were found to harbour 
MCF. A total of 54 multicentric foci 
(MCF) were detected. There were 21 
foci of hyperplasia without atypia, 
which were not included for analysis. 
Of the 54 MCF, 18 (33%) were detected 
by radiography, and 28 (52%) were 
detected by gross inspection and 
palpation and 8 (15%) by both. 
Of the 30 primary tumours, 27 were 
infiltrating duct carcinomas (IDC) and 3 
were infiltrating lobular carcinomas 
(ILC). Of the 54 MCF, 4 were ADH, 16 
were DCIS, 17 were IDC, 11 were 
LCIS and 6 were ILC. There were no 
foci showing ALH. Of 36 MCF with 
IDC as primary, 35 were ductal in 
origin and 1 was ILC. Of 18 MCF with 
ILC as primary, 16 were lobular in 
origin and 2 were ADH. The most 
malignant histological type of MCF in 
each breast is given in the Table 1. The 
histological type of MCF (whether 
infiltrating or in-situ) was not related to 
its distance from the edge of primary 
tumour nor to the percent volume of 
breast tissue that would be required to 
be excised to include the MCF. 
 
Table 1: The Most adverse histological type of MCF in Infiltrating duct and in 
infiltrating lobular carcinomas 
Primary tumour  The most adverse histological type of MCF 
 IDC  ILC  DCIS  LCIS  Nil 
IDC  (27)  9 1 6  -  11 
ILC (3)   -  2  -  1  - 
 
IDC= Infiltrating Duct Carcinoma, ILC= Infiltrating Lobular Carcinoma, DCIS= 
Ductal carcinoma in situ, LCIS= Lobular carcinoma in situ, MCF=Multicentric 
focus 
 
36 We investigated whether MCF were 
generated by lymphatic embolization 
from the primary tumour. Lymphatic 
emboli were present within the 
primary tumour in 3 of the 27 
primary IDCs. However, only 1 out 
of these 3 breast specimens 
harboured an MCF, and this too was 
a focus of DCIS. On the other hand, 
none of the 9 specimens that had 
IDC as MCF had lymphatic emboli 
in the primary tumour, suggesting 
that MCF were not emboli from the 
primary tumour but rather were 
independent malignant foci. In 
addition, in our analysis of spatial 
distribution in three dimensions as 
given below, we did not find any 
evidence of communications between 
the primary tumour and MCF. 
Distance calculation: We found that 
53% of patients had all MCF within 
2cm; 67% within 3cm, 80% of within 
4cm and 90% within 5cm. Thus, MCF 
would be left behind in 47% of the 
patients if the primary tumour were to 
be excised with a 2cm margin; in 33% 
with a 3cm margin and in 20% with a 
4cm margin and 10% with a 5cm 
margin. These findings are similar to 
those observed by Holland et al, 1985 
(Table 2). 
Table 2: Percent patients in whom MCF would be left behind with increasing 
excision margin of primary tumour 
Excision margin of 
primary tumour 
 
% patients in whom MCF would be left behind 
  Holland et al, 1985  Present series 
2 cm  42%  47% 
3 cm           17%            33% 
4 cm           10%            20% 
5cm            -              10% 
 
Relative Distribution of MCF and 
Primary tumour:  On calculating the 
relative distribution of MCF and 
primary tumour within the 4 
quadrants of the breast, we found 
that while the primary tumour was 
most common in the upper outer 
quadrant, MCF were widely 
distributed in all the 4 quadrants of 
the breast.  
When considered in terms of 
conventional quadrants, out of the 19 
cases that harboured MCF, 14 had MCF 
outside the index quadrant (a 90° sector 
of breast which had the primary tumour 
in its centre).  
The distribution of the primary tumour 
and MCF in the 4 quadrants was 
statistically significantly different (Chi 
sq. =8.65, p =0.034) (Table 3). Table 3: Relative Distribution of primary tumour and MCF in breast quadrants 
Quadrant Primary  tumour MCF 
Upper outer   14  13 
Upper inner  5  16 
Lower outer  10  14 
Lower inner  1  11 
The distribution of primary tumour and MCF in the 4 breast quadrants of the breast was 
significantly different. Chi-square = 8.65   p=0.034. 
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Relative 2-dimensional distribution of primary tumours and 
multicentric foci in the four breast quadrants 
 
Volume calculation: We calculated 
the proportion of patients in whom 
MCF would be left behind with 
increasing volume of breast tissue 
excised with the tumour (expressed 
as percent of total breast volume). 
When all patients were considered, 
18/30 (60%) had MCF beyond 10% of 
the breast volume, 15/30 (50%) had 
MCF beyond 25% of the breast volume 
(a quadrant), and 7/30 (23%) had MCF 
beyond 50% of total breast volume 
(Table 4).  
 Table 4: Percent patients in whom MCF would be left behind with increasing 
volume of breast tissue excised. 
% of total breast 
volume excised 
% patients in whom MCF 
would be left behind 
10% (~lumpectomy)  60% 
25% (~quadrantectomy)  50% 
50%   23% 
 
However, when only those breasts 
which actually harboured MCF were 
considered, then 95% of breasts 
(18/19) had MCF beyond 10%, 79% 
of breasts (15/19) had MCF beyond 
25% (a quadrant), and 37% of 
breasts (8/19) had MCF beyond 50% 
of breast volume including the 
tumour. Of the 15 cases that had 
MCF beyond the index quadrant, 7 
were infiltrating, (5 IDC + 2 ILC), 7 
were in-situ (6 DCIS + 1 LCIS) and 
1 was ADH.  The discrepancy (14 
vs. 15) between the results of 
analysis in 2- and 3-dimensions is 
related to the fact that in one case the 
MCF was within the anatomical 
quadrant as conventionally defined 
in two dimensions, but was beyond 
25% breast volume which included 
the primary tumour. 
We then calculated the distribution of 
the 54 MCF found in the study within 
increasing volumes of breast tissue 
around the tumour. Tables 5 and 6 show 
these distributions for primary IDC and 
primary ILC tumours, respectively. 
They show that the number of MCF 
contained within 10%, 11-25%, 26-50% 
and >50% of the breast volumes around 
the tumour were similar, indicating that 
MCF are scattered throughout the 
breast. The histological type of MCF 
(non-infiltrating or infiltrating) also had 
similar distributions within increasing 
volumes of breast tissue around the 
tumour. After exclusion of ADH and 
LCIS, these results remained 
unchanged. Atypical Lobular 
Hyperplasia (ALH) was not detected in 
any of the sections. Table 5:  Number of MCF contained within increasing volumes of breast tissue 
around the tumour, in 27 cases with primary IDC 
% breast volume 
around the tumour 
MCF contained within that breast volume 
  Total No.  Histological type of MCF 
    ADH  DCIS     IDC  ILC 
≤10%   8  -  5         3  - 
11-25%   10  -  4         5  1 
26-50%   13   1  5         7  - 
>50%   5  1  2         2  - 
 
Table 6:  Number of MCF contained within increasing volumes of breast tissue 
around the tumour, in 3 cases with primary ILC. 
% breast volume 
around the tumour 
MCF contained within that breast volume 
  Total No.  Histological type of MCF 
    ADH  LCIS        ILC 
≤10%   6  -  5            1 
11-25%   2  -  1            1 
26-50%   6   1  5            - 
>50%   4  1  -   3 
ADH= Ductal Hyperplasia with Atypia, DCIS= Ductal carcinoma in situ, ILCS= 
Lobular carcinoma in situ, IDC= Infiltrating Duct Carcinoma, ILC= Infiltrating 
Lobular Carcinoma,  MCF=Multicentric focus 
 In breast specimens that had IDC as 
primary tumour, presence of 
multicentricity was related to tumour 
size. Four out of 12 breast specimens 
with tumours < 3cm harboured MCF, 
while 12 out of 15 breast specimens 
with tumours ≥ 3cm harboured MCF 
(p=.02). However, the actual number 
of MCF present in each breast or 
their distance from the edge of the 
primary tumour were not related to 
the tumour size. The volume of 
breast, expressed as percent of the 
total breast volume, which would be 
required to be excised to remove all 
MCF, also did not correlate with the 
size of primary tumour. MCF were 
present beyond 25% of breast 
volume including the tumour in 7/15 
breasts with primary tumour <3cm 
and in 8/15 breasts with primary 
tumour  ≥ 3cm. There was no 
relationship between nodal status, 
age or menopausal status of the 
patient and MCF (their presence, 
actual number, distance from tumour 
edge, or, the percent volume of 
breast tissue that would be required 
to be excised to include it with the 
excision of primary). 
Discussion    
We found that 63% of our patients 
harboured multicentric foci in 
addition to the primary tumour. This 
incidence is similar to that found by 
other workers using the Egan’s 
technique (Lagios [Lagios, 1977], 
n=211: 56%, Egan [Egan, 1982],   
n=118: 69% and  Holland [Holland 
et al., 1985], n=282: 63%). Although 
in our study, breast specimens with 
primary tumours ≥3cm were more 
likely to harbour MCF than those 
with smaller tumours (p=0.02), there 
was no relationship between the 
tumour size and either the number of 
MCF or their distances from the tumour 
edge. When calculated according to 
breast volumes, there was no correlation 
between tumour size and the volume of 
breast tissue that would need to be 
surgically excised to include all MCF 
(expressed as % of total breast volume). 
There was no relationship between the 
histological type of MCF (whether 
infiltrating or in-situ) and the distance 
of MCF from the tumour edge or 
percent volume of breast tissue that 
would be required to be excised to 
include the MCF with the primary 
tumour (tables 5 and 6).  Age or 
menopausal status of the patient were 
not related to the presence, number or 
distance of MCF from the tumour edge. 
It is noteworthy that although 
radiography detected 33% of the MCF, 
they were missed in 52% of cases. Our 
findings regarding the distribution of 
MCF around the primary tumour, 
expressed as distances from the tumour 
edge, are similar to that of Holland et al, 
[Holland et al., 1985](Table 2).  We 
found that 53% of patients had MCF 
within 2cm, 80% of within 4cm and 
90% within 5cm of the tumour edge. 
The difference between our study and 
that of Holland et al (1985), however, 
lies in the fact that the latter group did 
not take the size of the breast into 
account, and expressed the distribution 
of MCF in only one dimension. 
Expressed in this way, in one 
dimension, an impression is created that 
MCF are mostly present around the 
primary tumour. Our approach to the 
analysis in 2- and 3-dimensions makes 
the following novel observations. 1) 
The relative distribution of primary 
tumour and MCF in the 4 breast 
quadrants was significantly different 
(p=0.034). We found that the primary 
tumour was more common in the upper 
outer quadrant while MCF were widely 
distributed in all 4 quadrants, suggesting that MCF are widely 
scattered throughout the breast.  2) 
When the 19 breasts that actually 
harboured MCF were considered, in 
as many as 79%  (15/19) MCF were 
present beyond 25% of breast 
volume including the tumour (index 
quadrant). When all patients were 
considered, half (15/30) harboured 
MCF beyond the index quadrant. 
Thus, even if a quadrant were 
excised, 50% of patients would still 
have MCF left behind. 
The above findings are at variance 
with the suggestion made by Holland 
et al that MCF are present in the 
index quadrant in close proximity of 
the primary tumour in 90% of cases 
and therefore could be responsible 
for local recurrence. Is our sample 
size of too small and our findings a 
result of play of chance?  Let the 
hypothesis be, as has been suggested 
by Holland et al (1985) that in 90% 
of cases MCF are contained within 
the index quadrant. If this hypothesis 
were true, then 25% of breast 
volume including the tumour would 
contain all MCF in 90% of breast 
specimens. Thus, we should have 
found all MCF within 25% of breast 
volume in 27 of the 30 (90%) breast 
specimens.  In actual fact, we found 
that all MCF were contained in the 
index quadrant in only 15 of 30 
(50%) breast specimens. The 
probability of our finding being due 
to play of chance is 1 in 1500 (27:3 
vs. 15:15, chi sq. =11.4, p=0.0007). 
Our finding that MCF lie beyond the 
index quadrant in 50% of breast 
specimens may have implications for 
breast conservation therapy (BCT). 
In large series of breast conservation 
studies, it has been seen that >90% 
of early breast recurrences occur in 
the quadrant that harboured the 
primary tumour ([Harris et al., 1981], 
[Clark et al., 1982], [Schnitt et al., 
1984], [Clarke et al., 1985], [Kurtz et 
al., 1989b], [Boyages et al., 1990], 
[Fowble et al., 1990], [Fisher et al., 
1992], [Clark et al., 1992], [Veronesi et 
al., 1993]). This is true whether or not 
radiotherapy is given ([Clark et al., 
1992]). If recurrences were to arise 
from MCF, then we would expect 50% 
of recurrences to occur in other 
quadrants. Since this is not the case, we 
conclude that early recurrences do not 
arise from MCF. Therefore, MCF in the 
index breast should behave in a fashion 
similar to putative MCF present in the 
opposite breast. This is borne out by the 
fact that recurrence rate in the 
remaining quadrants of the index breast 
is identical to that in the opposite breast 
(1% per year in both cases,[Kurtz et al., 
1989a]). We believe that recurrences in 
the index quadrant arise from a) the 
original primary tumour cells left 
behind, b) a new disease arising as a 
result of chromosomal instability, or c) 
from circulating metastatic cancer cells 
lodging in the highly vascular bed of 
the excised tumour. The latter is 
supported by the fact that patients who 
have local relapse in the breast after 
BCT have a relatively poor prognosis 
([Fisher et al., 1991b], [van Dongen et 
al., 1992]). 
In any case, if multicentric foci (MCF) 
do not give rise to breast recurrence 
then why should we treat them with 
either mastectomy or whole breast 
radiotherapy? It is as necessary or as 
unnecessary as treating the contralateral 
breast! It appears that local treatment of 
breast cancer could probably suffice to 
be truly local- at and around the site of 
the primary tumour!  
42 Summary  
We studied the spatial relationship 
within the breast between 
multicentric foci (MCF) and the 
primary tumour in 30 modified 
radical mastectomy specimens using 
Egan’s correlated pathological-
radiological method using 5mm 
slices of the whole breast. The 
relative positions within the breast of 
the primary tumour and MCF were 
used to calculate the relative 
distribution of primary tumour and 
MCF in the 4 quadrants of the breast 
and the percent breast volume that 
would be required to be excised to 
include all MCF. Nineteen (63%) 
breasts harboured MCF. The relative 
distribution of primary tumour and 
MCF in the 4 breast quadrants was 
significantly different (p=0.034). 
MCF were present beyond the index 
quadrant (25% of breast volume 
including the tumour) in as many as 
79% (15/19) of breasts that harboured 
MCF; and, in half the cases (15/30) 
when all breasts were considered. This 
is in variance with the suggestion put 
forward previously that MCF are 
contained within the index quadrant in 
90% of cases. Although the number of 
patients in the present series is small, 
the probability of our finding being due 
to play of chance is 1 in 1500. In large 
series of breast conservation studies 
>90% of early breast recurrences have 
been found to occur in the index 
quadrant. Our finding, that in half the 
patients (15/30) MCF are present in 
quadrants other than the index quadrant, 
suggests that MCF do not give rise to 
early breast recurrence. 
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Can magnetic-resonance imaging detect the 
clinically relevant multicentric foci? 
45 46 Introduction  
We have shown that when 
mastectomy specimens are examined 
by detailed radiological-histological 
correlational methods, small 
additional invasive or in-situ cancer 
foci are found in over 60% of 
patients; 80% of these lie remote 
from the index quadrant [Vaidya et 
al., 1996]. Since 90% of local 
recurrences occur in the index 
quadrant, we have questioned the 
clinical relevance of these small 
cancer foci that remain dormant for a 
very long time.[Baum et al., 1997]. 
Since most of these small cancers 
may not cause clinical cancers and 
endanger the patient’s life we wished 
to investigate whether there is any 
non-invasive and pre-operative test 
that might reveal which of these 
dormant cancers are clinically 
relevant. 
Angiogenesis is a prerequisite for 
tumour growth beyond 1–2 mm in 
diameter and is directly correlated 
with poor prognosis. [Weidner et al., 
1991].  Unlike radiography that 
relies on tissue density for detecting 
cancers, magnetic resonance imaging 
(MRI) relies on tumour vascularity 
and vascular permeability [Buadu et 
al., 1996], as demonstrated by 
contrast enhancement. MRI is highly 
sensitive for breast cancer detection 
but its specificity is relatively low 
[Heywang-Kobrunner et al., 1997]. 
We hypothesised that if any of these 
occult tumours were detectable by 
MRI, then these would be the ones that 
were potentially more dangerous. In 
that case, we would be able to 
geographically map these “more 
dangerous” tiny tumours and tailor 
treatment accordingly. We therefore 
tested how many of the occult tumours 
that are detected by the detailed 
radiological-histological method were 
detected by MRI. 
Method 
We evaluated prospectively whether 
small enhancing foci, seen separately 
from the main tumour on contrast-
enhanced MRI, were indeed cancer foci 
and whether MRI could detect all 
cancer foci identified by radiological-
histological correlation. We studied ten 
patients. All patients underwent 
preoperative contrast-enhanced breast 
MRI. High resolution transverse T1-
weighted 3D FLASH images (TR=18 
ms, TE=7 ms, FA=40°, TA=4 m 56 s, 
FOV=410 mm) before and after an 
intravenous bolus hand injection of 
dimeglumine gadopentetate (Magnevist, 
0·2 mL/kg) were acquired at 1·0 T 
(Siemens Magnetom Scanner 42 SP 
with dedicated breast coil). The 3D 
volume was 64 mm thick with 32 
partitions giving an effective slice 
thickness of 2 mm and this was 
sufficient to cover the entire breast in 
all cases. All patients underwent 
surgery for the breast cancer. Modified 
radical mastectomy was performed in 
four patients and wide local excision in 
six patients.  
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Specimen slices and mammograms of slices 
The surgical specimens were fixed 
and sliced at 5 mm intervals in the 
same plane as the MRI. An 
experienced breast pathologist 
performed routine histopathological 
examination and the remaining 
material was radiographed. Two 
observers (Jayant Vaidya and 
Michael Douek) identified 
radiological abnormalities 
(calcifications, densities, or 
spiculations) and all lesions that 
were deemed suspicious by either 
observer were mapped on to the 
specimen, sampled and examined 
histologically. A specialist 
radiologist (Margaret Hall-Craags) 
reviewed MRI images independently 
and findings were compared with 
histopathology results. 
Results 
On MRI, 19 enhancing foci separate 
from the main tumour were identified in 
seven out of ten patients (figure). On 
radiography of specimen slices, 71 
suspicious areas were sampled and 
histological examination revealed 15 
areas of ‘occult’ cancers in five 
patients. Of these 9 were in-situ and 6 
were invasive cancers. All five patients 
with cancer foci on histopathology were 
amongst the seven patients who had 
enhancing foci on MRI. In two of these 
five patients, the tumour was 
surrounded by widespread enhancement 
on MRI and all 11 (four+seven) areas 
sampled showed cancer foci. In all wide 
local excision specimens, the enhancing 
foci on MRI were within 11 mm of the 
tumour edge and therefore within the 
resected specimen.  
 
 
48 MRI Number  of 
patients 
Number  
of foci 
Separate MRI 
foci absent (3) 
No enhancement  3  0 
Focal enhancement  5  8  Separate MRI 
foci present (7)  Multiple enhancing foci  2  11
* 
Total 10  19
* 
 
*In the 2 patients with multiple enhancing foci, all 11 histological samples were 
found to harbour invasive or in-situ cancer and a count of 11 was awarded to MRI 
for comparison with histology. 
Histology Number  of 
patients 
Number  
of foci 
Separate histological foci 
absent (5) 
 5  0 
DCIS only  2  5 
IDC only  1  1 
Separate histological foci 
present (5) 
 
IDC + DCIS  2  5 IDC  
+ 4 DCIS 
Total  10 15 
 
N.B. Thus 5 specimens showed separate foci on histology- all these were had 
shown enhancement on MRI. 
A  B 
T1-weighted breast MRI before (A) and after (B) contrast-enhanced MRI -
Two separate enhancing foci (small arrows) are visible away from the 
primary tumour (large arrow) after contrast enhancement. Discussion 
Our data suggest that enhancing foci 
on MRI represent cancer foci and 
that MRI detected 14 out of 15 
cancer foci (sensitivity 93%). Of 
course, this is based on the 
assumption that the radiological-
histological correlational method is 
indeed the gold standard. If that is 
so, the specificity of MRI for tumour 
detection would be 79% (15/19). 
However, bearing in mind that the 
spatial resolution of MRI is of the 
order of 1–2 mm, it may yet transpire 
that MRI could have even greater 
sensitivity and specificity that may 
become apparent with an even more 
obsessive sampling of the specimen. 
Our findings provide strong 
circumstantial evidence that small 
enhancing foci on MRI represent 
cancer foci and that MRI is highly 
sensitive for the detection of invasive 
or in-situ cancer foci.  
This was contrary to our hypothesis 
that MRI might detect only a subset 
of the occult cancers in the breast- 
mainly those that might have 
stimulated local angiogenesis and are 
therefore more vascular. We thus 
realised that MRI might not be able 
to identify a subset of occult tumours 
that are clinically relevant allowing 
us to selectively treat patients. We 
found that MRI on the other hand is 
highly sensitive in detecting 
multicentric foci. Finding these 
enhancing foci on pre-operative MRI 
may prompt many a surgeons to advise 
their patients to undergo a mastectomy. 
The number of MRI machines is 
increasing worldwide and the additional 
cost of a breast coil is insignificant 
compared to the cost of the MRI. So we 
fear that when MRI is used for pre-
operative evaluation in breast cancer, 
many unsuspecting women will be 
found to have these ‘enhancing foci’ in 
their breasts. The surgeon will be in a 
dilemma and to be on the safe side 
might advice a mastectomy to a woman 
who might otherwise safely have had a 
breast conserving therapy, reversing the 
trend of the last 30 years.  
On the other hand, the high sensitivity 
of MRI could be used more 
constructively. Our results suggest that 
MRI could be used to investigate 
prospectively the clinical significance 
of unresected cancer foci in order to 
convincingly determine their natural 
history in the context of breast 
conserving surgery. A study in which 
women found to have enhancing foci on 
MRI but have no other evidence of 
multicentric tumours on clinical or 
radiological grounds are prospectively 
followed up, would be deemed ethical 
because breast MRI is still considered 
experimental for preoperative planning 
of surgery. In a few years we might be 
able to ascertain whether any of these 
latent occult tumours progress to an 
actively progressive phenotype.  
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The novel technique of intra-operative 
radiotherapy 
51 52 Introduction 
 
We have used a novel technology to 
deliver therapeutic radiation. The 
technique employs a miniature 
electron-beam driven x-ray source 
(the Photon Radiosurgery System 
(PRS) developed by the Photoelectron 
Corporation in Massachusetts, USA) 
that delivers low energy (50Kv) x-
ray radiation  directly to the tumour 
site/ tumour bed from the tip of a 
10cm long, 3.2mm diameter, tube. 
Being soft x-rays, there is quick 
attenuation of the radiation within 
tissues so that the dose is inversely 
proportional to the 3
rd power of the 
distance. Such quick attenuation 
reduces the damage to surrounding 
normal tissues and minimises the 
need for radiation protection to the 
operating personnel. The x-ray 
production itself is controlled very 
precisely and monitored in three 
ways – one within the X-ray source, 
one kept on the operating theatre 
table and third using thermo-
luminescent detectors (TLDs). The 
portability of the device enables 
radiation treatments to be delivered 
precisely and directly to the inside of 
tumours, or the tumour bed, while at the 
same time, minimising unwanted 
irradiation of surrounding tissue. 
Since the radiation consists of soft X-
rays, the beam is rapidly attenuated to 
reduce the dose to more distant tissue. 
Full measurements and calibration are 
carried out in a water phantom and in 
materials that simulate the radiation 
absorption properties of the breast. 
Depending upon the size of the surgical 
cavity, various sizes of applicator spheres 
are available and for each size, the 
radiation received is proportional to the 
time the machine is switched on and left 
in situ. The precise dose rate depends on 
the diameter of the applicator and the 
energy of the beam, both of which may 
be varied to optimise the radiation 
treatment. For example, a dose of about 5 
Gy can be delivered in about 20 minutes 
at 1cm from the margins of a 3.5 cm 
cavity after wide local excision of the 
tumour.  
The whole assembly is small and 
lightweight (Weight =1.8 Kg, 
Dimensions: X-ray generator body 7 x 
11 x 14 cm; applicator: 16 cm long 
conical applicator sheath with a 2 to 5 
cm applicator sphere at the tip) and 
hangs dependently from a mobile 
gantry in perfect balance remaining 
steady wherever it is positioned. If 
necessary, the chest wall and skin can 
be protected (95% shielding) by radio-
opaque tungsten-filled polyurethane 
caps, which can be cut to size on the 
operation table, another advantage of 
using soft x-rays. With this elegant 
approach the pliable breast tissue 
around the cavity of surgical excision 
wraps around the radiotherapy source, 
i.e. the target is ‘conformed’ to the 
53 source. This simple, effective 
technique avoids the unnecessarily 
complex and sophisticated 
techniques of using interstitial 
implantation of radioactive wires to 
provide high dose radiotherapy to the 
tumour bed or the even more 
complex techniques necessary for 
conformal radiotherapy by external 
beams with multi-leaf collimators 
from a linear accelerator. The quick 
attenuation of the radiation dose 
allows the treatment to be carried out 
in unmodified operating theatres. The 
walls usually incorporate shielding for 
microwave radiation from electronic 
equipment such as mobile phones and 
such walls provide enough protection to 
the staff. Furthermore, the biologically 
effective dose (BED) attenuates rapidly 
so that the highest radiation dose is 
received by tissue nearest the primary 
tumour and a much lower dose at the 
skin. Thus in theory, the biological 
effect and cosmetic outcome could be 
improved. 
The Physics and Radiobiology 
The miniature x-ray source (XRS) 
developed for the Photon 
Radiosurgery System contains a 
proprietary miniature x-ray tube, a 
high voltage power supply, and the 
associated electronic circuitry 
required to control and monitor the 
operation of the x-ray tube.  
The distal end of the x-ray tube is a 
thin probe extending outside the 
XRS enclosure. X-rays are emitted 
from the tip of the probe, which is 
inserted into the site to be irradiated. 
Within the XRS, an electron gun 
accelerates electrons towards a gold 
target at the tip of the probe. 
The last 2cm of the probe are made of 
beryllium, an x-ray transparent material. 
When the electrons strike the target, x-
rays are generated in a nearly spherical 
distribution centred at the tip of the 
probe. The x-ray tube (XRT) is a 
miniature electron gun and electron 
accelerator. Electrons are generated and 
accelerated towards a gold target at the 
end of a long, thin drift tube or probe. 
The operation of the x-ray tube requires 
that the filament be heated which, in 
turn, heats the cathode and an excess of 
electrons is generated by thermionic 
emission. Electrons produced by the 
gun are accelerated to the desired 
energy, and with the help of steering 
   
Schematic diagram of the applicator      The pliable breast tissue- wraps 
around the source 
54 coils, directed down an evacuated 
field-free tube towards a thin, gold 
target.  Anodes located in the 
electron gun assembly provide the 
accelerating potential of the electron 
beam. The vacuum envelope of the 
system is composed of a brazed 
metal/ceramic structure for good 
thermal and mechanical shock 
tolerance. The electron optics of the 
device are designed to provide a 
highly focused, stable spot of 
electrons at target. Following 
acceleration, the electrons enter a 
10cm long, 3mm diameter "needle" 
type, evacuated drift tube. The drift 
tube or probe passes through the 
deflection coils and is terminated 
with a beryllium (Be) window that is 
transparent to x-rays. The electron 
beam is directed to a point on the 
target. When fast electrons interact 
with matter, part of their energy is 
converted into electromagnetic 
radiation in the form of characteristic 
and bremsstrahlung radiation. The 
fraction of the electron energy 
converted into bremsstrahlung 
increases with increasing electron 
energy, and is largest for absorbing 
materials of high atomic number (the 
atomic number for gold is 79). This 
is the same process that results in the 
production of x-rays within 
conventional x-ray tubes. The result 
of this is the production of a 
symmetric distribution of radiation 
around the tip of the probe. 
The physics, dosimetry of this soft x-
ray device have been well studied and 
the probe has already been tested in 
pre-clinical studies.  
Radiobiological experiments [Astor et 
al., 2000] using cell cultures have 
suggested that the radiobiological 
effectiveness (RBE) of the PRS 
system is between 1.2 and 2.5. This 
was in agreement with 
microdosimetric analysis and modelling 
[Brenner et al., 1999]. The PRS radiation 
is found to induce both necrotic and 
apoptotic cell death in addition to rapid 
cell death through non-apoptotic 
pathway.[Kurita et al., 2000]. Animal 
experiments have demonstrated that PRS 
can induce well demarcated ablation in 
canine liver and kidney [Koniaris et al., 
2000;Solomon et al., 2001]. 
Thus, the characteristics of this 
radiation are:  
•  Low energy x-rays (50keV 
maximum) used to ensure minimal 
radiation dose to adjacent normal 
tissues and critical structures.  
•  Low voltage supply, 
approximately 12V, ensures no 
electrical hazard to the operator.  
•  The XRS is lightweight and 
portable, which makes it easily 
adaptable to any clinical application.  
•  The low energy x-rays produced 
by the XRS are easily shielded, and 
there are minimal radiation protection 
requirements in the operating room.  
•  The PRS has been cleared by the 
FDA after the report of this project, to 
be marketed for radiotherapy anywhere 
in the body and also carries a CE Mark 
allowing it to be marketed in the 
European Community for radiotherapy 
applications.  
•  We have developed a range of 
applicators from 2.5cm to 5cm for use 
55 in the breast, as detailed in the next 
section. 
•  A range of special Quality   
Assurance tools is supplied with 
every system to ensure maximum 
safety and ease-of-use. These are 
necessary as a result of the x-ray 
source's unique treatment geometry.  
The radiation dose at various distances
from the cavity margin varies as shown 
in the table, for the simulated assembly. 
 
Standard dosimetry table:  Calculations for a 3.5 cm diameter spherical applicator and a 
period of irradiation of 21 min as measured from the periphery of the sphere in a breast phantom. 
(PRS operating parameters:50Kv)  
PE probe (Gy)  External beam 
radiotherapy (Gy) 
Whole breast 
radiotherapy (Gy) 
Distance from the 
surface of the 
applicator  
PD BED  PD  BED  PD  BED 
0.1 cm  15  165  10  12  50  60 
0.2 cm  12.5  121  10  12  50  60 
0.5 cm  8.75  59  10  12  50  60 
1 cm  5  21.7  10  12  50  60 
PD= Physical x-ray dose, BED= Biologically effective dose, . 
The biologically effective dose (BED) is given by the equation (Dale 1985), BED= D x (1 + 
(d/(α/β)), where D is the total physical dose, d is the physical dose per fraction and α/β is the 
biological coefficient which is 10 for early and tumour effects when radiotherapy is delivered in 
fractions of about 2Gy. For a single dose, we have assumed the value of α/β to be equal to 1.5. It 
could actually range from 1.5 to 4. 
 
 
Dosimetry around the bare probe in water (in terms of dose rate) 
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56 Dosimetry around the applicator (in terms of physical dose with a prescription of 
5Gy at 1cm)  
Physical dose in Gy 
0  5  10  15  20 
1 
20 Gy at 1mm  5 
Distance 
from 
applicator 
surface in 
mm 
9 
13 
17 
21 
1 Gy at   27mm  25 
 
Positioning the X-ray source  
It is important that the x-ray source 
(XRS) is very stable and does not 
move at all during the treatment. It 
was thought that the movement of 
the chest wall during respiration 
would cause enough displacement of 
the x-ray source and the applicator 
within the tumour cavity to 
jeopardise the correct dosimetry. 
Hence a special suspending gantry 
was designed.  
This is a large gantry that suspends 
the XRS with the help of a hydraulic 
counter-balance system such that it 
remains stable in any position that it is 
placed. While doing treatments, it was 
noticed that in actual fact, there is 
hardly any movement of the XRS 
during normal respiration and therefore 
there is no need for the large, heavy and 
awkward gantry. A simple arm to fix 
the XRS to the operating table would be 
adequate. Subsequently, the PeC 
Company established a strategic 
alliance with Carl-Zeiss and the 
commercial device uses a multi-armed 
device to hold the XRS in position the 
system being called INTRABEAM.  
The special prototype gantry and the new Intrabeam 
Development of the machine for 
Brain tumours 
The machine was originally 
developed for the treatment of brain 
tumours using stereotactic frames. 
This development started in 1992 
and the machine was used for 
treatment of brain tumours since 
1994.  [Butler et al., 1998;Cosgrove et 
al., 1997;McDermott et al., 
1996;Douglas et al., 1996] [Cosgrove 
et al., 1997;Cosgrove et al., 1999] 
Conceptualisation and adaptation 
for the breast: use of special 
applicators 
In the spring of 1996, we began a 
dialogue with the company to adapt 
the machine for use in the breast. 
This would need to adapt the 
technique for use in a very different 
part of body. As opposed to the 
brain, where there are bony landmarks 
whose relationship to neural structures 
is relatively fixed, breast is a very 
mobile organ. There are no structures - 
reference points – that have a constant 
relationship to a tumour bed. We felt 
that movement of the chest wall during 
respiration would also change the 
configuration the chest wall enough to 
make a significant difference. So we 
had to apply a different strategy. Firstly 
we assessed the shape of the cavity. 
Shape of the cavity after wide local 
excision 
We assessed the shape of the cavity 
after wide local excision using a fast 
setting wound dressing material 
(Cavicare). Within 15-20 seconds of 
mixing the two components the foam 
that is placed into the cavity starts 
setting and within 1-2 minutes, the cast 
of the cavity can be removed to be 
studied. We found the shape of the 
58 cavity to be rather irregular; 
nevertheless the shape was that of a 
multisided pyramid with the base 
resting on the posterior/deep wall. 
We also realised that this cavity 
could easily be made spherical if the 
pliable breast tissue were wrapped 
around a rigid applicator so that the 
tissue immediately beyond the 
surgical excision would be closely 
applied to the surface of the 
applicator and thus get the highest 
dose of radiation. 
The technique of giving intra-
operative radiotherapy  
Sterilisation issues 
In the first few cases using the 
Photoelectron's Photon Radio 
Surgery (PRS) X-Ray Source (XRS), 
we sterilised the whole X-ray source. 
This was done using Plasma 
sterilisation. Sterilising the XRS 
meant that the it had to be delivered 
to the Central Sterilisation 
Department at least 24 hours in 
advance and, when it was returned, it 
needed to be re-calibrated in the 
sterile atmosphere of the operation 
theatre by the medical physicists 
team downed in sterile gowns and 
gloves. This took about 1 hour of 
additional time of the physicists on 
the day of the surgery. After the first 
few cases, we also found that the tip 
of XRS accumulated an oxidative 
product of Molybdenum viz., 
Molybdenum trioxide. Molybdenum 
trioxide is potentially toxic - irritant 
to eyes and upper aero-digestive 
system and there is some evidence of 
its carcinogenicity in mice and male 
rats. A solution to these problems 
was to enclose the XRS in a large 
sterile plastic bag. We used a large 
transparent plastic bag (38.1cm 
x63.5cm x99cm or 15x25x39 inches, 
40µ thick) with a pleat on either side- 
that is ubiquitous in our operation 
theatres, easy to sterilise and costing 
almost nothing. The XRS was 
calibrated on the previous day at the 
convenience of the medical physicists 
and kept un-sterilised. The applicators 
were sterilised, each in separate covers. 
During surgery, the sterile plastic bag 
was modified- a hole was cut at its 
bottom - to accommodate the applicator 
sphere. Then, the applicator was 
inserted in plastic bag such that the 
sphere protruded out of it and the 
conical sheath remained inside the bag. 
The edges of the newly created hole 
were now sealed with sterile tape to the 
junction of the applicator globe and 
shaft. The bag was then inverted inside 
out. The XRS was now lowered into the 
applicator and locked in and the power 
supply cord attached. The bag was now 
lifted over the XRS so that it covered 
the XRS. The bag was kept in place 
with sterile plastic tapes. This procedure 
of covering the XRS was inspected and 
approved by the Consultant 
Microbiologist. This adaptation 
considerably reduced the time the 
physicists needed to spend in the 
operating theatre. 
Operative technique 
A single prophylactic dose of 
intravenous antibiotic (Cefuroxime 
1.5gm) is given at induction of 
anaesthetic. The wide local excision 
(WLE) is carried out the usual way and 
immaculate haemostasis achieved. The 
depth of excision always includes the 
pectoralis fascia so that there is no 
breast tissue beyond the deep margin. 
This is especially important on the left 
side. One or two gauze pieces are left in 
the breast wound and axillary surgery is 
performed. This consists of either the 
59 usual axillary dissection or sentinel 
node biopsy, alone or in combination 
with axillary dissection as part of 
another ongoing clinical trial. 
Haemostasis of the breast wound is 
now rechecked. This is very 
important since, even tiny ooze from 
capillaries can collect significant 
amount of blood over the duration of 
radiotherapy and this could 
potentially cause a distortion of the 
cavity around the applicator. 
Distortion of the cavity can change 
the dose that the target tissues 
receive. In addition we have found 
that the temperature of the cavity 
rises by 2°C from an average of 
32°C that is present in the operative 
cavity in the operating theatre. This 
increase in temperature could dilate 
the blood vessels and cause an ooze. 
The diameter of the cavity is now 
measured with a disposable tape 
measure cut to 4cm or 5cm. This and 
the judgement of how well the breast 
wraps around the applicator – actually 
inserting the applicators in the wound 
and visualising the apposition is very 
useful – will determine the size of the 
applicator. The usual size of the 
applicator is either 3.5, 4 or 4.5 cm. We 
have used the 3 or 5cm applicators only 
a few times.  
 
 
Cavity is measured with a cut tape 
 
 
The applicator is inserted in the cavity to assess the closeness of fit 
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with a No 1 silk mounted on a hand-
held needle. This step is very 
important and needs to be taken very 
carefully because the dose to the 
target tissues depends on how well it 
is taken. This stitch should be taken 
deep to the whole cavity edges, 
through the breast tissue and not in 
the subcutaneous tissues, such that 
on tightening the purse string, the 
skin should not get pulled too close 
(<1cm) to the applicator; at the same 
time, on pulling the purse-string, the 
breast tissue should appose to the 
surface of the applicator and wrap 
around it. It is important to visualise 
and ascertain during this phase, how 
well the target breast tissues appose to 
the applicator surface. It adheres 
naturally. 
If the tumour is on the left side, a 
tungsten-impregnated rubber shield is 
used to cap the applicator, to protect the 
heart and coronary vessels. The 
applicator cap needs to be positioned 
such that it apposes the bare muscle on 
the chest wall.  
 
 
Purse string suture taken with a No 1 silk on a hand-held needle 
 
 
Tumour cavity in a left breast – and the shield being placed on chest wall 
61  
Since the Intrabeam device is not 
sterile, it is wrapped in a sterile 
polyethylene bag. At first, a hole is 
cut at the closed end of the bag for 
the applicator sphere to come out 
which is taped at its neck.  
The bag is now turned inside out. 
Once the purse string and position of 
the gantry is ready, Intrabeam is 
attached to the applicator and the bag 
reversed over the Intrabeam to cover 
it- and taped in place. In the commercial 
device- modelled over this prototype is 
now available with pre-designed holes 
and tapes to cover the Intrabeam device. 
Once the applicator is in place, the 
position of the chest wall shield is 
ascertained, the purse string is tightened 
carefully. Care is taken to ensure that all 
breast tissue in the cavity apposes 
applicator and no part of skin is less 
than 1cm from the applicator. 
 
Applicator is wrapped in sterile polyethylene bag and taped 
 
 
The X-ray source is being inserted into the applicator 
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Purse string is now tied securely  
 
Distance from applicator to skin 
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The whole assembly 
 
 
 
 
 
 
 
 
 
 
 
 
64 Frequently the skin edge flips over 
the applicator. In order to avoid this 
getting excessive radiation dose, a 3-
0 Prolene stitch is now taken in the 
dermis of the skin edge in order to 
pull it away from the shaft of the 
applicator so that it does not come in 
direct contact with the applicator or 
in direct line of the applicator with 
only an air gap in between.  
The minimum distance between skin 
at the site of TLD/RCP and the 
applicator is measured. All care is 
taken that this is not less than 1cm. If 
the cavity is such that the best 
positioned purse string still draws 
one part of the skin too close to the 
applicator then a small piece of gauze 
soaked in saline, and 0.5cm to 1cm 
thick is inserted between the skin and 
applicator such that the gap between the 
applicator surface and the skin is at 
least 1cm. If the tumour is very 
superficial we have preferred to take a 
small ellipse of skin that might be 
involved - as would be the normal 
oncological practice.  
  Three Thermo-Luminescent Detectors 
(TLD) and a sheet of Radio-chromatic 
paper (RCP) is placed adjacent to the 
skin edges and kept in place with 
transparent tapes.  
When the XRS is lowered into the 
breast wound we have found that 
Prolene stitch everting skin edges 
 
Placement of purse-string, RCP and TLD 
65 lowering the operation table to the 
lowest level, helps in balancing the 
XRS in the most stable position. The 
position of the XRS should be 
usually vertical and stay in its 
position once it is left free to hang. 
Once the XRS and the applicator is 
inserted and well balanced, a 
Tungsten impregnated sheet covers 
the wound around the applicator. 
This blocks 95% of radiation and 
reduces the amount of radiation in 
the operating theatre to very low 
levels and that in the corridor to near 
zero levels. 
The anaesthetist wearing a lead 
gown sits behind a portable lead 
shield and the physicists are located 
just outside the operation theatre, 
along with the portable computer and 
monitoring equipment. The surgeons 
and nurses un-scrub and go out of 
the theatre.  
Once the radiotherapy is completed, 
the shield is removed, the purse-
string cut and the XRS delivered to 
the Physics team. The TLDs and 
Radiochromatic paper is handed over 
carefully mapping the position of 
each of the TLD. 
Haemostasis is confirmed and wound 
closed. We used a 2-0 prolene 
subcuticular stitch in early cases, 
leaving it for 14 days before removal. 
Since the last year we have used 3-0 
monocryl absorbable monofilament 
suture which is absorbable and does not 
need to be removed, but the steristrips 
are left in place for 14 days, unless 
there is need to remove them earlier.  
The axillary wound is always drained 
with a Redivac drain and the breast 
wound sometimes drained, the choice 
based on individual patient. The breast 
drain is removed within 24 hours to 
reduce the chance of causing a puckered 
wound. 
Giving IORT increases the operating 
time by 45 minutes on average (range 
34 to 60 minutes).  
The prescribed dose is 5Gy at 1cm. This 
delivers a physical dose of about 20Gy 
at the surface of the applicator. The 
time to deliver this dose depends upon 
the size of the applicator- generally 
larger the applicator, longer the 
duration. For a 3.5cm applicator, the 
 
Intrabeam in place and site covered with protective shield 
66 time is usually 24-25 minutes and for 
a 5cm applicator is it is usually 
around 38 minutes. The radiation 
from the probe varies by a small 
fraction at every session and is 
calculated on site – hence the small 
range of durations even for the same 
size of the applicator. 
Postoperative care 
The postoperative care is not 
different from the usual. If there was 
a breast drain, it is removed at 24 
hours and the patient is usually home 
after removal of drain within 3-6 
days. 
Radiation safety 
The operation and radiotherapy are 
carried out in the usual operating 
theatres with no special shielding apart 
from the portable lead shield and lead 
aprons. The measurement of radiation 
dose on the anaesthetist’s body is nearly 
undetectable.  
 
 
Summary 
•  Assess the size 
•  Achieve meticulous haemostasis 
•  Prepare the applicator in the plastic bag 
•  Position the shielding cap if tumour on Left side 
•  Prolene stitches for reflecting skin edges if required 
•  Purse string in breast tissues 
•  Attach the applicator (already in plastic bag) to the XRS 
•  Lower the applicator in the wound – and pulling the purse string 
•  Adjust and ascertain close fit of breast-wrap-around the applicator 
•  Tie the purse string 
•  Reassess the closeness to skin etc 
•  Place the TLDs 
•  Place the shields over the wound 
•  After radiotherapy- reconfirm haemostasis and close the wound with 
subcuticular monocryl sutures. 
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These are the photographs of the first case on 2 July 1998 
 
             
 CHAPTER 5 
 
 
The pilot study of intra-operative boost 
radiotherapy 
69 70 Time course : events leading up to 
the setting up of the pilot study 
After completion of the study of 
whole organ analysis of mastectomy 
specimens (Chapter 2) the paper was 
presented at the Hong Kong 
International Cancer Congress in 
November 1995. This was the time 
when I proposed that radiotherapy to 
the index quadrant alone is probably 
sufficient for early breast cancer.  
The paper was submitted to British 
Journal of Cancer for consideration 
for publication and was finally 
accepted in April 1996. In April 
1996, I started clinical work with 
Professor Michael Baum at the 
Royal Marsden Hospital. Between 
April 1996 to October 1996 the 
protocol for intra-operative 
radiotherapy was developed based on 
the pathological /biological rationale 
described in the BJC paper.  
Photoelectron corporation agreed to 
sponsor a part of the Research 
fellow’s salary to develop the 
machine and adapt it for treatment of 
breast cancer. As discussed in the 
chapter on technique, we developed 
the various applicators for use in the 
breast. There was considerable delay 
caused by the Medical Devices 
Agency before these were approved 
for clinical use. 
We proposed a long-term strategy 
for improving the local treatment of 
breast cancer in early 1997 as 
follows: 
Long-term strategy for improving the 
delivery of local treatment for breast 
cancer 
Pathological basis of localised 
radiotherapy. 
Spatial distribution of dormant cancers 
in the breast  
Clinical evidence of sites of local 
recurrence 
The Hypothesis 
Radiotherapy to the quadrant alone 
might be as good as radiotherapy to the 
whole breast in selected patients 
The tools and methods for easier 
delivery of treatment 
Intra operative radiotherapy  
Interstitial stereotactic radiotherapy of 
small cancers 
Establishing the efficacy and safety of 
the tools 
Effect of interstitial radiotherapy in 
elderly women who would otherwise 
not undergo surgery. (Outcome 
measure: local control) 
Effect of Intra-operative radiotherapy 
immediately after wide local excision as 
a substitute for the routine local boost. 
(Outcome measure: feasibility and local 
recurrence) 
Planning randomised trials 
(multicentre and in India) 
Early breast cancers: WLE + AD + 
localised RT vs. WLE + AD + Standard 
RT 
Elderly women: Interstitial RT + Tam 
vs. Tam only 
Small breast cancers including screen 
detected cancers: Interstitial RT only vs. 
standard Surgery + standard RT 
Depending upon the results of the 
trials, application of the new 
techniques to benefit women world-
wide 
----------------------------------------------------------------- 
The ethical approval for the intra-
operative boost radiotherapy project 
was given in October 1996. 
However, the medical devices agency 
(MDU) did not approve of the new 
device until June 1998.  
71 During this period I tried to perform 
several experiments with Comet 
assay to evaluate the radiation dose 
and its effects at various distances. 
However, the dose from the PeC x-
ray source fell off very quickly- so 
that the cells placed on a single 
microscope glass-slide received a 
differential dose. These were 
therefore not analysable using the 
Comet assay. 
The first clinical trial using the PRS 
device was aimed to test its safety 
and feasibility and was commenced 
on 2 July 1998. 
Background 
Over the past 30 years, there has 
been a dramatic change in the local 
management of breast cancer from 
very radical to more conservative 
surgical operations, with the 
widespread use of radiotherapy in 
conjunction with wide local excision 
of the tumour itself. This shift away 
from radical surgery has been 
prompted by randomised clinical 
trials that have clearly demonstrated 
that conservative breast surgery 
followed by radiotherapy is 
equivalent to more radical 
procedures in overall survival [Early 
Breast Cancer Trialists' 
Collaborative Group, 1995]. 
However, although the outcome is 
‘conservative’ the intention is 
‘radical’ with the radiotherapy fields 
encompassing virtually all of the 
tissues previously excised by radical 
mastectomy. This approach needs to 
be reappraised. A component of the 
rationale for the less radical 
approach is that in large studies of 
breast conservative therapy more 
than 90% of early breast recurrences 
have been found to occur at the site 
of the original primary tumour. This 
is true whether or not radiotherapy is 
given [Fisher et al., 1986] and whether 
or not the margins are involved [Vaidya 
and Baum, 1998]. Furthermore, this is 
the case in spite of the fact that, when 
mastectomy specimens are examined by 
detailed radiological-histological 
correlational methods, small additional 
invasive or in situ cancer foci are found 
in over 60% of patients, with 80% of 
these situated remote from the index 
quadrant. The relative distribution of 
primary tumour and these foci in the 
four breast quadrants is significantly 
different [Vaidya et al., 1996]. Hence it 
appears that these additional cancer foci 
do not in general give rise to local 
recurrence which more probably 
develops from the cells that surround 
the primary tumour. These may be 
overtly malignant or morphologically 
normal, yet capable of malignant 
progression, as evident by the loss of 
heterozygosity in these ‘normal’ cells 
within the index quadrant [Deng et al., 
1996]. We have suggested that the next 
step is a clinical trial to test whether 
radiotherapy to the index quadrant 
alone can achieve as good a local 
control as radiotherapy to the whole 
breast [Baum et al., 1997] [Vaidya and 
Baum, 1998].  
This approach of irradiating the index 
quadrant alone has been tested in two 
clinical trials and in fact (contrary to the 
popular myth) the results of these trials 
are encouraging. The Christie Hospital 
Trial [Ribeiro et al., 1993] randomised 
708 patients to receive either the 
standard wide field (WF) radiotherapy 
or a limited field (LF) radiotherapy to 
the index quadrant. They found that 
overall there was a higher recurrence 
rate in the latter (LF)  arm. In the 
limited field arm, a constant size of 
radiotherapy field was used, 
irrespective of the tumour size, and this 
could have resulted in several instances 
72 of ‘geographical misses’. More 
importantly, when the results were 
analysed according to the type of the 
primary tumour, it was found that 
limited field radiotherapy was 
inadequate only in infiltrating lobular 
cancers or cancers with extensive 
intraductal component (EIC). In the 
504 cases of infiltrating duct 
carcinoma, there was no significant 
difference in the local recurrence 
rates of the two arms. In the much 
smaller (n=27) Guy’s Hospital Study 
[Fentiman et al., 1991] [Fentiman et 
al., 1996], a single continuous 
application of an iridium-192 
implant delivering 55 Gy over 5-6 
days replaced the standard 
radiotherapy regimen of whole breast 
radiotherapy plus tumour bed boost. 
The authors found a 20% increase in 
local recurrence compared to 
historical controls. However, as 
discussed in a letter in response to 
the study [Dale et al., 1997], it was 
pointed out that the Biologically 
Effective Dose (BED) of the 
implant-only arm was 20% lower 
than the conventional radiotherapy 
arm and this almost completely 
explained the difference. In addition 
12/27 patients in this study were 
node positive and 15/27 had 
involved margins - putting these 
patients at high risk of local 
recurrence anyway. 
Methods and Design 
We report here the pilot study 
approved by the University College 
London Hospitals Ethics Committee 
in which a novel method of 
radiotherapy is used to deliver 
therapeutic radiation to the tissues 
around the primary tumour 
immediately following excision, with 
a degree of precision impossible with 
an external beam. The novel technology 
is called the Photon Radiosurgery 
System (PRS) developed by the 
Photoelectron Corporation in 
Massachusetts, USA and is now 
commercially available as Intrabeam.  
The detailed technical details of the 
device and the operative technique have 
already been described in the preceding 
chapter. 
 
Patients diagnosed using triple 
assessment (physical examination, 
imaging and cytology or histology), to 
have operable breast cancer and suitable 
for breast conserving surgery were 
recruited in the pilot study, after a full 
informed consent. In every case Dr 
Jeffrey Tobias, the consultant clinical 
oncologist, obtained the informed 
consent. 
Each patient underwent wide local 
excision and axillary clearance. The 
details of the technique have been 
described in the preceding chapter. In 
the first 3 cases, the complete PRS 
device was sterilised. This required the 
Quality Assurance analysis to be done 
on the previous day before sterilisation 
and repetition in the operating theatre 
under sterile conditions. From the 4th 
case onwards, we wrapped up the XRS 
with sterile plastic bag, with a hole for 
the sterile applicator to pass through. 
Not only has this made the operation 
streamlined, it has also significantly 
reduced the time spent by the medical 
physics teams in the operation theatre. 
Since this modification, the average 
time needed to set-up the system at the 
end of excision was 12 minutes. When 
the lesion was on the left side, the chest 
wall was protected by thin 
polyurethane- tungsten impregnated 
sheets that could either be applied to the 
applicator or custom-made to fit on the 
chest wall. This reduced the radiation 
by 99% and protected the heart and 
73 coronary vessels. The applicator 
sphere was inserted into the breast 
cavity and a deep surgical purse-
string suture was inserted in the 
subcutaneous plane to bring together 
the target breast tissue so that it 
applies well to the surface of the 
PRS applicator sphere and holds it in 
place during radiotherapy, as 
described in detail in the preceding 
chapter. Our third patient had 
radionecrosis of the skin close to the 
scar, which we believe was the site 
of one of these subcutaneous 
stitches. Since then we have been 
retracting the skin with a 3-0 prolene 
stitch and ensuring that no part of 
skin is less than 1cm from the 
applicator surface. Essentially these 
'conforming' stitches allowed hands-
on-conformation of the target to the 
source of radiation. The radiation 
was switched on for 21 to 28 minutes 
depending upon the size of the 
applicator sphere, and using an 
energy of 50kV a dose of 5 Gray 
(Gy) was delivered at 1cm distance 
from the cavity margins. After 
completion of radiation, the 
'conforming' stitches were removed 
and the skin was sutured in the usual 
manner with a subcuticular prolene 
stitch, which was left in place for 14 
days. 
The follow up of these patients was 
as usual with 3 monthly visits to the 
outpatients clinic and yearly 
mammograms. Any other 
investigations such as ultra-
sonography or fine needle aspiration 
cytology were performed if 
prompted by symptoms or signs. 
We assessed the cosmetic results of 
the patients with photographs and by 
comparing patient’s own assessment 
of the cosmetic result. We asked the 
patients to score the appearance and 
texture of the breast on an analogue 
scale of 1 to 10, 10 being the best. We 
also asked her at the same time, to give 
a similar score to what she would have 
expected the appearance and texture to 
be, again on an analogue scale of 1 to 
10, 10 being the best. The satisfaction 
index was calculated by dividing the 
patient’s score for the actual (observed) 
appearance (and texture) by her score 
for what she would have expected it to 
be (expected). We felt that ultimately, it 
is the patient’s own assessment that is 
more accurate depiction of the ‘real’ 
cosmetic outcome. For comparison with 
other studies, the ‘objective’ assessment 
of photographs by an independent panel 
would of course be more relevant. 
 
Results 
We have completed 26 cases of intra-
operative radiotherapy for breast 
cancer. The patients were diagnosed to 
have early operable breast cancer 
suitable for breast conserving surgery. 
The age ranged from 30 –80 years 
(Mean 51.5). The pathological tumour 
size ranged from 0.42 cm to 4.0 cm. 
The applicator size was 3.5 cm in 15 
cases, 4cm and 3cm in 3 cases each, and 
4.5 cm in 3 cases and 2.5 cm in 1 case. 
In all except the first case, the operating 
voltage was 50Kv @ 40microamperes. 
The time required to treat the prescribed 
dose of 5Gy at 1cm ranged from 21.1 
min to 28.7 minutes. In the first case, 
we used a 40 kV voltage and took 36.8 
minutes.  
Three patients received intraoperative 
radiotherapy as the only form of 
radiotherapy. One patient was blind and 
80 year old and not very suitable for 
daily postoperative visits for external 
boost radiotherapy. In a joint decision, 
she was prescribed 7.5 Gy at 1cm 
effectively giving about 23 Gy to the 
74 cavity margin as the only 
radiotherapy. Another patient had a 
contralateral breast cancer treated 14 
years ago with interstitial wire boost 
and whole breast radiotherapy. In 
order not to overlap radiation beams 
in the sternal region, she was 
prescribed 6 Gy at 1cm giving 20Gy 
to the cavity margin as the only 
radiotherapy. The third patient 
(Patient number 21 in the pilot study) 
was a lady who well understood the 
rationale of our subsequent 
randomised study and chose not to 
undergo the 5-wk course of whole 
breast radiotherapy, although we had 
not yet started the randomised trial to 
test this approach. All other patients 
received the routine external beam 
radiotherapy to the whole breast 
(50Gy over 5 wks, 25 fractions). 
No patient has had major operative 
or postoperative complications, in 
general as well as regards the wound. 
Two patients had some problem with 
wound healing one of which we 
believe was due to excessive 
radiation and radionecrosis. This was 
our third patient as mentioned 
before, who had radionecrosis of an 
area of skin close the applicator. This 
resulted in delayed wound healing by 
secondary intention. After this case, 
we measured the skin dose using 
Thermoluminscent detectors (TLD). 
The mean of the highest dose of 
radiation at the skin surface was 4.6 
Gy (95% CI 3.6 – 5.6, median 3.7). 
It has been between 5-10 Gy in 4 
patients but has never reached about 
10Gy. None of these 4 patients has 
had any complications. 
  In the 80-year-old blind lady, both 
the axillary and primary wound had 
delayed wound healing that was 
probably age related. One other 
patient had wound infection - but the 
wound healed satisfactorily within 2 
weeks and did not delay her adjuvant 
treatment. Some non-tender transient 
erythema around the scar was seen in 3 
patients.  
The longest follow up is 45 months, 
with a median of 34 months and a 
minimum of 27 months. No patient has 
had a local recurrence. None of the 
patients whom we found suitable have 
refused to participate in the study. 
Many patients found the technique 
logical and could immediately see the 
practical advantage of fewer visits to 
the radiotherapy department. The 
concept of giving the radiotherapy to 
the tumour bed ‘there and then’ also 
was very attractive.  
The actual score of appearance of breast 
and texture of breast, as judged by the 
patients themselves, either matched or 
exceeded their expected score in 21 out 
of 25 patients. At 12-24 months after 
surgery, the satisfaction index 
(observed/expected score) was 1.2 
(95% CI 1.1-1.4) for breast appearance, 
and 1.2 (95% CI 1.0- 1.4) for breast 
texture.  
Discussion  
In the present protocol, the PRS was 
used for boosting of the tumour bed in 
conjunction with external beam 
irradiation to the whole breast which 
provided a saving of 1 week of 
radiotherapy treatment time and 
travelling for the patient. In those 
patients undergoing sentinel node 
excision with immediate frozen section, 
intra-operative radiotherapy could 
actually be delivered during the time 
waiting for the frozen section results.  
In addition, the PRS technique has 
advantages over other types of 
brachytherapy. At present, both low-
dose-rate and high-dose-rate 
brachytherapy are employed in order to 
75 maximise local dosage for improved 
local control, but the techniques are 
time-consuming and expensive. 
Careful placement of semi-flexible 
I
192 IR wires probably represents the 
“gold standard” brachytherapy 
technique at present but geometrical 
accuracy is important and the 
implant must be removed at a later 
date, increasing the workload and 
creating additional problems of 
radiation protection.  
Intraoperative radiotherapy has been 
explored in the past, employing 
massive and expensive linear 
accelerators that required relocation 
of the operation theatre in the 
radiotherapy suite. Mobile linear 
accelerators are now being used by 
several groups in the world, most 
notably Professor Umberto 
Veronesi’s group. The advantage of 
using the linear accelerator (e.g. 
NOVAC–7) high-energy electrons is 
that the actual treatment time is 
reduced to a few minutes. However, 
the positioning of the equipment 
takes much longer and the total time 
for treatment is about 25 to 35 
minutes. Furthermore, the shape of 
the radiation is different from the one 
which we use – it is in the form of a 
radiation beam- so that the target 
tissue – the breast cavity - needs to 
be brought facing the radiation 
source. With the Intrabeam device, 
the radiation is delivered from within 
the breast, which intuitively appears 
a much more elegant approach. 
Nevertheless, whichever technique is 
able to accurately and relatively 
inexpensively deliver radiotherapy to 
the target tissues in the operating 
theatre in a reasonable time would 
revolutionise the local management 
of breast cancer. 
We believe we are the first to use this 
approach and the technique we use is 
simple, portable, and can be used in a 
routine operation theatre. It provides a 
simple form of brachytherapy, which 
could potentially provide equivalent 
benefit with a lesser demand on 
professional time expended. We 
recognise that the follow up of this 
study is relatively short (median 34 
months and longest 45 months) for 
assessing local recurrence rates, but this 
study was a pilot phase II study mainly 
testing the feasibility, safety and 
acceptability of the technique to the 
patient and not local control, which will 
be tested in the next phase- the 
randomised trial. Nevertheless, it is 
encouraging to have a 0% local 
recurrence rate at nearly 3 years of 
follow up. 
Another important value of the pilot 
project is that it has demonstrated that it 
is safe, at least in the relatively short 
term, to deliver a very high dose of 
radiotherapy –the Intraoperative dose in 
one fraction followed by 50Gy of 
postoperative whole breast 
radiotherapy. The lack of side effects 
until now is probably due to the fact 
that the high dose is small and for the 
same reason, we expect that the late 
fibrosis, if any, will not be disfiguring.  
  This method of delivery of 
radiotherapy offers excellent radiation 
dosimetry and does not have the risk of 
a “geographical miss”. The treatment is 
delivered at the earliest possible time 
after the surgery. It has been suggested 
that a large proportion of local 
recurrence after breast conserving 
therapy is because of a geographical 
miss of the boost dose. It has been 
estimated that the boost dose could miss 
between 24% to 88% of the target 
volume [Sedlmayer et al., 1996;Hunter 
76 et al., 1996;Krawczyk and Engel, 
1999;Machtay et al., 1994]. Thus a 
large proportion of local recurrences 
could be attributed to geographical 
miss alone.  
  In patients with high risk of local 
recurrence (e.g. larger tumours with 
high nuclear grade and with involved 
nodes) this approach can offer the 
most optimal mode of delivery of 
radiotherapy, and may have the 
potential to reduce the local 
recurrence rate substantially. 
It is the next phase, that we would 
test whether giving targeted localised 
radiotherapy in this manner is 
equivalent to the routine 6-weeks 
course of postoperative radiotherapy 
in selected patients; then this 
technique has a potential to save 6 
weeks of external beam radiotherapy 
time for both the patient and the 
overstretched resources of 
radiotherapy departments.  
We received ethics approval and 
have begun in March 2000, a 
randomised trial (called Targit- 
Targeted Intraoperative 
Radiotherapy) comparing 
conventional radiotherapy to 
radiotherapy delivered to the index 
quadrant alone using the PRS – this 
is described in the chapter 7. 
 
Summary 
 
Introduction: We believe that 
conservative treatment of breast 
cancer may not require radiotherapy 
that encompasses the whole breast. 
This chapter discusses the clinico-
pathological basis for this view as 
well as a novel therapeutic approach 
that allows intra-operative 
radiotherapy to be safely and 
accurately delivered to the target 
tissues in a standard operating theatre. 
The Rationale: Whole-organ analysis 
of mastectomy specimens reveals that 
80% of occult cancer foci are situated 
remote from the index quadrant. In 
contrast, over 90% of local recurrences 
after breast conservative therapy occur 
near the original tumour- even when 
radiotherapy is not given. Therefore, the 
remote occult cancer foci may be 
clinically irrelevant and radiotherapy to 
the index quadrant alone might be 
sufficient.  A Novel Technique The 
Photon Radiosurgery System (PRS) is an 
ingenious portable electron-beam driven 
device that can typically deliver, intra-
operative doses of 5 - 20 Gy, 
respectively, to 1cm and 0.2cm from the 
tumour bed over about 22 minutes. The 
pliable breast tissue - the target - wraps 
around the source providing optimal 
conformal radiotherapy. Being soft x-
rays, the dose attenuates rapidly (α~1/r
3), 
reducing distant damage. Results In our 
pilot study of 26 patients (age 30-80 
years, T=0.42-4 cm), we replaced the 
routine post-operative tumour bed boost 
with  targeted  intra-operative 
radiotherapy. There have been no major 
complications and no patient has 
developed local recurrence although the 
median follow-up time is short 34 
months.  Conclusion  It is safe and 
feasible to deliver targeted  intra-
operative radiotherapy (Targit) for early 
breast cancer. This novel method of 
delivery of radiotherapy, used alone, 
could be used in a randomised trial 
testing the hypothesis that index quadrant 
irradiation alone may be adequate local 
treatment for selected cases of breast 
cancer. In other patients, in whom whole 
breast irradiation is deemed necessary, 
this method can be used to accurately 
deliver the tumour bed boost at a high 
therapeutic ratio, without the risk of a 
geographical miss, with a potential to 
reduce the overall local recurrence rate. 
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Percutaneous minimally invasive Stereotactic 
Interstitial primary radiotherapy using the 
Photon Radiosurgery System for women found 
unfit to undergo surgery 
79 80 Background 
There is a relatively large group of 
women with breast cancer in the 
elderly age group who have 
significant co-morbid conditions that 
raise the risk of operative 
intervention. This group of elderly 
women can contribute to more than 
half of all breast cancers diagnosed 
in an ageing population [Yancik et 
al., 2001]. Since a high proportion of 
these tumours are oestrogen receptor 
positive, the traditional treatment of 
these women has been oral 
tamoxifen alone. There have been 
three randomised trials testing 
whether local treatment is beneficial 
for elderly women with breast 
cancer. In the Nottingham trial, 
[Robertson et al., 1992], 135 
consecutive patients aged over 70 
years with operable primary breast 
cancer (< 5 cm) were randomised to 
either wedge mastectomy or 
tamoxifen 20 mg twice daily as 
initial therapy. At a mean follow up 
of 65 months, there was no 
difference between the two groups in 
terms of overall survival or cause of 
death. However, failure of 
locoregional control was 
significantly greater in the tamoxifen 
group. The authors concluded that 
optimum treatment for elderly 
patients with operable breast cancer 
should include mastectomy. In the 
trial from St George’s Hospital, 
London [Gazet et al., 1994] 
conducted between 1982 and 1989, 
200 patients aged 70 or over seen in 
one Breast Unit, who were 
considered to have a surgically 
resectable cancer of the breast were 
prospectively randomized to primary 
surgery or tamoxifen 20 mg per day. 
At a median follow-up of 6 years 
(range 3-11 years), there were 61 events 
in the tamoxifen arm while and 50 
events in the surgical arm. There were 
33 deaths in the tamoxifen group and 28 
deaths in the surgical group of which 17 
and 15, respectively were directly 
attributable to breast cancer. The 
disease-free interval did not differ 
between the two groups. In the 
tamoxifen group, 39 had no progression 
of their disease and a further 21 
benefited from subsequent surgery. In 
the surgical group 50 had no recurrence 
of their disease and a further 10 
benefited from subsequent tamoxifen 
therapy. Thus surgery, offered the most 
time free from disease.  
The largest trial to address this issue is 
the recently concluded CRC clinical 
trial [Latteier et al., 1997;Bates T, 
2001;Bates et al., 1991;Latteier et al., 
1997]. They prospectively randomised 
450 women over 70 years of age with 
operable breast cancer to receive either 
tamoxifen 40 mg per day, or the same 
dose of tamoxifen plus breast surgery. 
In this pragmatic trial, the extent of 
surgery was not prescribed. Overall, 
there were 149 deaths among the 220 
women receiving surgery-plus-
tamoxifen, compared 120 deaths among 
with 230 women receiving tamoxifen 
alone (RR=0.82, 95% CI 0.64- 1.04). 
However, when breast cancer deaths 
were considered, there were 36 in the 
surgery arm compared with 61 in the 
tamoxifen-only arm (RR =0.62, 95%CI 
0.41-0.94). Of those who received 
tamoxifen only, 34% achieved complete 
response (CR), 11% partial response 
(PR), and 38% remained stable. Median 
response durations were 38 months 
(CR) and 14 months (PR) and 33 
months (stable). Ninety-one women 
(40%) in the tamoxifen-only group had 
subsequent breast surgery. Survival of 
those with delayed surgery was no 
worse than for those in the primary 
81 treatment arm (RR =1.16 95%CI 
0.85-1.60).  
These results suggest an effect of 
early local treatment, in the form of 
surgery, had an effect on overall and 
cancer specific survival. Thus the 
local treatment of breast cancer in 
this age group should be given high 
priority. However, many of these 
women are frail and surgical 
treatment is not applicable because 
of co-morbid conditions. If the 
patient is not fit enough to withstand 
surgery, some form of effective local 
treatment can be reasonably assumed 
to be of benefit.  
As discussed earlier, we believe that 
this local treatment many not need to 
involve anything more than 
treatment of the index quadrant of 
the breast. We piloted the use of the 
PRS system, using the bare probe 
alone in this group of women, using 
novel minimal intervention therapy 
incorporating three converging 
technologies: a - the Fisher 
Mammotest table for digital real-
time tumour localisation    b- the 
Mammotome Vacuum biopsy system 
for excision biopsy and c- the 
PRS400(PeC) for localised portable 
radiotherapy.   
The Physics  
The dose of radiotherapy at the tip of 
the XRS is very high. The difference 
between these treatments and those 
that we piloted for intra-operative 
use was that in these women the 
tumour was not excised. Thus, while 
planning radiotherapy dosimetry we 
calculated a dose of 5 Gy at 1cm 
from the surface of the tumour, so 
that the effective area of normal 
breast tissue that would be radiated 
would be similar to that in the intra-
operative study while the tumour 
itself received a very high dose of a 
single dose of radiotherapy in a small 
volume. Typically, the physical dose at 
the centre of the tumour is about 135 
Gy. 
While planning the dosimetry for this 
pilot, we modelled the dose as if the 
nearly spherical tumour was the 
applicator that we used for intra-
operative radiotherapy, so that the dose 
at 1cm from the tumour surface was 
similar to that received by normal breast 
tissue after surgical excision. Thus the 
prescribed dose was 5Gy at 1cm from 
the tumour surface. This usually 
allowed the treatment to be delivered in 
6-12 minutes for tumours ranging from 
1cm to 3cm in diameter. 
The Technique  
A Fisher Mammotest prone table uses 
two digital mammographic images 30° 
apart to stereotactically compute the 
location of lesions in the breast. The 
intervention devices are mechanically 
compatible with the system. Thus, the 
Mammotome vacuum biopsy apparatus 
and the PRS400 X-ray source can be 
mounted on the calibrated stand and can 
be directed to the correct location 
within the breast with real-time 
monitoring.  
The patient lies prone while the breast 
is suspended under the table between 
the image sensor and a small windowed 
compressing pad. The Mammotome 
vacuum biopsy apparatus is targeted at 
the lesion through a tiny incision in the 
breast following local anaesthesia. 
Using this equipment, it is usually 
possible to take about 1-2 cm3 of tissue. 
This is adequate for tissue diagnosis, 
can be therapeutic for benign lesions 
and may achieve near complete 
excision for small screen detected 
malignant lesions [Beck et al., 2000]. 
PRS400 (PeC) is an electron-beam 
82 driven soft x-ray source, which 
provides a point source of low 
energy X-rays at the tip of a 3.2mm 
diameter tube that can be positioned 
in the breast through the tract created 
by the Mammotome needle. With a 
50kV machine, the typical dose is 
about 130Gy and 20 Gy at the 
surface of the tumour delivered in 8- 
12 minutes in a routine x-ray room. 
With this approach, the area of 
maximum tissue anoxia - the most 
likely site of failure receives the 
highest dose and the normal tissues 
receive the least.  
The X-ray source is not sterilised. A 
sterile thin transparent plastic, 
relatively stiff tube with a flange at 
the base - that slides smoothly over 
the 3.2mm bare probe is used. These 
tubes are pre-sterilised in disposable 
packs.  It does not interfere with the 
radiation dose. It is slid onto the 
probe just before it is inserted into 
the breast as described below. 
After diagnosis of the carcinoma, 
usually in a previous outpatient visit, 
by triple assessment, patients were 
invited to take part in the trial. Once 
informed consent was obtained the 
procedure was performed in the 
radiology department in a morning 
session, on an outpatient basis.  
Ethics approval for this study 
included the permission to withhold 
tamoxifen for 1 month after 
treatment, following which it was 
started at 20mg per day. We assessed 
the response to radiotherapy using 
serial contrast-enhanced MRI scans 
of the breast, pre-operatively, at 6 
days, at 1 month and at 6 months. In 
this way, the scans until 1 month 
were able to give an indication of the 
response of the tumour to only the 
radiotherapy. 
The patients received the 
radiotherapy on the Mammotest 
machine. MRI was performed before 
and on at various periods after the 
radiotherapy was completed. Tamoxifen 
was started after 1 month.  
Description of the first case. 
A 73 year old lady presented with a 
lump in her breast. Clinically, it was a 
2.5 cm tumour in the upper outer 
quadrant, with no palpable axillary 
lymphadenopathy. Ultrasonography and 
mammography revealed a 2.5 cm 
tumour and fine needle aspiration 
confirmed a duct carcinoma. Several 
months ago, she was diagnosed to have 
motor neurone disease, confirmed on 
MRI, causing pseudobulbar palsy, the 
main symptom being slurring of speech. 
She could not therefore be offered 
surgery, although it has been shown to 
be beneficial, in addition to systemic 
tamoxifen.  
After a full informed consent, she 
underwent, Mammotome vacuum 
biopsy followed by localised 
radiotherapy for this tumour using the 
Photon Radiosurgery System (PRS) on 
the Fisher Mammotest prone table. 
Following radiotherapy we excised two 
83 more cycles of core biopsies using 
the Mammotome in an attempt to 
partially excise the tumour.  
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During the whole procedure, the 
patient was prone on the table, which 
has a window for the relevant breast. 
The breast was then suspended between 
the image sensor and a small windowed 
compressing pad, under the table. The 
Mammotome vacuum biopsy apparatus 
is mounted on the calibrated stand and 
was directed to the correct location 
through a tiny incision on the breast 
under local anaesthetic. The position of 
the tip of the Mammotome needle was 
ascertained in real time by taking two 
stereotactic digital mammography 
images. 
In this case, the Mammotome was used 
as above to make a tract and take 2 core 
biopsies from the centre of the tumour. 
The Mammotome was then removed 
from the breast, while keeping the 
breast in its position. 
Mammotome biopsy in progress 
The bare probe of the PRS X-ray source 
was then covered with a sterile 
transparent plastic sheath. The PRS was 
now mounted on the stand and the tip 
stereotactically directed to the centre of 
PRS400 device in position the tumour in the breast. The 
position of the tip was again 
ascertained in real time to be in the 
centre of the tumour and then the 
radiotherapy was started. During the 
radiotherapy, the radiographer 
remained in the room behind a 
shield. Over 12 minutes, the tumour 
received a varying dose, from 134 
Gy at the centre to 23.5 Gy at the 
surface. The closed skin was at 2.5 mm 
received 16 Gy. The whole procedure 
was completed in 50 minutes.  
These are the early MRI pictures that 
demonstrate, apart from a small area in 
the periphery, a very promising near 
complete absence of enhancement in 
the post- treatment image of the tumour.  
MRI- Before Treatment 
 
Pre-contrast............Post-contrast 
 
6 days after Treatment 
 
Pre Contrast .............Post-contrast 
Clinically, the skin looked normal 
and the patient suffered no pain, 
bruise or any discomfort at all. MRI 
at 4 weeks and at 6 months revealed 
that even this marginal enhancement 
had gone away. Core cut biopsies taken 
at the time of the MRI, 1wk and 4wks 
after the radiotherapy treatment, 
85 showed progressive evidence of 
apoptosis, necrosis and fibrosis. The 
tumour was impalpable at 3 months. 
At the last follow up visit 12 months 
after the treatment, the patient was 
disease free as regards breast cancer, 
but her neurological condition had 
deteriorated considerably and she 
died at 13 months. 
Results and Discussion 
As a demonstration of principle, we 
have treated 3 patients with 
symptomatic breast cancer aged 73, 
78, and 85 years. The aim was to 
partially resect the tumour and 
develop a track for the radiotherapy 
probe. The main treatment modality 
was intended to be radiotherapy. 
These patients had considerable co-
morbid conditions- partial 
pseudobulbar palsy in the first and 
cardiac dysfunction in the other two. 
The cytological diagnosis of cancer 
was established a preceding 
outpatient visit. The tumour size was 
2.5cm, 3cm and 2.8cm. All patients 
tolerated the procedure well.  
The tumour samples taken by 
Mammotome after radiotherapy 
revealed histological evidence of 
coagulative necrosis and radiotherapy 
damage. In every patient, there was near 
complete loss of tumour vascularity on 
contrast-enhanced MRI within 6 days of 
treatment, apart from a thin rim of 
enhancement, which disappeared in the 
follow up scans at 1, 3 and 6 months. 
All lumps were impalpable by 3 months 
and the patients were disease free at 13, 
18 and 12 months following treatment.  
Two patients (1st and 3rd) succumbed 
to their co-morbid conditions, and thus 
did not suffer consequences of the 
breast cancer. The second patient 
remains recurrence free. The 
combination of these three evolving 
technologies can yield the diagnosis, 
localisation, part excision and 
radiotherapy in a single session under 
local anaesthetic in these frail women. 
The application with the biggest 
therapeutic potential is possibly the 
treatment of small screen detected 
cancers, in whom standard surgery and 
radiotherapy may represent over-
treatment.  
The MR Images and histopathological 
slides at various times are shown in 
following pages. 
 
 
86 Case 1 
25 March 1999 Pre treatment  
Pre-contrast       Post-contrast   
   
Subtraction image 
 
Core biopsy: Invasive duct carcinoma 
87 26 Mar 1999- PRS treatment 
 
1 Apr 1999: 6 days post treatment 
Pre contrast     Post contrast 
   
 
Histology – fibrosis and dying tumour cells 
        
88 21 April 1999 - 4 weeks 
Pre contrast       Post contrast  
    
 Subtraction 
 
Histology: progressive fibrosis   occluded vessels 
     
 
apoptotic cells 
 
89 23 June 1999 (3 months) 
Pre contrast       Post contrast  
   
 
Subtraction 
 
 
No Palpable tumour- no biopsy taken 
90 Case 2  
22 Sep 99 Pre treatment 
Pre contrast       Post contrast  
   
 
 
8 October 1999 PRS Treatment 
 
 
Histology  
Pre treatment   &   15 min after treatment 
     
91 20 October 1999 (12 days) 
Pre contrast       Post contrast 
   
 
 
 
12 Apr 2000-(6 months) 
Pre contrast       Post contrast  
   
92 Case 3 
2 Dec 1999 Pre treatment 
Pre contrast      Post contrast  
   
 
 
3 Dec 1999 PRS Treatment  
 
 
Histology  
Pre treatment      15 min after radiotherapy 
     
 
93 15 Dec 1999 (12 days) 
Pre contrast       Post contrast  
   
 
 
 
12 February 2000 (2 mon) 
Pre contrast       Post contrast 
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The randomised trial of targeted intraoperative 
radiotherapy 
 
95 96 The problem of local treatment of 
breast cancer 
Although there is strong evidence for 
the effectiveness and safety of breast 
conserving therapy (BCT) a large 
proportion of women still undergo 
mastectomy. In a sample of over 
16000 women treated for Stage I and 
II breast cancer North-eastern 
America in 1994, breast-conserving 
therapy was performed in only 
42.6% of patients [Morrow et al., 
2001]. Apart from having T1 and 
EIC- negative tumours, the main 
predictor of undergoing BCT. 
Women over 70 were less likely to 
receive radiation and overall only 
86% of patients who underwent BCT 
received radiation therapy. Many 
women in India frequently choose 
mastectomy because they cannot live 
or travel every day to the metropolis 
like Mumbai or Delhi to receive the 
6 weeks of postoperative 
radiotherapy. This is not limited to 
developing countries alone. Similar 
dilemmas are faced by women in 
remote areas of the developed world 
as well. The inverse relationship of 
travel distance to radiotherapy centre 
and receipt of breast conserving 
therapy has been documented in 
Australia [Craft et al., 1997] and the 
USA [Athas et al., 2000;Nattinger et 
al., 2001]. In the large US [Nattinger 
et al., 2001] study using SEER 
dataset, living between 15-20 miles 
away from the radiotherapy facility 
reduced the odds or receiving breast 
conserving surgery (BCS) from 1 to 
0.76 and if the distance was more 
than 40 miles, it reduced the odds of 
receiving radiotherapy after BCS 
from 1 to 0.55. When the travel 
distance was <10 miles, 82% of 
patients received radiotherapy after 
BCS; when it was 50-75 miles, 69% 
received it and when it was >=100 
miles, only 14% received it. These 
patients accounted for 39%, 22% and 
14%, respectively, of those would have 
been eligible for BCS + radiotherapy 
[Athas et al., 2000].  
In the countries where the health system 
is delivered by the State, e.g., the UK 
National Health System, there are long 
waiting lists for postoperative 
radiotherapy. Overall, breast cancer 
contributes almost a third of patients to 
the radiotherapy units and any measure 
to free up radiotherapy resources would 
be welcome. 
The rationale of a change in strategy for 
local treatment of early breast cancer is 
described in the earlier chapters of this 
thesis. In short, it appears that the 
symptomatic cancer usually restricts 
itself to the original quadrant in the 
breast.  
Despite finding many other widely 
scattered small occult or dormant 
cancers in the diseased breast, it appears 
that these do not usually give rise to 
local recurrence. Local recurrence 
occurs at the site of the original primary 
tumour site in more than 90% of cases.  
Surprisingly, this is true whether or not 
radiotherapy is given and whether or 
not margins of the primary excision are 
involved. Various theories to explain 
this phenomenon have been discussed. 
Whether we can explain this 
satisfactorily or not, the practical 
consideration is that local recurrence 
probably arises either from or within the 
cells surrounding the primary tumour. 
Hence this should be the target of our 
therapies. The clinical implication of all 
these studies was that it is perhaps 
effective to only treat the index 
quadrant of the breast. Surgical excision 
of the whole index quadrant can result 
in recurrence rate equal to that achieved 
97 by wide local excision and 
radiotherapy [Veronesi et al., 1993]. 
However, quadrantectomy can be 
very disfiguring and 20-30% of 
patients are not satisfied with the 
outcome [Amichetti et al., 1995]. 
Substituting the large quadrant 
surgery by using lumpectomy and 
local field external radiotherapy has 
been tested against the usual wide 
field radiotherapy in the Manchester-
Christie hospital trial, as discussed in 
the previous chapter. The cosmetic 
outcome of this type of external local 
field radiotherapy was also very 
poor, leading the abandoning of this 
approach.  
We have pioneered the use of a 
novel therapeutic advance in 
radiotherapy technology for breast 
cancer. We have piloted the 
technique as described earlier and 
found it safe and feasible in a routine 
operating theatre [Vaidya et al., 
2001].  
The current on-going clinical trial 
will test whether radiotherapy to the 
index quadrant alone can achieve as 
good a local control as radiotherapy 
to the whole breast. This approach 
has been tested in the Christie 
Hospital Trial mentioned earlier. In 
this trial although the cosmetic 
outcome was poor, the local control 
was equal in the two arms- i.e., 
localised radiotherapy was adequate 
for patients with infiltrating duct 
carcinoma, but not for patients with 
infiltrating lobular cancers or cancers 
with extensive intraductal 
component (EIC). In the current trial, 
these latter patients will receive 
whole breast radiotherapy.  
Recent evidence, available after this 
thesis was drafted, suggests that 
index quadrant radiotherapy alone is in 
indeed effective when used in selected 
patients. Several groups have published 
pilot studies and one randomised trial is 
in press. When patients with small 
infiltrating duct cancers with 
uninvolved nodes are treated with 
interstitial brachytherapy with 
radioactive wires, the recurrence rate is 
between 0% and 4% at 2-5 year follow 
up (see table) 
Methods and Design 
Targit is a randomised trial to test 
whether a single fraction of 
radiotherapy delivered intra-operatively 
and targeted to the tissues at the highest 
risk of local recurrence is equivalent to 
standard 6-weeks' postoperative 
radiotherapy after breast conserving 
surgery in selected patients with early 
stage breast cancer who are suitable for 
breast conserving surgery. The major 
endpoint is local recurrence rate but in 
addition cosmesis, patient satisfaction 
and health economics will be assessed.  
If this single dose of intraoperative 
radiotherapy is proven to be equivalent 
to the standard 6 weeks postoperative 
radiotherapy, the implications are 
obvious. It will save money and effort 
for the health service and for the 
patients. In addition, many women from 
the developing world will be able to 
avail of breast conserving surgery, 
instead of having a mastectomy just 
because they do not live near a 
radiotherapy centre. 
This trial has been approved by the 
University College Hospitals Ethics 
Committee (99/0307) and we have 
begun accrual on 29 March 2000.  We 
have randomised 29 patients to date 
(June 2001).  
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Institution 
Radio-
therapy 
tech-
nique 
Median 
follow 
up  
Crude local 
recurrence 
rate (actual 
numbers) 
Ninewells Hosp, Dundee, UK [Samuel et al., 
1999] 
LDR 5.6  0%  (0/11) 
Ochsner Clinic, USA [King et al., 2000]  LDR/HDR  3.8  1.3% (2/150) 
London Regional Cancer Centre, Canada 
[Perera et al., 1997] 
HDR 1.7 2.6%  (1/39) 
William Beaumont Hospital, USA [Vicini et 
al., 2001] 
LDR/HDR 3  0%  (0/174) 
Orebro Medical Centre, Sweden [Samuel et 
al., 1999;Johansson et al., 2000] 
PDR 2.8  2.3%  (1/43) 
University of Kansas, USA [Krishnan et al., 
2001] 
LDR 4  0%  (0/24) 
National Institute of Oncology Hungary 
[Polgar et al., 2000] 
HDR 4.5 4.4%  (2/45) 
National Institute of Oncology Hungary 
[Polgar et al., 2000] 
HDR/EBRT 2  0%  (0/78) 
Tufts University, USA [Wazer et al., 2001]  HDR  2  0% (0/30) 
European School of Oncology, Milan, Italy 
[Veronesi et al., 2001] 
IORT <1  0%  (0/84) 
LDR=low dose rate; HDR=high dose rate; PDR=pulsed dose rate; IORT=intraoperative 
(electrons) radiotherapy; 
Title of the trial  
TARGIT- TARGeted  Intraoperative 
radioTherapy vs. Post-operative 
radiotherapy :A randomised 
controlled trial to compare targeted 
intra-operative radiotherapy with 
conventional post-operative 
radiotherapy after conservative 
breast surgery for women with early 
stage breast cancer 
Hypothesis 
Strategy 1 (Targit) – All patients will 
receive targeted intraoperative 
radiotherapy. If the histopathological 
analysis shows any of the following 
features suggesting high risk of local 
recurrence elsewhere in the breast 
(lobular carcinoma, or extensive 
intraductal component (EIC>25%)), 
they will also receive whole breast 
external beam irradiation.  
Strategy 2 (control) – All patients 
receive whole breast external beam 
irradiation including conventional 
tumour bed boost. 
The hypothesis is that Strategy 1 and 
Strategy 2 are equivalent. 
Eligible patients 
•  All patients aged 18 years and above 
(some centres may decide at outset to 
recruit only women above 40 or even 
65 years of age) 
•  Operable breast cancer (T 1-3, N0-1, 
M0) suitable for breast conserving 
surgery 
•  Cytological or histological 
confirmation of carcinoma 
99 •  Contralateral breast cancer in the 
past – these patients will be 
randomised to a separate stratum. 
Exclusion criteria 
•  More than one obvious cancer in 
the same breast as diagnosed by 
clinical examination, 
mammography or ultrasonography. 
•  Bilateral breast cancer at the time of 
diagnosis 
•  Patients undergoing primary 
medical treatment as initial 
treatment of invasive breast cancer 
•  Histological diagnosis of invasive 
lobular carcinoma or EIC 
•  Confirmed deleterious mutation in 
the BRCA1 or BRCA 2 genes. 
These patients appear to have an 
extremely high (nearly 50%) risk of 
local relapse in a conserved breast 
[Haffty et al., 2002] 
End Points 
Local tumour control (defined as 
recurrent tumour in the ipsilateral 
breast) 
Patients will be regularly monitored 
as per the individual centre’s policy 
provided this meets the minimum 
criteria for follow-up of symptomatic 
breast cancer patients as defined by 
the Breast Specialty Group of the 
British Association of Surgical 
Oncology.  Confirmation of 
recurrence will follow clinical 
examination and cytology or biopsy. 
Cosmetic result 
Photographic assessment by a physician 
and breast care nurse not participating 
in the trial will be performed at 2 years.  
The assessors will be kept ignorant as to 
which of the treatments any particular 
patient received.  Photographs will be 
assessed for cosmetic outcome and 
normal tissue damage using a 
standardised rating scale. 
Patient satisfaction  
About delivery of treatment and the 
acceptability of the cosmetic result will 
be elicited at 6 weeks and at 2-3 months 
(for those not receiving chemotherapy) 
or at 8-9 months (for those receiving 
chemotherapy) and at similar times 
after the completion of postoperative 
radiotherapy for those in the control 
arm. 
Patients will be requested to fill in a 
diary during postoperative radiotherapy 
and at a corresponding time in the 
IORT arm. Apart from the time that is 
spent to attend the daily sessions of 
radiotherapy, it will also record the 
feeling of tiredness and hindrance to 
daily work on a score of 0-3 
Health economics 
A protocol to evaluate the cost of the 
new treatment in comparison to 
standard breast irradiation will be 
developed in the feasibility stage of the 
trial. 
 
 
 
100 Trial Schema 
 
*or if the patient is at high risk of 
ipsilateral recurrence* 
 
*May 2002 modification e.g., patients less than 45yrs, pT>2 cm, pN positive, grade 3, 
ER negative. This is subsequent modification of the protocol.   
Treatment Policy Statements 
 
Only clinical centres with the Photon 
Radiosurgery System or who are 
able to refer patients to such a centre 
may enter patients to the trial.  Prior 
to entry of any patients each centre 
will register with the trials office and 
complete a Policy Statement which 
will define the categories of patients 
to be entered (e.g. some centres may 
elect only to enter older women) and 
some details of treatment policy (e.g. 
fractionation and dose of 
conventional radiotherapy to be 
used).  Any change to practice 
during the course of the trial must be 
notified to the trials office in writing 
prior to implementation.  This is to 
enable the trials office to audit 
patients entered and treatment 
received. 
 
Centres with newly acquired 
equipment must consult the principle 
clinical investigator at University 
College Hospitals prior to entering 
patients into the trial. 
 
Treatments 
Surgery 
All patients will have local excision 
of the primary tumour following 
appropriate clinical work-up but no 
special assessments prior to 
randomisation will be required.   
Surgery will be according to usual 
local practice but at least Level II 
axillary node dissection must be 
performed unless protocols for 
sentinel node excision are being 
followed.  Similar surgical technique 
must be employed in all patients 
regardless of the randomisation. It is 
impractical to blind the surgeon to 
whether the patient will be receiving 
intra-operative radiotherapy. However, 
in a pragmatic trial, it is the package 
that is being tested- and if it transpires 
that wide local excision and targeted 
intraoperative radiotherapy is effective, 
without compromising cosmetic 
outcome, then it does not really matter 
that a slightly wider excision was 
performed by the surgeon. The 
wideness of excision will be assessed 
prospectively using the ratio of tumour 
size and specimen weight as an 
indicator. 
 
Radiotherapy 
Intra-operative radiotherapy will be 
delivered in the operating theatre 
immediately after the operative 
procedure. The dose of the intra-
operative radiotherapy will be 
prescribed as 5 Gy physical dose at 1cm 
from the applicator surface.   
 
Planning protocols for the conventional 
radiotherapy will vary from centre to 
centre but for each centre a written 
policy will be required.  All patients 
randomised to receive conventional 
radiotherapy within this trial to should 
be treated in accordance with this 
policy.  Dosage should only be applied 
to the chest wall – axillary, supra-
clavicular and internal mammary nodes 
should not be irradiated by discrete 
fields.  Patients with previously 
irradiated adjacent fields for example, 
those with previous contra-lateral breast 
cancer, will need to have the 
radiotherapy fields modified according 
to local policies. 
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Extensive Intraduct Component  
Patients found on pathological 
examination of the operation 
specimen to have either invasive 
lobular cancer or extensive intra-duct 
component will receive external 
beam radiotherapy since these 
patients are at a higher risk of 
developing recurrence in the 
ipsilateral breast at a site other than 
that of the excised primary. For those 
patients randomised to intra-
operative radiation this will be in 
addition to the treatment they have 
already received. 
 
The issue of positive margins 
In the pilot study we only had one 
patient with positive margin- which 
was the deep margin. Since this was 
the blind lady who had received the 
higher (7.5Gy at 1cm) dose of 
radiotherapy, the area adjacent to the 
tumour bed would have received 
about 23Gy which was thought to be 
adequate therapy and a decision to 
give no further treatment was taken 
jointly in the multidisciplinary 
meeting and with the patient. In the 
randomised trial, the policy is to re-
excise those patients with grossly 
positive margins and re-radiating the 
new ‘correct’ tumour bed if they 
were randomised to the intra-
operative radiotherapy arm. Previous 
IORT should not contra-indicate this 
because the previously radiated area 
would have been excised in the re-
excision. 
 
Adjuvant Systemic Therapy 
Following completion of randomised 
therapy patients may be 
recommended appropriate adjuvant 
therapy according to local practice or 
trial protocols.  The policy for such 
treatments will be declared in the Policy 
Statement. 
 
Trial Administration 
Randomisation and data management of 
the trial will be carried out at the CRC 
and UCL Cancer Trials Centre.   
Clinical queries should be addressed to 
the Principle Investigator.  A Working 
Party comprised of clinicians, a 
physicist, a statistician and the trial co-
ordinator will regularly review the 
progress of the trial and address any 
problems. 
Data Monitoring Committee (DMC) 
An independent DMC will be appointed 
(or that constituted for the CRC Breast 
Cancer Trials Group will be used with 
the agreement of the Working Party).   
They will review the data collected 
during the feasibility trial and 
recommend whether the full study 
should be implemented. 
 
Subsequent meetings will be scheduled 
at their direction but these are likely to 
be annually for the first two years of the 
trial whilst accrual gains momentum.   
More frequent meetings may be held at 
their or the Working Parties request. 
 
There are no formal stopping rules for 
the trial – these may be determined in 
discussion with the DMC but should a 
difference between the treatments in 
local recurrence reach p < 0.001 serious 
consideration to continuation will be 
given. 
Randomisation 
When we first applied for ethics 
approval, we had proposed that the 
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the Zelen Method.  
The UCL ethics committee did not 
approve of this as a matter of general 
principle and we have used the 
standard randomisation procedure for 
the trial. Fortunately, as discussed 
later, we do not feel that his has 
reduced the patient accrual.   
However, it is important to note down 
the arguments for this case- for it may 
be required to be done in other 
centres as given in the next 4 
paragraphs. 
Then numbers needed for the same 
power with standard randomisation 
are smaller. 
 
Patient entry into trial 
Patients will be randomised prior to 
surgery but only after being informed 
of the trial and given written 
information.  Every patient deemed 
suitable for the trial will be entered 
into the randomisation procedure 
once informed consent has been 
gained.”    
 
Statistical Considerations 
Patient Numbers and Power 
Calculations 
The CRC Trial comparing the 
outcome for patients with good 
prognosis early breast cancer 
demonstrated a local recurrence rate 
of 9% at five years in the arm treated 
with conventional radiotherapy.  The 
objective of the trial is to determine 
whether the use of intra-operative 
radiotherapy gives equivalent rates of 
local control to those obtained using 
external beam treatment.  We define 
equivalence as ruling out a hazard 
ratio of greater than 1.5 (i.e. a change 
in recurrence rate from 9% to 13.5%).  
Since the use of the new technique 
would employ less resource this small 
increase in absolute rate is deemed 
acceptable.  Thus, equivalence will be 
concluded if the upper limit of the 2-
sided 90% confidence interval for the 
hazard ratio does not exceed 1.5.  Given 
the recurrence rates above, we could 
expect at five years about 75 events from 
about 850 patients entered per arm.  If 
the population hazard ratio is one then 
the expected 90% confidence interval 
will be (0.7, 1.31). 
Therefore to demonstrate equivalence 
with 90% confidence intervals the 
observed log hazard must fall below 
[log(1.5)-0.269 = 0.137].  The 
probability that this will occur when the 
true hazard ratio is one is 80% (i.e. the 
trial will have the power to demonstrate 
equivalence with 80% power with 833 
patients per arm if the treatments are 
truly identical. 
Recent modification of trial design 
During the 3
rd European Breast Cancer 
Conference at Barcelona in March 
2002, several investigators from 
Australia, Europe and  USA met to 
discuss the multicentre participation in 
the  Targit trial. It appeared that most 
investigators would find it safer and 
wiser to restrict entry to those patients 
who are at lower risk of local 
recurrence. These patients would firstly 
be a subset of patients suitable for 
breast conserving surgery and secondly 
have a low local recurrence rate in the 
range of 2-4%. In order to run an 
equivalence trial among these patients 
the sample size would need to be 
between 6000-8000 patients, making 
the trial rather impractical. It was 
suggested by the author that we should 
rather flip the trial over. Instead of 
setting up the trial to prove   
EQUIVALENCE of Targit and 
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radiotherapy, we should set it up to 
prove a DIFFERENCE between two 
strategies (not treatments).  
This is because we can expect that 
Targit will reduce local recurrence 
rates if given in addition to external 
beam radiotherapy in patients with 
high risk of local recurrence because 
of higher local dose, better 
biologically effective dosimetry and 
no geographical misses. At the same 
time, we can expect that in the low-
risk group receiving Targit  to have a 
local recurrence rate equivalent to 
conventional postoperative 
radiotherapy (<1% change from the 
background risk of 3-4%). 
Thus, in addition to patients with 
lobular carcinoma and EIC, patients 
with pathological tumour size > 2cm, 
involved lymph nodes, nuclear grade 
3 and oestrogen receptor negative 
(ER -ve) patients will receive whole 
breast postoperative radiotherapy 
following  Targit. With this 
modification we could still expect 
between 45-60% of patients 
undergoing breast conserving 
surgery to receive Targit as the only 
mode of radiotherapy. 
Thus the modified hypothesis is that 
Strategy 1 is better than Strategy 2. 
Overall, for both the high-risk and 
low-risk groups together, we should 
get a reduction in local recurrence 
rates- say  from 9% (overview data) 
to 4%. Power calculations reveal that 
we would need 419 patients in each 
arm to see that 5% reduction in local 
recurrence rate with a 95% 
confidence and 80% power. 
Such a trial of course does not 
address a very elegant or clean 
scientific question (viz. is Targit 
alone equal to whole breast 
radiotherapy +boost), but it is 
pragmatic and will compare two 
strategies rather than treatments. If the 
trial is positive, strategy 1 can be 
adopted as standard treatment with a 
small risk that in good prognosis 
patients there may be a <1% increase in 
recurrence rates. If no difference is 
demonstrable, then it will be up to 
individual clinicians and patients to 
decide whether the cost saving and 
convenience is worth taking the risk of 
increasing the local recurrence by a 
maximum of 5%. The Strategy 1 will 
still have the potential of time, money 
and breasts. 
The visible change in the original Targit 
protocol algorithm would only be the 
addition of high-risk groups to the 
Lobular and EIC box- as has been 
shown with an asterix* 
Finally, if we extend the latest estimates 
from the Oxford  
if we reduce local recurrence by 5% we 
should expect to improve overall 
survival by 1% but of course that is not 
being tested in this trial. 
Statistical Analysis 
The major endpoint is the incidence of 
local recurrence.  This will be compared 
on the basis of ‘intention to treat’ (i.e. all 
randomised patients will be analysed) 
and the log rank test will be used.  This 
will be performed once the baseline data 
have been compared to test the 
randomisation and to define whether any 
stratified analyses are required.  In 
addition ratios of radiological lesion size 
to clinical and pathological size will be 
compared to ensure that the extent of the 
surgical procedure was similar in both 
groups.  The specimen weight will also 
be collected.  
 
In addition exploratory subgroup 
analyses will be performed on the main 
endpoint including variables such as 
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nodal involvement. 
The first randomised patient was 
operated on 29 March 2000. We have 
randomised 29 patients to date (June 
2001). Patient characteristics of first 24 
patients are given in the table.  
Cosmetic result and patient 
satisfaction will be simple 
comparisons of the scoring achieved. 
 
Ethical Considerations 
The patient is usually informed about 
possibility of the novel treatment (in 
context of the pilot study or the 
randomised trial) at the time of giving 
the diagnosis when the preliminary 
discussion about the treatment takes 
place in presence of the breast care 
nurse. This can frequently be the first 
visit in our one-stop clinic. For the pilot 
study, after the 1
st case in July 1998, 
there were local administrative 
problems and proper accrual did not 
start until January 1999 and by January 
2000, we had accrued 26 patients. 
During the pilot study almost all 
patients who were approached had 
agreed to participate.  
This trial, as for most randomised 
studies includes an experimental 
treatment.  However, in this case the 
availability of the new procedure is 
strictly limited.  There very few 
machines in clinical centres and even 
at those centres that have the 
equipment, not all patients can be 
given the new procedure.  However, 
should the new technique provide 
adequate local control and cosmesis, 
and be acceptable to patients it will 
markedly reduce the need for 
external beam radiotherapy for early 
breast cancer. This will enable a 
major saving of resource.  The ideal 
time to implement a full randomised 
assessment is while the technology is 
at fairly early stage of development.  
Since there are insufficient resources 
to give the new technique to all 
patients randomisation is the most 
ethical way to proceed.  In the pilot 
study, every patient deemed suitable 
for intra-operative radiotherapy and 
approached gave consented for the 
procedure.  We expect therefore a 
high acceptance of the novel arm.   
All patients will be informed of the 
trial and given the opportunity to 
participate.  Patients will be given a 
period (several days depending on 
the clinic timings) to consider entry 
and complete the consent form.   
Randomisation will only proceed 
once a signed consent form has been 
received at the clinic. 
In the one year period after we started 
the randomised trial, we have 
approached 32 of the 34 possibly 
eligible patients. The idea of being able 
to avoid the 6 weeks of daily treatment 
is very appealing to patients and most 
wish to take the 50% chance of 
receiving it. Only 3 have refused entry 
into the trial- the reasons in two patients 
was – ‘too much to take in at that time’ 
and one of them actually asked to be 
included on the morning of surgery- 
which of course was too short a notice.  
One patient randomised to receive 
postoperative radiotherapy was 
misinformed by the breast care nurse 
that she was allocated to the intra-
operative arm and hence came prepared 
for it and insisted that she be given the 
treatment. After long discussions it was 
decided to be done- as a trial violation. 
Unfortunately, the tumour was lobular 
carcinoma and she needed to take 5 
weeks of postoperative radiotherapy. 
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receive intra-operative radiotherapy 
did not receive it because the 
radiotherapy monitor did not work. 
This was only the second time in 2.5 
years that we had a problem with 
equipment. The first time, was our 
(possible) 3
rd patient in the pilot 
study, when one of the theatre 
runners knocked down the 
equipment and broke the quality 
assurance equipment.  In the 
randomised study, 3 patients 
randomised to the IORT arm had to 
take 5 wks of postoperative 
radiotherapy because of lobular 
histology. One elderly patient 
randomised to take postoperative 
radiotherapy has refused to take it 
despite prolonged discussions. 
The complications, local recurrence 
rates and cosmetic outcome have 
been analysed only for the purpose 
of this chapter. The maximum follow 
up is 18 months and the median is 10 
months. There was one post-
operative wound infection and this 
was in the Post-operative arm. The 
maximum dose of radiation to the 
skin has been on an average 3Gy 
(95% CI 2.2-3.9). The cosmetic 
outcome has been excellent in both 
arms. No formal comparison is 
possible at this time, but it appears 
that the patients are very much 
satisfied (of the 11 patients assessed, 
the satisfaction index for appearance 
as well as texture was above 1 in all 
the 6 Targit patients but it was below 
1 in 4 out of 6 post-operative 
radiotherapy patients). There has 
been no local recurrence in either 
arm. 
Discussion 
Several international investigators 
have now joined to form an steering 
committee and have submitted the 
first joint abstract to the ESTRO 2002 
meeting. This includes results from 
three centres with a total of 94 patients 
treated using this method.  With several 
centres collaborating it can be expected 
that the recruitment in the randomised 
trials will be excellent. 
The national and international 
implications of development of such a 
novel approach can be considerable. 
Treatment of breast carcinoma often 
represents a third or more of the total 
case-load of radiotherapy units 
worldwide. Many women from the 
developing world and remote areas of 
the developed world (e.g. Outback of 
Australia and rural USA) cannot benefit 
from breast conserving therapy because 
of the large distances between their 
home and the radiotherapy centre. For 
more privileged woman, the avoidance 
of 6 weeks of daily visits to a 
radiotherapy centre would be a great 
advantage. Furthermore, in our pilot 
study we have found that in terms of 
operational expenses the novel 
technique needs about 3 man-hours and 
45 minutes each of operation theatre 
time and patient time. The conventional 
6-week course of post-operative 
radiotherapy on the other hand, costs 
about 9 man-hours, 6 hours of 
radiotherapy room time and 30 - 60 
hours of patient time. If the cost of 
conventional radiotherapy were £5000, 
considering only the 66% saving of 
man-hours the novel technique would 
save £3750 per patient.  So, if we 
assume that 60% of the 27000 breast 
cancer patients diagnosed every year in 
the UK, are treated by conservative 
surgery, the novel technique would 
potentially save about 60.75 million 
pounds (0.60 x 27000 x 3750) per year 
for the NHS. In addition, the saving of 
expensive resource time on linear 
accelerators would of course be 
substantial. 
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undergone immense changes in the 
last century-these have been 
prompted mainly by changing 
models of disease. In addition, 
change was brought about by 
developments in other fields of 
medicine, for example, availability 
of good anaesthetic technique 
allowed Halsted to perform major 
surgery. More recently, patient 
advocacy groups have prompted 
change. Paradoxically this was less 
relevant for the development of 
conservative breast surgery but is 
becoming increasingly important in 
the demand for sentinel node biopsy 
in today’s patient/ consumer/ client 
led world.  
Breast cancer treatment is mainly 
directed towards achieving two 
goals- local tumour control with 
cosmetic outcome as an important 
secondary aim and systemic control 
with personal cure of the disease as 
the final goal. This thesis deals with 
the former- the optimal local control 
of disease. 
The history of breast cancer 
treatment and the concept of local 
recurrence are dealt with in detail in 
the first chapter. It appears from 
various clinical trials of breast 
conserving surgery that clinically 
relevant invasive duct carcinoma is 
to some extent a “focal” disease that 
is limited to one quadrant of the 
breast. This may be related to the 
suggestion that chromosomal 
abnormalities arise at an early age 
and are therefore distributed in a 
segmental fashion along the primary 
branches of the duct system. These 
chromosomal abnormalities are 
probably more important in 
developing a milieu that is conducive 
for transformation rather than actual 
transformation itself because, the 
segmental nature is restricted to 
clinically expressed invasive ductal 
carcinoma rather than occult or latent 
cancers. The spatial distribution of 
latent in situ cancer, as described in the 
second chapter, is on the other hand not 
segmental in nature, i.e., occult cancers 
are distributed evenly in all quadrants of 
the breast with no difference in such 
distribution between individual cancer 
types. It appears that for development 
of invasive ductal cancer, the local 
milieu of the surrounding breast tissue 
is very important and when a conducive 
milieu is present in any one area of the 
breast, it promotes the growth of 
tumours, both primary and recurrent. 
For lobular cancers and for breasts 
harbouring extensive intra-ductal 
cancer, it appears that the surrounding 
milieu is either less important or, is 
already conducive to cancer growth in 
all areas, so that clinically important 
cancers can develop in all areas of the 
breast. In addition invasive lobular 
cancers have been characterized by 
their ability to secrete proteolytic 
enzymes allowing an alternative 
mechanism of local progression to the 
expansile growth of invasive duct 
cancers. Further studies in breast cancer 
should involve investigating the 
characteristics of breast milieu 
commonly called ‘field change’ that 
induces or promotes cancer growth in 
particular quadrants.  
The next phase in this project was to 
test the hypothesis that there might be a 
pre-clinical test that could characterise 
the clinical relevance of occult cancers. 
We hypothesised that Magnetic 
resonance imaging- which relies on 
tumour vascularity for producing 
contrast enhanced images, might be 
able to detect tumours that are more 
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clinically relevant. However, 
contrast enhanced MRI proved to be 
perhaps too sensitive and was able to 
detect almost all occult cancers that 
we could subsequently detect using 
detailed histopathology. We 
concluded that we should use this 
new tool with caution and not allow 
ourselves to be precipitated into a 
mastectomy for the majority of 
patients thus overthrowing the 
wisdom gleaned from the robust 
results of breast conservation trials.  
These being the biological 
implications of our findings, the 
clinical implications were rather 
straightforward, albeit going against 
the current dogma of breast 
conservative surgery. The argument 
for whole breast radiotherapy after 
breast conservative therapy arose 
from the idea that breast cancer is a 
multifocal/multicentric disease, with 
most (90%) of the multifocality in 
proximity to the primary tumour. 
This was the explanation given for 
the increased incidence of local 
recurrence near the primary tumour. 
Our whole organ analysis in 3-
dimensions found that occult 
tumours were present in all 
quadrants and not related to the 
spatial distribution of the primary 
tumour and are thus not relevant for 
early local recurrence – which occurs 
most commonly in the index 
quadrant rather than anywhere else, 
for reasons yet to be elucidated. If 
the widespread multifocality is not 
clinically relevant, then the standard 
whole breast radiotherapy after 
breast conserving surgery is of 
questionable value.  
We present the problems faced by 
patients undergoing breast 
conserving therapy and health care 
systems delivering it. The 6-wk course 
of radiotherapy is costly and 
inconvenient at best and prohibitive at 
worst. Many women living in 
geographically remote areas, far from a 
radiotherapy centre, cannot take the 6-
wk holiday in the metropolis to take the 
radiotherapy course, and not many 
welfare states can provide for their 
accommodation or transport. Frequently 
these women have to choose between 
mastectomy and breast conservation, on 
the basis of, not the nature of the 
cancer, but on whether they can afford 
commute daily, or to live near the 
radiotherapy centre for the 30 visits 
during the course of radiotherapy. A 
solution to these problems is to deliver 
radiotherapy only to the quadrant of 
primary tumour with a technique that 
can do it in one sitting- preferably in the 
operating theatre at the time of the 
primary surgery. We describe one such 
technique of delivering therapeutic 
radiation in a standard operating theatre. 
The machine is called Photon 
Radiosurgery System (PRS). This 
technique directs soft x-rays generated 
with a portable lightweight electron-
beam-driven device. These x-rays are 
generated at the centre of an applicator 
that can be placed in the tumour bed. So 
the radiation is from within the breast 
and as the pliable breast tissue wraps 
around the applicator, true conformal 
radiotherapy dosimetry is achieved. The 
highest dose is delivered to the tissues 
immediately adjacent to the applicator 
and normal tissues like skin do not get 
significant radiation damage. Since the 
high dose region is of a small volume 
we expect that the late fibrosis, if any, 
will not be disfiguring.  
We had two tasks- first to test the novel 
radiotherapy technique and then to test 
then novel approach of single dose 
112 index quadrant radiation. In the first 
phase, we substituted the 
conventional 1wk course of tumour 
bed boost with intra-operative 
radiotherapy using the PRS device; 
the remaining 5-wk course of whole 
breast radiotherapy (50Gy, #25) was 
delivered as usual. In the pilot phase 
we tested the feasibility of 
conducting the clinical trial- patient 
acceptability, the logistics of co-
ordination between the radiotherapy, 
radiation physics and surgical 
departments and the clinical results. 
We found the usual resistance to 
change in the administrative circles- 
but the business proposition of 
possible saving money for NHS was 
attractive to the management. The 
patient acceptability was the least 
difficult area- only 2 of the patients 
offered the novel treatment refused 
to take part in the pilot study. Many 
patients were keen not to take the 
5wk course, suggesting to us that 
recruitment in the next phase of the 
project would be relatively easy. The 
pilot study and the operative 
technique are described in the 4th 
and 5th chapters. There has been no 
local recurrence in any of the 
patients on the pilot study at the 
median follow up of 34 months and 
the cosmetic outcome is good and 
the patients are satisfied. The results 
of the pilot study were instrumental 
in getting FDA approval for the PRS 
device. 
We also used the PRS device in 
another increasingly common 
clinical situation. Elderly patients 
who are not fit for surgery, but are 
nevertheless known to benefit from 
local treatment are frequently treated 
with tamoxifen alone for the want of 
suitable local therapy. We tested the 
use of PRS radiotherapy as the 
primary treatment in these cases. We 
used the Fischer Mammotest prone 
table- for stereotactic localisation of the 
primary tumour and Mammotome 
vacuum biopsy for limited excision 
under local anaesthetic. After 
calibrating the Fischer table for the PRS 
device, we placed the tip of the bare 
PRS probe in the centre of the tumour. 
The radiation dose of over 130 Gy was 
achieved at the centre with the 
periphery of the tumour receiving about 
20 Gy. We found remarkable response 
to this treatment. The contrast-enhanced 
MRI, just 6 days after treatment 
revealed an almost absence of vascular 
enhancement in the tumour. All these 
patients with other co-morbid 
conditions and short life expectancy 
have lived the rest of their life without 
suffering from the morbid sequele of 
breast cancer. 
Encouraged by the results of the pilot 
phase, we started the randomised trial in 
March 2000, to test the hypothesis that 
radiotherapy to the peri-tumoural 
tissues alone is adequate local 
treatment. We called it TARGeted 
Intraoperative radioTherapy (TARGIT) 
trial. The randomisation procedure was 
much easier than expected. We were 
able to recruit more than 90% of 
patients eligible for the trial. Only 3-4 
patients have refused to take part- 
mainly because the option of entry into 
trial is usually given early in the 
discussions about treatments and it was 
too much to take in for the patient. The 
early cosmetic results are good and 
there has not been any recurrence 
although the follow up time is short. 
Since the numbers needed to prove 
equivalence are 850 in each arm, a 
multicentre trial was deemed a 
necessity. A recent modification will 
change the trial from an equivalence 
trial to a trial to test whether a strategy 
113 using Targit for all patients and 
additional whole breast radiotherapy 
for high-risk patients reduces local 
recurrence rates compared with 
conventional postoperative 
radiotherapy. Such a trial will need 
419 patients in each arm to show a 
reduction in local recurrence from 
9% to 4%. 
The implications of proving TARGIT 
equal to 6-wk course of radiotherapy 
are far reaching. Firstly, it will save the 
ordeal that these women have to face to 
come daily for the ‘radiotherapy shot’. 
As one woman in our trial described it 
to BBC’s Tomorrow’s world- ‘I felt a 
bit of a fraud… have I really had cancer 
treatment? I had finished all my 
treatment and was back at work in 2 
days’. In the more ‘prosperous’ 
countries, it will mean saving millions 
of pounds and radiotherapy resources 
and for the thousands of women in the 
developing countries and remote areas 
of developed world, it will mean they 
can preserve their breasts!  
This trial has attracted worldwide 
interest and several investigators 
from Australia, India, UK, Italy and 
USA are keen to join in. The 
protocol of the randomised study has 
been peer-reviewed and published on 
the Lancet Website. 
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127 128 Pilot study - Patient Characteristics
Sr 
No
Date of 
Surgery
HospNo Age 
(yrs)
height 
(cm)
weight 
(kg)
bra-
size
bra- 
cup
Ethnic 
origin
Menopa
usal 
status
Other 
Medical 
history
1 02/07/1998 93074699 59 165.0 59.0 38 C Caucasian Post-
2 17/09/1998 98052875 71 155.0 64.0 36 C Caucasian Post-
3 10/02/1999 99002414 51 160.0 67.0 38 C Caucasian Peri- Asthma
4 03/03/1999 U/FN1171 43 160.0 59.1 34 A Caucasian Peri-
5 24/03/1999 99009704 36 157.0 48.0 34 A Caucasian Pre-
6 07/04/1999 96003407 34 173.0 65.0 36 A Caucasian Pre- Polycystic 
kidney
7 07/04/1999 E/VA0143 47 163.0 56.0 34 A Caucasian Post-
8 14/04/1999 91033939 65 155.0 70.0 40 B Caucasian Post- Asthma, 
High BP
9 14/04/1999 99014609 41 160.0 95.0 38 D Caucasian Pre-
10 05/05/1999 92041175 80 152.0 48.0 32 A Caucasian Post- Blind
11 12/05/1999 99025004 47 168.0 67.0 36 B Jewish Pre- Ovarian 
cysts
12 23/06/1999 99029406 46 170.0 61.0 34 B Black 
Carribean
Pre-
13 30/06/1999 U/FC8805 72 177.8 73.2 38 D Caucasian Post- Rt Breast 
cancer -
BCT 1984
14 30/06/1999 91118496 56 169.0 64.0 34 E Caucasian Post-
15 07/07/1999 99024760 47 163.0 70.0 38 B Caucasian Post- Borderline 
mucinous 
ca ovary
16 14/07/1999 99026480 49 163.0 61.0 34 C Indian Peri-
17 20/10/1999 95040397 43 158.8 48.00 34 A Indian Peri-
18 03/11/1999 99055515 31 158.0 45.0 34 B Chinese Pre-
19 03/11/1999 99059814, 
MZC00882
45 147.3 126.0 36 B Jewish Pre- depression
20 10/11/1999 95015227 53 167.6 126.0 34 A Black 
Carribean
Peri-
21 17/11/1999 98023506 55 168.9 70.0 38 DD Caucasian Post- On HRT
22 17/11/1999 U/BZ6707 69 167.0 105.7 42 D Caucasian Post-
23 01/12/1999 U/FP7647 53 161.3 54.0 36 B Caucasian Pre-
24 19/01/2000 99028455 52 156.0 55.0 34 C French Peri-
25 26/01/2000 93068967 34 172.0 60.0 30 FF Indian Pre-
26 22/03/2000 93074379 73 Jewish Post- R breast  
1987
Age
Ht. 
(cm)
Wt. 
(Kg)
Bra 
Size Bra Cup
Mean 52.0 162.7 68.7 35.7 A7
SD 13 7.2 21.9 2.63 B 7
95% CI 5.1 2.8 8.4 1.01 C 5
UCL 46.9 160.0 60.3 34.7 D 3
LCL 57.1 165.5 77.1 36.7 DD 1
Median 50.0 163.0 64.0 36.0 E1
Min 31.0 147.3 45.0 30.0 FF 1
Max 80.0 177.8 126.0 42.0 ? 1
129 Pilot study-Intra-operative radiotherapy details
Sr No Applicator 
(cm)
Heart 
shield
IORT 
Dose @ 
1cm
IORT 
time 
(min)
Cumulative 
photon 
count
Average 
Photon 
Count
Max 
TLD
Avge 
TLD 
skin 
dose
1 3.5 Yes 5.0 36.8 60302977 1638668
2 4 Yes 5.0 28.18 82787142 2937798
3 3.5 5.0 22.7 81598491 3594647
4 3.5 Yes 5.0 21.1 71591442 3392959
5 3.5 Yes 5.0 23.11 83685594 3621185
6 3.5 5.0 21.14 76852826 3635422
7 3 Yes 5.0 26.48 95588259 3609829
8 3.5 5.0 22.59 76942624 3406048
9 4 5.0 28.74 96644147 3362705
10 3.5 Yes 7.5 32.63 115611422 3543102
11 3.5 5.0 21.58 72269326 3348903
12 2.5 5.0 23.42 84323289 3600482
13 4.5 Yes 6.0 42.57 152542300 3583329 6.5 5
14 3 4.0 22.4 80287366 3584257 2.3 1.6
15 3.5 Yes 5.0 21.09 71087060 3370652 4.8 3.1
16 4 Yes 5.0 26.97 96249937 3568778 3.4 2.9
17 4 5.0 26.24 88757587 3382530 3.5 3.3
18 3.5 Yes 5.0 21.65 73390350 3389855 9.2 6.5
19 3 5.0 27.16 91285790 3361038 4.5 4.2
20 3.5 5.0 21.95 70136311 3195276 7.6 6.1
21 3.5 Yes 5.0 21.03 71562702 3402886 1.4 1.2
22 4.5 Yes 5.0 33.37 112981391 3385717 8.9 7.9
23 3.5 Yes 5.0 21.03 70932894 3372938
24 4.5 5.0 33.91 119442153 3522328 3.7 3.1
25 4.5 5.0 34.34 115911180 3375398 2.1 1.7
26 4 5.0 27.08 91395830 3375031 1.8 1.5
IORT 
time 
(min)
Cumulative 
photon 
count
Average 
Photon 
Count
Max 
TLD 
(Gy)
Avge 
TLD 
(Gy)
Mean 26.5 88621553 3367760 4.6 3.7
Applicator Sizes SD 5.9 20594388 384593 2.7 2.1
2.5cm 1 95% CI 2.3 7916071 147830 1.0 0.8
3cm 3 UCL 24.3 80705483 3219930 3.6 2.9
3.5cm 13 LCL 28.8 96537624 3515590 5.6 4.5
4cm 5 Median 24.8 83236368 3391407 3.7 3.1
4.5cm 4 Min 21.0 60302977 1638668 1.4 1.2
Max 42.6 152542300 3635422 9.2 7.9
130 Pilot study- Operation and IORT time
S
er 
N
o.
SNB 
Start
Op 
Start
Op 
End
IORT 
Start
IORT 
End
All End
IORT 
Setup
IORT
Op 
Time
Ext RT 
Start
Ext RT 
End
Ext 
RT 
(Gy)
#
1 14:05 14:55 15:20 16:00 16:35 0:25 0:37 2:30 07/08/98 18/09/98 50 25
2 14:30 14:45 16:50 0:28 2:20 04/11/98 15/12/98 50 25
3 11:30 11:40 12:40 13:00 13:22 13:35 0:20 0:22 1:55 11/03/99 22/04/99 50 25
4 11:05 13:30 0:21 2:25 05/05/99 15/06/99 50 25
5 10:20 11:00 11:50 12:05 12:28 12:55 0:15 0:23 1:55 27/10/99 03/12/99 50 25
6 9:15 9:25 10:20 10:34 11:08 11:24 0:14 0:21 1:59 04/10/99 11/11/99 50 25
7 12:00 12:15 12:45 13:00 13:40 14:00 0:15 0:26 1:45 17/05/99 01/07/99 50 25
8 12:30 12:45 13:15 13:32 13:56 14:30 0:17 0:23 1:45 17/05/99 29/06/99 50 25
9 14:45 14:55 15:18 15:30 16:00 16:15 0:12 0:29 1:20 23/09/99 04/11/99 50 25
10 11:45 12:30 12:48 13:30 13:45 0:18 0:33 2:00 No Post op RT
11 11:15 11:55 12:06 12:30 12:50 0:11 0:22 1:35 07/06/99 00/01/00 50 25
12 11:40 12:05 12:25 12:35 13:00 13:10 0:10 0:23 1:05 12/07/99 23/08/99 50 25
13 15:55 16:55 17:05 17:48 18:00 0:10 0:43 2:05 No Post op RT
14 12:45 13:08 13:42 14:05 14:30 14:45 0:23 0:22 1:37 23/08/99 07/10/99 50 25
15 16:40 18:48 0:21 2:08 12/08/99 23/09/99 50 25
16 13:45 13:54 14:25 14:34 15:00 15:10 0:09 0:27 1:16 05/08/99 10/09/99 50 25
17 13:04 15:15 0:26 2:11 13/12/99 27/01/00 50 25
18 13:05 15:19 0:22 2:14 17/04/00 24/05/00 50 25
19 10:30 12:45 0:27 2:15 No Post op RT
20 12:10 14:20 0:22 2:10 05/01/00 09/02/00 50 25
21 8:40 9:05 10:20 0:21 1:15 No Post op RT
22 10:24 13:10 0:33 2:46 24/01/00 28/02/00 50 25
23 15:05 17:16 0:21 2:11 19/01/00 22/02/00 50 25
24 15:25 17:45 0:34 2:20 Had Bilateral mastectomy
25 13:43 16:10 0:34 2:27 01/08/00 11/09/00 50 25
26 11:30 13:00 0:27 1:30 50 25
    Operation + IORT time
 IORT 
Setup IORT Total
n1 3 2 6 2 6
Mean 00:15 00:26 01:57
SD 00:05 00:05 00:26
95%CI 00:01 00:02 00:10
UCL
00:13 00:24 01:47
LCL 00:17 00:28 02:07
Median 00:15 00:24 02:02
Min 00:09 00:21 01:05
Max 00:25 00:43 02:46
131 Pilot study - Histopathology
Sr No Specime
n Wt. 
(gm)
Sp. 
X 
(cm)
Sp. 
Y 
(cm)
T     
X 
(cm)
T   
Y   
(cm)
Lymph 
Node 
dissected
Lymph 
nodes 
involve
d
Histology Grade DCIS LCIS
15 4 1 1 9 0 I D C 2 0
23 2 6 4 4 5 1 2 0I D C 1 1 0
32 6 6 5 1 1 9 0I D C 3 1 0
45 6 6 6 2 2 8 0I D C 1 1 0
52 5 5 4 1 1 9 0I D C 3 1 0
64 2 6 5 1 1 1 8 0I D C 3 0 0
7 17 4 4 0.4 0.4 13 0 Tubular 1 1 0
87 2 4 4 3 3 6 0 ILC 110
91 0 2 8 8 2 2 2 5 0I D C 3 0 0
10 68 10 6 3 2 10 0 IDC 2 1 0
11 21 6 4 4 15 1 IDC 3 EIC 0
12 21 5 4 2 0 1 0 IDC 1 1 1
13 0 10 9 3 0 13 0 IDC 3 1 0
14 42 7 4 2 2 10 0 ILC 101
15 72 7 7 2 0 12 0 IDC 2 1 0
16 90 9 8 1 0 1 0 IDC 2 1 1
17 75 9 9 3 0 13 0 IDC 3 0 0
18 23 6 6 2 0 10 0 IDC 3 1 0
19 19 5 5 3 0 20 0 IDC 3 0 0
20 35 6 6 2 2 6 0 IDC 3 1 0
21 80 7 6 2 2 1 0 IDC 2 0 0
22 220 13 11 4 4 18 0 IDC 2 0 0
23 29 7 6 2 1 13 2 IDC 2 0 0
24 93 8 7 3 3 9 0 ILC 201
25 34 7 5 3 3 6 1 IDC 3 1 0
26 79 9 6 3 2 14 0 IDC + ILC 310
Sr No Specimen 
Wt.
Sp. 
X 
(cm)
Sp. 
Y 
(cm)
T     
X 
(cm)
T    
Y   
(cm)
Lymph 
Node 
dissected
Lymph 
nodes 
involved
Mean 56.3 7.6 5.9 2.2 1.5 12.1 0.2 IDC 21
SD 45.0 3.5 1.8 0.9 1.3 4.7 0.5 Tubular 1
95% CI 17.3 1.3 0.7 0.3 0.5 1.9 0.2 ILC 3
UCL 39.1 6.2 5.2 1.9 1.0 10.2 0.0 ILC+IDC 1
LCL 73.6 8.9 6.6 2.5 2.0 14.0 0.4
Median 42.0 6.8 5.5 2.0 1.5 12.0 0.0 Grade 1 6
Min 0.0 4.0 3.5 0.4 0.0 6.0 0.0 Grade 2 12
Max 220.0 21.0 11.0 4.0 4.5 25.0 2.0 Grade 3 8
0
132 Pilot study -Patient Satisfaction
Case No.
Appearance 
Expected
Appearance 
Actual
Appearance-
O/E
Texture 
Expected
Texture 
Actual
Texture 
Exo/Obs
1 7 9.00 1.29 7 8.00 1.14
2 6 8 1.33 6 8 1.33
3 7 9 1.29 7 8.5 1.21
4 5 9.00 1.80 3 8.00 2.67
5 4 7.00 1.75 5 8.00 1.60
6 8 8 1.00 7 8 1.14
7 8 4.00 0.50 8 4.00 0.50
8 8 10.00 1.25 9 9.00 1.00
9 8 8 1.00 9 9 1.00
10 8 9 1.13
11 10 10
12 9 8.00 0.89 9 8.00 0.89
13 5 5 1.00 5 7 1.40
14 8.5 7.00 0.82 8.5 7.00 0.82
15 5 9 1.80 5 9 1.80
16 6 8 1.33 8 8 1.00
17 4 8 2.00 5 7 1.40
18 7 8 1.14 7 8 1.14
19 88 1.00 77 1.00
20 9 10 1.11 9 10 1.11
21 6 9 1.50 5 9 1.80
22 9 10.00 1.11 9 8.00 0.89
23 8 9 1.13 8 9 1.13
24 6 9.00 1.50 6 9.00 1.50
25 8 7.00 0.88 7 5.00 0.71
26
Sample size 23 24 23 24 25 24
Means 6.9 8.2 1.2 7.0 8.0 1.2
Std Dev 1.58 1.47 0.36 1.67 1.36 0.44
95% CI 0.65 0.59 0.15 0.67 0.53 0.18
Lower CL 6.3 7.6 1.1 6.3 7.5 1.0
Upper CL 7.6 8.8 1.4 7.6 8.6 1.4
*Patients were asked to give a score between 1 to 10, 10 being the best
Assessment in this table are at 12 - 24 months
133 Satisfaction Index - Appearance
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134 Satisfaction Index - Texture
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135 Targit Trial Allocation
Trial No. Hosp No. Allocated Received
Date of 
Surgery
BCTA 001001 99003147 Postop Postop 29/03/00
BCTA 001002 97037297 Postop Postop 05/04/00
BCTA 001003 97041624 IORT IORT 22/05/00
BCTA 001004 M/184521 IORT IORT 26/06/00
BCTA 001005 U/EH9157 Postop Postop 19/07/00
BCTA 001006 92013347  IORT IORT 31/07/00
BCTA 001007 E/G1544  Postop
Postop
02/08/00
BCTA 001008 92009449 Postop IORT+Postop 07/08/00
BCTA 001009 00038414  IORT IORT 09/08/00
BCTA 001010 00039748 Postop Postop 16/08/00
BCTA 001011 93080167 IORT IORT 30/08/00
BCTA 001012 91144767 IORT IORT 15/11/00
BCTA 001013 91116415 IORT IORT 22/11/00
BCTA 001014 U/AS3533 Postop Postop 29/11/00
BCTA 001015 97066902 IORT IORT 29/11/00
BCTA 001016 00054580 Postop Nil 01/12/01
BCTA 001017 M/364301 Postop Postop 01/12/01
BCTA 001018 95029497 IORT IORT+Postop 26/01/01
BCTA 001019 00066220 IORT Postop 01/02/01
BCTA 001020 U/AE5416 Postop Postop 19/03/01
BCTA 001021 UBD5206 Postop Postop 04/04/01
BCTA 001022 M308851 Postop Postop 28/03/01
BCTA 001023 96003378 IORT IORT 04/04/01
BCTA 001024 93089517 IORT IORT+Postop 28/03/01
136 Targit trial - Patient Characteristics
Trial No. DOB Religion
Ethnic 
origin
Age
Meno-pausal 
status
BCTA 001001 06/10/48 none White 52 Post
BCTA 001002 07/06/49 COE White 51 Post
BCTA 001003 30/06/69 Evangeli Whte 31 Pre
BCTA 001004 07/10/56 none White 44 Pre
BCTA 001005 14/07/29 COE White 71 Post
BCTA 001006 01/05/55 COE White 45 Pre
BCTA 001007 07/09/55
none
45 Pre
BCTA 001008 07/03/49 other White 51 Pre
BCTA 001009 18/06/30 COE White 70 Post
BCTA 001010 29/07/55 White 45 Pre
BCTA 001011 09/11/22
RC White 78 Post
BCTA 001012 19/03/49
RC White
52 Post
BCTA 001013 02/09/32 RC White 68 Post
BCTA 001014 24/12/27 COE White 73 Post
BCTA 001015 15/12/51 COE Black  49 Pre
BCTA 001016 17/07/23 White 78 Post
BCTA 001017 15/12/28 COE White 73 Post
BCTA 001018 01/11/43 Greek White 57 Pre
BCTA 001019 01/09/56 Hindu Asian 44 Pre
BCTA 001020 03/07/36 RC White 65 Post
BCTA 001021 11/02/41 COe White 60 Post
BCTA 001022 09/07/32 COE White 69 Post
BCTA 001023 01/01/58 RC White 43 Pre
BCTA 001024 17/07/35 Protesta White 66 Post
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Targit trial - Operation and IORT details
Trial No. Start End IORT 
time
Total 
Time
Appli
cator 
(cm)
IORT 
Dose
Gy 
@1cm
Cumulative 
photon 
count
Average 
photon count
Max 
TLD
Avg 
TLD 
skin 
dose
BCTA 001001 09:20 10:25 01:05
BCTA 001002 15:05 15:40 00:35
BCTA 001003 13:20 16:00 00:40 02:40 5 5 136504916 3390584.103 4 3.4
BCTA 001004 10:20 13:15 00:27 02:55 4 5 88287553 3309128.673 2.3 1.8
BCTA 001005 11:40 12:45 01:05 3.5
BCTA 001006 15:00 17:00 00:21 02:00 3.5 5 71389143 3365824.752 3.7 3.2
BCTA 001007 09:00 10:00 01:00
BCTA 001008 11:00 13:00 00:26 02:00 4 5 88498136 3372642.378 8.6 6.4
BCTA 001009 11:50 13:50 00:26 02:00 4 5 88446174 3388742.299 5.9 3.5
BCTA 001010 15:10 16:15 01:05
BCTA 001011 15:35 17:55 00:32 02:20 4.5 5 106760452 3378495.316 4.1 2.6
BCTA 001012 13:05 15:50 00:40 02:45 5
5
134625835 3381708.993 1.6 1.4
BCTA 001013 14:15 17:05 00:32 02:50 4.5 5 106419301 3376246.859 2.1 1.5
BCTA 001014 12:14 13:35 01:21
BCTA 001015 14:20 17:15 00:25 02:55 4 5 85140813 3377263.507 2.1 1.8
BCTA 001016 10:31 11:50 01:19
BCTA 001017 12:00 14:00 02:00
BCTA 001018 15:25 17:35 00:43 02:10 5 5 1152923496 27038543.53 3.1 2
BCTA 001019 15:35 17:05 Aborted 01:30 4
BCTA 001020 15:35 17:05 01:30
BCTA 001021 14:50 16:00 01:10
BCTA 001022 14:50 16:00 01:10
BCTA 001023 11:43 14:05 00:33 02:22 4.5 5 111865833 3360343.436 4 3
BCTA 001024 12:03 14:20 00:27 02:17 4 5 90712513 3383532.749 3.4 2.4
Theatre Time Applictor size
IORT Posto
p
IORT 
time
Size No
Mean 2:23 1:16 31.38 3.5 1
SD 0:26 0:24 7.02 4 5
95% CI 0:10 0:09 3.97 4.5 3
UCL 2:13 1:07 27.40 53
LCL 2:33 1:25 35.35
Median 2:21 1:10 31.52
Min 1:30 0:35 21.21
Max 2:55 2:00 42.64
Mean difference 1 hr 7 minutes p<0.00001
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138 Targit trial - Histopathology
Trial No. side
sp 
weig
ht
Margi
ns
T Histology Gr
DC
IS
LC
IS
EIC ER PR
LN 
diss
LN 
inv
BCTA 001001 L8 5 1 . 5 I D C 31 9
BCTA 001002 R6 7 2 . 1 I D C 21 1 1 1 1
BCTA 001003 L2 . 5 I D C 3 1 1 6
BCTA 001004 L3 . 0 I D C 3 1 8
BCTA 001005 L1 . 0 I D C 2 1 1 1 2
BCTA 001006 L5 1 2 . 1 I D C 11 1 18
BCTA 001007 R 17 1.0 1.5 IDC 2 1 1 1 10
BCTA 001008 R 40 1.0 2.5 ILC 2 1 1 8
BCTA 001009 L7 8 1 . 4 I D C 31 8 1
BCTA 001010 R8 6 2 . 5 I D C 31 1 1 1 3
BCTA 001011 L3 . 0 I D C 2 1 1 1 1 3
BCTA 001012 R 212 1.5 IDC 3 1 19
BCTA 001013 L2 . 5 I D C 3 1 1 1 2 1 6
BCTA 001014 R5 5 1 . 2 I D C 21 1 19
BCTA 001015 L 43 1.7 Mucinous 2 1 1 1 20
BCTA 001016 L5 2 3 . 0 I L C 2 1 1 1 1 6
BCTA 001017 L9 81 . 04 . 0 I D L C 31 1 1 2 616
BCTA 001018 L 140 3.9 ILC 2 1 1 18
BCTA 001019 R8 0 2 . 8 I D C 31 1 1 1 4 2
BCTA 001020 R 156 1.7 IDC 3 1 10
BCTA 001021 R 110 2.0 IDC 3 1 18 9
BCTA 001022 L3 . 0 I D C 2 1 1 1 1 1 4
BCTA 001023 L9 5 3 . 5 I D C 31 1 4
BCTA 001024 L2 . 0 I L C 2 1 1 1 2
139 Targit trial - Patient Satisfaction
Case 
No.
Arm Appearance 
Expected
Appearance 
Actual
Appearance-
Obs/Exp
Texture 
Expected
Texture 
Actual
Texture 
Obs/Exp
1 Postop 5 10 2.00 8 10.00 1.25
2 Postop 89 1.13 5 9 1.80
3 IORT 6 7 1.17 7 7 1.00
4 IORT 4 10.00 2.50 6 10.00 1.67
5 Postop
6 IORT 5 7 1.40 6 8 1.33
7 Postop
9 5.00 0.56
77
1.00
8 Postop 8 2.00 0.25 8 3.00 0.38
9 IORT 8 10 1.25 6 8 1.33
10 Postop
11 IORT 6 9 1.50 9 9 1.00
12 IORT 5 10.00 2.00 5 10.00 2.00
13 IORT
14 Postop 9 8.00 0.89 8 9.00 1.13
15 IORT
16 Postop
17 Postop 8 5 0.63 8 2 0.25
18 IORT
19 IORT
20 Postop
21 Postop
22 Postop
23 IORT
24 IORT 8 8.00 1.00 8 8.00 1.00
Satisfaction Index
         Appearance           Texture
IORT Postop IORT Postop
Mean 1.64 0.94 1.39 1.14
SD 0.51 0.63 0.39 0.46
95% CI 0.45 0.55 0.34 0.40
UCL 1.19 0.39 1.05 0.73
LCL 2.09 1.49 1.73 1.54
p=0.061 p=0.328
*Patients were asked to give a score between 1 to 10, 10 being the best
Assessment times- 3-12 months
  
140 Complication -1 
 
Radionecrosis of skin occurred in 1 patient (Pilot No.3) because 
the dermis was too close to the applicator 
Surgery + IORT on 10 Feb 1999, Ext RT 11Mar-22Apr 1999 
 
25 May 1999  
Satisfaction(O/E): Appearance 6/7, Texture 7/7 
 
29 June 1999       21 September 1999 
  
 
19 October 1999  30 November 1999 Satisfaction (O/E): 
Appearance 8.5/7, Texture 7/7 
 
 
   30 Jun 2000 O/E: App 9/7, Tex 8.5/7      7 June 2001 O/E: App 8/6, Tex 8/6 
141  
Complication -2 
 
Delayed wound healing occurred in 1 patient (Pilot No.10) 
Surgery + IORT (7.5Gy @ 1cm and no Post-op RT)  
on 5 May 1999 
 
 
25 May 1999     29 June 1999 
 
 
6 July 1999      10 August 1999 
 
 
21 September 1999 –healed      7 Nov 2000 
Satisfaction (O/E) (patient is blind) Texture 8/9 
 
 
 
 
We have now delivered Targit in 41 cases and we have 
not had any more problems with wound healing 
 
142 Examples of good cosmetic results (Pilot Study) 
 
Pilot No 6 
 
26 Months. Satisfaction(O/E): Appearance 8/6, Texture 8/6 
 
Pilot No 16 
 
19 months. Satisfaction (O/E): Appearance 8/8, Texture 8/8 
Pilot No 17 
 
20 months. Satisfaction (O/E): Appearance 8/4, Texture 7/5 
Pilot No 23 
 
18 months. Satisfaction (O/E): Appearance 9/9, Texture 9/9
143 Examples of poor cosmetic results (Pilot Study) 
 
Pilot No 4 
 
22 months. However, patient was very satisfied with cosmesis Satisfaction 
(O/E): Appearance 8/5, Texture 9/5 
 
Pilot No 7 
 
24 months. Satisfaction (O/E): Appearance 4/8, Texture 4/8 
This was the poorest score given 
 
Pilot No 12 
 
24 months. Satisfaction (O/E): Appearance 8/9, Texture 8/9 
 
Pilot No 14 
 
24 Months. Satisfaction (O/E): Appearance 7/8.5, Texture 7/8.5 
144 Examples of cosmetic results in the randomised trial 
(Formal analysis will be performed at 2 years) 
RCT (001) – Post-operative radiotherapy 
 
12 months Satisfaction index(O/E): Appearance 10/5, Texture 10/8 
 
RCT (002) – Post-operative radiotherapy 
 
 
12 months Satisfaction index(O/E): Appearance 8/5, Texture 5/8 
145 Examples of cosmetic results in the randomised trial 
(contd.) 
(Formal analysis will be performed at 2 years)  
 
RCT (006) Targeted intraoperative radiotherapy 
 
 
12 months Satisfaction(O/E): Appearance 7/5, Texture 8/6 
 
 
RCT (009) – Targeted intraoperative radiotherapy 
 
 
12 months Satisfaction (O/E): Appearance 10/9, Texture 10/9 
 
146 Related Presentations, Publications and Citations  
 
Invited Presentations 
 
1.  Multicentricity of breast cancer: Whole organ analysis and clinical implications ( 
Oral) J S Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P Sharma, I Mittra. at 
the  7th Biennial National Conference of Indian Society of Oncology and 
International Symposium on new perspectives in oncology in collaboration 
with Indo-American Cancer Congress Inc., USA. at Lukhnow, 1 March, 1996. 
2.  Multicentricity of breast cancer: new findings and their clinical and biological 
implications. (Oral) at the J S Vaidya, I Mittra, M Baum. 1st Annual Meeting of 
the Indian Breast Group at Tata Memorial Hospital, Bombay 2 March 1997 
3.  Future implications of novel imaging and biopsy techniques. As a Faculty at the 
International Workshop: Multidisciplinary approach to breast cancer 
diagnosis, Hamburg, Germany, 12-14 October 1998. 
4.  Novel radiotherapy techniques at the Middlesex hospital. JS Vaidya Meyerstein 
Institute of Oncology Seminar, London, 18 Feb 1999 
5.  Radiosurgery an innovative approach to management of early breast cancer. (45 
min) JS Vaidya, Surgical Forum Meeting of the Department of Surgery, Norfolk 
and Norwich Hospital, 22 Jun 1999.  
6.  Novel radiotherapy techniques at the Middlesex hospital. JS Vaidya Meyerstein 
Institute of Oncology Seminar for radiographers, London, 4 August 1999. 
7.  Radiosurgery: an innovative approach to local treatment of breast cancer. Jayant 
S Vaidya.  (1 hr) Invited talk at the Massachusetts General Hospital, Harvard 
Medical School, Boston, USA. 7 Sep 1999 
8.  Radiosurgery: an innovative approach to local treatment of breast cancer. Jayant 
S Vaidya. Invited discussion at the Cleveland Clinic, Cleveland,  OH, USA, 8 
Sep 1999 
9.  Radiosurgery: an innovative approach to local treatment of breast cancer. Jayant 
S Vaidya. Invited discussion at the Our Lady of Mercy Medical School, New 
York, USA, 13 Sep 1999 
10.  Breast Conservative Therapy- novel approaches- Targeted Intraoperative 
Radiotherapy. Jayant S Vaidya. (20 min) invited lecture, at the Breast Cancer in 
the New Millenium – in Nagpur, India 18 February 2000. 
11.  Gave a live interview on Carlton Television (ITV) on Intra-operative 
Radiotherapy for breast cancer, London Today 1.30 – 1.40pm, 8 Nov 2000. 
12.  Featured in the BBC’s Tomorrow’s World with interviews taken while 
performing surgery and intra-operative radiotherapy for breast cancer, London, 
7.30pm, 8 November 2000 
13.  Targeted Intraoperative Radiotherapy- A novel approach to local treatment of 
breast cancer. JS Vaidya (30min) Invited lecture at the Satellite symposium by 
Photoelectron corporation, 23
rd Annual San Antonio Breast Cancer 
Conference, San Antonio, USA, 9 Dec 2000.  
14.  Targeted Intraoperative Radiotherapy for breast cancer- A randomised trial JS 
Vaidya (15min) Invited lecture, Satellite Symposium on Intraoperative Radiotherapy International Conference of Radiation Oncology (ICRO), 
Melbourne, Australia 31 Jan 2001 
15.  Targeted Intraoperative Radiotherapy- A novel approach to local treatment of 
breast cancer. JS Vaidya (10min) Oral presentation, International Conference 
of Radiation Oncology (ICRO), Melbourne, Australia 31 Jan 2001 
16.  BBC television interview at Saturday Breakfast News during Dec 2001/Jan 2002. 
17.  Intraoperative radiotherapy Breast Cancer 2002, Breakthrough breast cancer, 
London.UK  27 Feb 2002 
18.  Intraoperative radiotherapy for breast cancer- the UK experience at the 8
th 
Annual Clinical Oncology Symposium: Current concepts and developments in 
Intraoperative radiation oncology, New York, USA.  8 March 2002 
19.  Targeted Intraoperative radiotherapy- rationale, technique and results. 3
rd 
European Breast Cancer Conference. Barcelona, Spain,  20 March 2002 
20.  Targeted Intraoperative radiotherapy- rationale, technique and results. Congress 
of the Portuguese Society of Radiology and Radiotherapy,  Portugal 17 May 
2002 
21.  Targeted Intraoperative radiotherapy for early breast cancer- a randomised trial. 
American Brachytherapy Society meeting. Florida, USA  22 May 2002 
22.  Targeted Intraoperative radiotherapy-a randomised trial 4
th Milan Breast Cancer 
Conference, Milan, Italy  5 June 2002 
23.  Targeted Intraoperative radiotherapy-a randomised trial 5
th UK breast cancer 
trialists meeting, Birmingham, UK 17 June 2002. 
 Proferred Papers and Posters 
 
24. Multicentricity of Breast Cancer: A whole organ analysis and clinical 
implications. ( Poster) J S Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P 
Sharma, I Mittra. At the Surgical Oncology Update by International College of 
Surgeons and Tata Memorial Hospital, and was awarded the first prize, Bombay, 
9-10 August 1995. 
25. Multicentricity of Breast Cancer: A whole organ analysis and clinical 
implications.  (Oral) J S Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P 
Sharma, I Mittra. at the Weekly Clinical meeting at the Tata Memorial Hospital, 
Bombay, 7 September, 1995.  
26. Multicentricity and its influence on conservative breast cancer treatment strategy 
(Oral) J S Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P Sharma, I Mittra. at  
the Hong Kong International Cancer Congress on 19 Nov 1995. 
27. Multicentricity  of Breast cancer: new findings and their clinical and biological 
implications. (Oral) J S Vaidya, I Mittra, M Baum, at Joint Meeting on 
Senology and 2nd International Conference of European Society of 
Mastology (EUSOMA) at Florence, 21 March1997. 
28.Local Recurrence of Breast Cancer: New concepts about its biology and clinical 
relevance  J S Vaidya, I Mittra, M Baum. at the Tripartite meeting of British 
Oncological Association, Association of Cancer Physicians, and Royal College 
of Radiologists, St Andrews, 7 July 1997 
29.Local Recurrence of Breast Cancer: New concepts about its biology and clinical 
relevance J S Vaidya, I Mittra, M Baum. at the 5th Nottingham International 
Breast Cancer Conference,  19 Sept 1997. 
30. MRI in detection of Breast Cancer Multicentricity.(oral) J S Vaidya, M Douek, M 
Hall-Craggs, T Davidson, M Baum, I Taylor(Oral) at the British Breast Group 
Meeting. Cambridge, 31 October 1997  
31. MRI in detection of Breast Cancer Multicentricity.(poster) J S Vaidya, M Douek, 
M Hall-Craggs, T Davidson, M Baum, I Taylor  at British Association of 
Surgical Oncologists (BASO) and British Association for Cancer Research 
(BACR) Conference  27-28 November 1997. 
32. Local recurrence has nothing to do with residual disease. (20 min) J S Vaidya at 
the Biennial Presidential Conference of the British Oncological Association, 
Royal Society of Medicine, 2 March 1998. 
33. Radiosurgery: a novel method of treatment of early breast cancer. JS Vaidya, M 
Baum, JS Tobias, D D’Souza, , K Harte, P Mulvey, S Naidu, A Sliski, E 
Thompson, TR Varrichionne. International Meeting on Whole-Body 
Stereotactic Radiotherapy, Edinburgh, 19 September 1998. 
34.  Radiosurgery: A novel method of treatment of early breast cancer. JS Vaidya, M 
Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E 
Thomson, TR Varricchionne. British Breast Group Meeting. Sheffield, UK, 9 
October 1998. 
35.  Radiosurgery: A novel method of treatment of early breast cancer. JS Vaidya, M 
Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E 
Thomson, TRVarricchione. North London Cancer Network-Breast Cancer 
Tumour Board-Away Day, Royal Society of Arts, London 13 November 1998. 
36.  Radiosurgery: A novel method of treatment of early breast cancer. JS Vaidya, M 
Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E 
Thomson, TRVarricchione. British Association of Surgical Oncologists (BASO) Silver Jubilee Scientific Meeting, The Royal College of Surgeons of 
England, London, 26-27 November 1998. 
37.  Use of Photon Radiosurgery System for intra-operative, pre-operative and as 
primary radiosurgery for breast cancer . JS Vaidya, M Baum, JS Tobias, D 
D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E Thomson, TRVarricchione. 
Breast Symposium for the Pearce Gould Visiting Professor, London, 20 Mar 
1999.  
38.  Radiosurgery an innovative approach to management of early breast cancer. JS 
Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan 
Sliski, E Thomson, TRVarricchione Charles Grant Clark Prize Seminar, 
London 24 Jun 1999.- and won the 2
nd Prize  
39.  Radiosurgery an innovative approach to management of early breast cancer. JS 
Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan 
Sliski, E Thomson, TRVarricchione BOA/BACR/ACP tripartite meeting, 
Edinburgh, 12 Jul 1999 
40.  Radiosurgery an innovative approach to management of early breast cancer. JS 
Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan 
Sliski, E Thomson, TRVarricchione 6
th Nottingham International Breast 
Cancer Conference, Nottingham, 22-24 September 1999.  
41.  Percutaneous excision biopsy and minimally invasive radiosurgery a novel 
approach to management of breast cancer. JS Vaidya, MA Hall-Craggs, M Baum, 
JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E Thomson, 
TRVarricchione 6
th Nottingham International Breast Cancer Conference, 
Nottingham, 22 -24 September 1999. 
42.  Intra-operative radiotherapy: an Update (20 min) Breast Tumour Away Day of 
the North London Cancer Network, Barbican, London, 6 Oct 1999 
43.  Radiosurgery: an innovative approach to local treatment of breast cancer. (Poster) 
JS Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan 
Sliski, E Thomson. British Association of Surgical Oncologists Annual 
Scientific meeting, Portsmouth, 21-23 November 1999. 
44.  Targeted Intraoperative Radiotherapy- A novel approach to local treatment of 
breast cancer (Poster – 25 cases of the Pilot Study). JS Vaidya, M Baum, JS 
Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E Thomson 5
th 
Annual Multidisciplinary Symposium on Breast Diseases, Rome, Italy, 12-16 
February 2000. 
45.  Targeted Intraoperative Radiotherapy- A novel approach to local treatment of 
breast cancer. JS Vaidya (oral presentation) at the British Association of Surgical 
Oncologists BASO Annual Scientific Meeting, Royal College of Surgeons of 
England, London, 28 Nov 2000 
46.  Targeted intraoperative radiotherapy (Targit) for early breast cancer- a 
randomised trial. JS Vaidya, (8 min) Oral presentation, Radiological Society of 
North America, (narrated PowerPoint presentation) Chicago, 26-30 Nov 2001 
47.  Targeted Intraoperative Radiotherapy for early breast cancer- A randomised trial 
JS (Poster) Vaidya, M Baum, JS Tobias, M Keshtgar, R Sainsbury, I Taylor, S 
Morgan, D D'Souza, K Harte,  Alan Sliski, E Thomson 23
rd San Antonio Breast 
Cancer Conference, USA 10-13 Dec 2001 Peer-reviewed Papers 
 
1.  [Chapter 7] Targeted Intraoperative radiotherapy (Targit)- A randomised 
controlled trial to compare targeted intra-operative radiotherapy with 
conventional post-operative radiotherapy after breast conserving surgery for 
women with early stage breast cancer.  Jayant S Vaidya, Jeffrey S Tobias, 
Michael Baum, Joan Houghton. The trial protocol has been accepted by the 
Lancet and is published on its website-in December 1999 at 
http://www.thelancet.com/info/info.isa?n1=authorinfo&n2=Protocol+review&uid
=9920 
 
2.  [Chapter 6] Percutaneous Minimally invasive stereotactic Primary Radiotherapy 
Jayant S Vaidya, Margaret Hall-Craggs, Michael Baum, Jeffrey S Tobias, Mary 
Falzon, Derek P D’Souza, Steve Morgan Lancet Oncology  2002;3:252-253 
 
3.  [Chapter 6] Minimally invasive therapy for the treatment of breast tumours 
Margaret A. Hall-Craggs and Jayant S. Vaidya European Journal of Radiology, 
Volume 42, Issue 1, April 2002, Pages 52-57  
 
4.  [Chapter 5]Targeted Intraoperative Radiotherapy (TARGIT): an innovative 
method of treatment for early breast cancer. JS Vaidya, M Baum, JS Tobias, D 
D'Souza, S Morgan, M Metaxas, S Naidu , K Harte, Alan Sliski, E Thomson 
Annals of Oncology August  2001:12:1075-1080. 
 
5.  [Chapter 4] The technique of delivering targeted Intraoperative radiotherapy 
(TARGIT). JS Vaidya, M Baum, JS Tobias, D D’Souza, S Morgan. Eur J Surg 
Oncol  In Press (June 2002) 
 
6.  [Chapter 3] Can magnetic resonance imaging help elucidate natural history of 
breast cancer multicentricity? Michael Douek, Jayant S Vaidya, Sunil R Lakhani, 
Margaret Hall-Craggs, Michael Baum, Irving Taylor. The Lancet 14 March 
1998; 351:801-802. ,  
 
7.  [Chapter 3] Magnetic resonance imaging and breast cancer multicentricity. M 
Douek, JS Vaidya,  I Taylor, M Baum The Lancet 22 August 1998.352:652-653   
 
8.  [Chapter 2] Multicentricity and recurrence of breast cancer  M Baum, J S 
Vaidya, I Mittra, The Lancet. 18 Jan 1997; 349: 208.  
 
9.  [Chapter 2] Multicentricity of breast cancer: Whole organ analysis and clinical 
implications JS Vaidya, JJ Vyas, RF Chinoy, NH Merchant, OP Sharma, I Mittra. 
Br J  Cancer.  Sept 1996; 74 (5): 820-824. Commentary in The Lancet  9 Nov 
1996; 348: 1257-1258  
 
10.  [Chapter 1] Clinical and Biological Implications of the Milan breast conservation 
trials. Jayant S Vaidya, Michael Baum [Editorial]. Eur J Cancer  August 1998; 
34(8):1143-1144.  
 Abstracts 
 
1. Multicentricity and its influence on conservative breast cancer treatment strategy J 
S Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P Sharma, I Mittra. In the 
proceedings of the Hong Kong International Cancer Congress,  November 
1995. 
2. Multicentricity of breast cancer: whole organ analysis and clinical implications J S 
Vaidya, J J Vyas, R F Chinoy, N M Merchant, O P Sharma, I Mittra. In the 
proceedings of the 7th Biennial National Conference of Indian Society of 
Oncology (ISO) and International Symposium on new perspectives in 
oncology in collaboration with Indo-American Cancer Congress Inc. (IACCI), 
USA. March 1996. 
3. Local Recurrence of Breast Cancer: New concepts about its biology and clinical 
relevance J S Vaidya, I Mittra, M Baum, Br J Cancer July 1997 (76:suppl-
1)(O03):17  
4. Local Recurrence of Breast Cancer: New concepts about its biology and clinical 
relevance J S Vaidya, I Mittra, M Baum, The Breast August 1997;6(4):248-249. 
5. Multicentricity of breast cancer: new findings and their clinical and biological 
implications. J S Vaidya, M Baum, I Mittra, Breast, October1997;.6(5):325  
6. MRI in detection of breast cancer multicentricity M Douek, J S Vaidya, S R 
Lakhani, M A Hall-Craggs, M Baum, I Taylor. Eur J Surg Oncol Dec 
1997;23(6):591 
7. Preoperative MRI does not influence the amount of breast tissue excised in 
conservative cancer surgery  M Douek, JS Vaidya, T Davidson, SR Lakhani, MA 
Hall-Craggs, M Baum, I Taylor. Eur J Cancer 1998;34(S5): p.189 
8. Detection of breast cancer multicentricity with MRI. M Douek, J Vaidya, T 
Davidson, SR Lakhani, MA Hall-Craggs, K Blanchard, M Baum, I Taylor. 
Anticancer Res 1998;18:3837  
9. MRI currently does not influence the amount of breast tissue excised in 
conservative cancer surgery M Douek, JS Vaidya, T Davidson, SR Lakhani, MA 
Hall-Craggs, M Baum, I Taylor. Anticancer Res 1998;18:3838  
10.Radiosurgery: A novel method of treatment of early breast cancer. JS Vaidya, M 
Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan Sliski, E 
Thomson, TRVarricchione. Eur J Surg Oncol. 1998;24(6):619. 
11.MRI in the detection of breast cancer multicentricity AU: Douek M, Vaidya J, 
Lakhani SR, Blanchard K, Hall-Craggs MA, Davidson T, Baum M, Taylor I  Br J 
Surgery, 1998, Vol.85, No.S1, p.66 (2)  
12.Pre-operative detection of breast cancer multicentricity with MRI Douek_M, 
Vaidya_J, Davidson_T, Lakhani_SR, HallCrag_MA, Blanchard_K, Baum_M, 
Taylor_I Eur J Cancer, 1998, Vol.34, No.S5, P.319 (3)  
13.Radiosurgery: An innovative method of local treatment of breast cancer. . JS 
Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, P Mulvey, Alan 
Sliski, E Thomson, TRVarricchione. Br  J Cancer. 1999; July 1999;80:(Suppl6-
P285):100 
14.Targeted intraoperative Radiotherapy-(Targit) A novel approach to local treatment 
of early breast cancer. JS Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S 
Naidu, P Mulvey, Alan Sliski, E Thomson The Breast Journal Sep/Oct 2000 Vol 
6(5):339 
15.Targeted intraoperative Radiotherapy-(Targit) A novel approach to local treatment 
of breast cancer. JS Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  , S Naidu, 
S Morgan, Alan Sliski, E Thomson European Journal of Surgical Oncology Dec 
2000;26(8): 862  16.Targeted intraoperative Radiotherapy (Targit): A novel approach to local treatment 
of breast cancer. JS Vaidya, M Baum, JS Tobias, D D'Souza, K Harte,  S Naidu, S 
Morgan, M Metaxas Alan Sliski, E Thomson Radiotherapy & Oncology Jan 
2001;58(suppl 1)S10:31 
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